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Irritable bowel syndrome 
Irritable bowel syndrome (IBS) is a highly prevalent disorder of brain-gut-interaction that 
is characterized by recurrent abdominal pain in combination with alterations in bowel 
habits.3 Based on predominant stool pattern, IBS can be subtyped as diarrhea-
predominant (IBS-D), constipation-predominant (IBS-C), mixed type (IBS-M), or 
unclassified IBS (IBS-U). Besides abdominal pain and disturbed defecation, many patients 
experience additional gastrointestinal (GI) symptoms such as abdominal cramping4, 
bloating (subjective sensation of abdominal fullness) and/or distention (objective 
increase in abdominal girth)5,6, flatulence7, and dyspepsia.8 Symptoms are known to 
occur in episodes9 with a chronic relapse remitting nature and vary widely between as 
well as within subjects, reflecting the complex, heterogeneous and multifactorial 
phenotype of IBS.10 
 
IBS is part of a spectrum of functional GI disorders (FGID), ‘classified by GI symptoms 
related to any combination of the following: motility disturbance, visceral hypersensitivity, 
altered mucosal and immune function, altered gut microbiota, and altered central nervous 
system (CNS) processing’, in absence of an identifiable organic cause. Other FGIDs 
include, but are not limited to functional heartburn, functional dyspepsia, belching, and 
functional constipation.11 IBS often overlaps with these FGIDs12-16 and is likely to have, at 
least to some extent, common underlying etiological mechanisms. In addition, IBS is also 
associated with various other intestinal, extra-intestinal, and psychiatric conditions, e.g. 
gastro-intestinal reflux disease (GERD), pelvic floor dyssynergia, chronic fatigue 
syndrome17, overactive bladder, fibromyalgia, increased somatization, depression, and 
anxiety.18 
Symptom-based diagnosis 
At present, specific biomarkers to confirm IBS are not available and a diagnosis is made 
based on presence of typical symptoms.19,20 Alarm symptoms that may require further 
investigations before diagnosing a patient with IBS are presented in Box 1.1. 




Alarm features for IBS* 
 1. Blood in the stools, unless caused by fissures or hemorrhoids 
 2. Onset of symptoms after 50 years of age 
 3. Fever 
 4. Unintended weight loss 
 5. Nocturnal symptoms 
 6. Family history of coeliac disease, inflammatory bowel disease, or colon cancer 
 7. Abdominal mass 
 8. Appetite loss 
 9. Ascites 
 10. Anemia 
 
Box 1.1 Alarm features for IBS, presence of any of the following symptoms may warrant further 
investigation. 
 
Since 1978, several criteria have been described to aid diagnostic accuracy of IBS both in 
research and clinical setting.21 The Rome III diagnostic criteria (Box 1.2) were released in 
20062 and were, until recently, the golden standard to diagnose IBS with an estimated 
sensitivity and specificity of 69.6% and 82.0%, respectively.22 
 
Rome III diagnostic criteria2 for IBS* 
Recurrent abdominal pain or discomfort, on average: 
At least 3 days per month in the last 3 months 
Associated with 2 or more of the following: 
1. Improvement with defecation 
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance of stool) 
*Onset of symptoms at least 6 months prior to diagnosis 
 
Box 1.2 Rome III diagnostic criteria for IBS, published in 2006. 
 
In 2016, the Rome IV criteria (Box 1.3.) have been published1 and have an estimated 
sensitivity and specificity of 62.7% and 97.1%, respectively.23 The Rome IV criteria 
comprise two main updates when compared to Rome III: 1) The term abdominal 
discomfort has been removed, leaving the presence of abdominal pain the key 
requirement for IBS; 2) The frequency threshold of symptoms has been increased to at 
least 1 day per week.  
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Rome IV diagnostic criteria1 for IBS* 
Recurrent abdominal pain, on average: 
At least 1 day per week in the last 3 months 
Associated with 2 or more of the following: 
4. Related to defecation 
5. Associated with a change in frequency of stool 
6. Associated with a change in form (appearance of stool) 
*Onset of symptoms at least 6 months prior to diagnosis 
 
Box 1.3 Rome IV diagnostic criteria for IBS, published in 2016. 
 
Prevalence and socioeconomic burden of IBS 
IBS is highly prevalent and occurs in 5-20% of the population, with variations due to 
differences in diagnostic criteria used and geographical areas investigated. Furthermore, 
it has been shown that women and young people are more often affected.24 
 
Although IBS is not associated with increased mortality, it has a major impact at societal 
level. The high prevalence, increased healthcare utilization, and loss in productivity in 
patients with IBS result in both high direct and indirect costs. IBS patients, for example, 
have more consultations with a medical professional regarding their IBS, receive more 
diagnostic investigations, and use more prescribed or over the counter drugs than 
patients without the IBS diagnosis. Total annual direct costs per patient were estimated 
to range between $742-7547 (USA), €567-862 (France), and €791 (Germany).25,26 
Moreover, because IBS is associated with various comorbidities, studies have shown 
that the majority of healthcare charges in IBS patients was in fact for non-GI medical 
conditions and not for IBS.27,28 In addition, IBS patients are more likely to be both absent 
from work (absenteeism) and impaired in productivity during work (presenteeism), 
compared to non-IBS patients.29 Prior studies have estimated annual indirect costs per 
patient with IBS, being $748 (in Canada), $335 (in the United Kingdom), and €995 (in 
Germany).25,30 
 
As healthcare systems differ between countries, findings from studies on healthcare 
costs are difficult to compare. In the Netherlands, the economic burden of IBS in the 
first three years after diagnosis was investigated by Flik et al., using an insurance 
database.31 They observed that direct costs increased with 486 and 2328 euro after IBS 
was diagnosed in primary versus secondary care, respectively. Further data from a 
societal perspective on costs for the Dutch situation are lacking. 
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It is well-recognized that IBS is associated with a pronounced interference with daily life 
activities and a decrease in quality of life (QoL)25,32,33, with QoL scores comparable to or 
even lower than in patients with GERD, diabetes, migraine, and asthma.34 When 
applying the ‘time-trade-off method’, the mean reported QoL scores of an IBS patient 
correspond to a 35-year-old patient willing to sacrifice 10-15 years of the remaining 40 
years (of life expectancy) in exchange for immediate perfect health.25,35 Albeit 
hypothetical, this clearly demonstrates the considerable burden experienced by these 
patients.  
Pathophysiology of IBS 
Although the pathophysiology of IBS is complex, multifactorial, and incompletely 
understood, there is now substantial evidence for several mechanisms to be involved. 
Risk factors for IBS include female sex, a history of GI infections, previous abdominal 
surgery, use of antibiotics, somatic pain (e.g. migraine), endometriosis, and psychological 
factors, such as acute psychological stress, a history of stressful life events or sexual 
abuse, the presence of anxiety, depression, and somatization.18 Furthermore, research 
data strongly suggests that a aberrant brain-gut-interaction has a central 
pathophysiologic role. Other factors implicated in IBS pathophysiology include visceral 
hypersensitivity, genetic susceptibility, disturbed intestinal motility, low grade immune 
activation, intestinal dysbiosis, excess fermentation by colonic microbiota, impaired gas 
tolerance, abdomino-phrenic dyssynergia, alterations in bile-acid metabolism, and 
psychological comorbidities.5,6,18 It is assumed that several mechanisms, when present at 
the same time, lead to symptoms in the individual patient with IBS. These symptoms and 
underlying factors differ between subgroups of IBS.10 The pathophysiology of IBS is 
depicted schematically in Figure 1.1. Some of the key-mechanisms involved will be 
described in the following paragraphs. 
 
Altered brain-gut-interaction is a key factor that likely contributes to abdominal pain, 
which is a typical hallmark of IBS. Thresholds for abdominal pain are lowered (allodynia) 
and abdominal pain levels are higher (hyperalgesia) in patients with visceral 
hypersensitivity, which can be measured using the barostat procedure. The proportion 
of IBS patients with visceral hypersensitivity varies between studies and ranges to up to 
60%.36 Viscero-sensory function entails a bidirectional interaction between the enteric 
and spinal nerves and the central nervous system. From the gut, visceral stimuli travel 
from nerve endings located in all layers of the intestinal wall and mesentery37 to afferent 
neurons residing in the dorsal root ganglia.38 From the dorsal horn, afferent input is 
conveyed via spinal pathways to subcortical regions such as the nucleus of the solitary 
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1 
tract in the brain stem, the primary relay station for vagal afferent information39,40, and 
then transduced to other parts of the brain. The vagal nerve carries afferents from 
mechano- and chemoreceptors throughout the entire GI tract, with the exception of 
the descending colon and rectum that are innervated by splanchic nerves41, and is 
thereby a key nerve regarding viscero-sensory function.42-44 When visceral stimuli reach 
the brain, perception of the sensation can occur depending upon the type and fortitude 
of the stimulation, but also depending on central, supraspinal, and spinal bidirectional 






















Figure 1.1 Pathophysiological mechanisms in Irritable Bowel Syndrome. 
 
 
Abdominal pain may originate from various anatomical levels: a) nerve endings and 
nerves can become abnormally activated or sensitized at the intestinal level; b) input can 
be altered at the spinal cord level; and c) stimuli can be modulated aberrantly at the 
spinal, supraspinal, and/or central level. 
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One of the mechanisms at the intestinal level that is associated with IBS, in at least a 
subset of patients, is immune activation. Several studies have shown increased numbers 
of mucosal mast cells, eosinophils, and T-lymphocytes in the small and large intestine of 
IBS patients versus healthy controls.18 Furthermore, the mast cells found were located 
more closely to nerve endings and were more often in degranulating state in IBS 
patients, than in controls.18,38 This intestinal immune activation may result in increased 
intestinal permeability, which leads to further low-grade immune cell infiltration.18 
Peripheral pro-inflammatory chemokines, cytokines, prostaglandins, substance P, 
calcitonin G-related peptide (CGRP), and several neurotrophins can subsequently 
activate and sensitize intestinal sensory nerve endings, thereby mediating nociceptive 
processes. This finding has been underscored by the fact that mucosal mediators 
derived from biopsy supernatants of patients with IBS provoked greater activation of 
visceral pain pathways when applied to intestinal preparations, compared with 
controls.18,38  
 
Nociceptive neurons that play a role in the intestinal nerve sensitization associated with 
IBS can express Transient Receptor Potential (TRP) channels. The TRP family comprises 
numerous ligand-gated cation channels located in nociceptive neurons of vagal, spinal, 
and splanchnic primary afferents or in immune cells.45,46 They are expressed in multiple 
visceral organs and have various chemo-, thermo-, and mechano-sensory functions.47,48 
Several types of TRP channels are present in the GI tract and have been implicated in 
visceral pain generation or inhibition, such as TRP Vanilloid 1 (TRPV1), TRP Ankyrin 1 
(TRPA1), TRP Vanilloid 4 (TRPV4), and TRP Melastatin 8 (TRPM8). The most widely 
studied nociceptor, TRPV1, can be activated by high temperatures, low pH and 
exogeneous stimulants, e.g. the pungent substance in hot chili peppers (capsaicin); 
mustard oil; and anandamide.48 Activation results in release of several proinflammatory 
neurokines such as substance P and CGRP. The role of TRPV1 modulation in sensory 
hyperalgesia has been established in animal models of visceral pain.49 In addition, several 
studies demonstrated an increased colonic TRPV1 expression in IBS patients when 
compared to controls50,51, and elevated pain responses to capsaicin compared to 
controls.52 TRPA1 is co-existing with TRPV1 on visceral afferents and likely functioning 
through interaction with TRPV1.45 TRPA1 has mechano-sensory properties and in 
addition can be activated by low temperatures and various pungent compounds, e.g. 
cinnamon, garlic, and hydrogen peroxide. TRPV4 can be activated by osmosis, 
mechanical force, and slightly warmer temperatures than room temperature. Besides 
long-standing evidence from animal models that TRPA1 and TRPV4 are implicated in 
pain generation, a recent study has shown increased TRPA1 and TRPV4 mediated 
responses by neurons derived from biopsies of IBS patients, compared with healthy 
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controls. In addition, this study demonstrated that supernatants of rectal biopsies of IBS 
patients, but not healthy controls, sensitized TRPA1 and TRPV4 in murine sensory 
neurons.53  
 
Whereas several TRP channels exhibit pro-nociceptive properties, there are indications 
that TRPM8 has anti-nociceptive effects. TRPM8 can be activated by several factors 
including low temperatures and cooling compounds, e.g. menthol, the main constituent 
of peppermint oil. TRPM8 has been suggested to exhibit antinociceptive properties by 
impeding the mechano- and sensory effects of TRPA1 and TRPV1 by cross-
desensitization.54 Moreover, results from an animal colitis model suggest that TRPM8 
activation by agonist icilin can reduce cytokine and chemokine levels and as such, also 
has an anti-inflammatory effect.55 Taken together, these results implicate that TRPM8 
may be able to counteract abdominal pain and thereby may have therapeutic 
applications. However, more data on this topic, in particular from in vivo studies, is 
warranted to comprehend the exact role of TRP channels and their interaction in 
visceral nociceptive processing and immune function. 
 
Intestinal dysbiosis is another factor that can contribute to sensitization of nerves and is 
associated with IBS, at least in subgroups of patients. A microbiota signature that has 
been confirmed by several comprehensive studies is the increased 
Firmicutes/Bacteroidetes ratio56, a relative depletion of Bifidobacteria and a general 
lower diversity of the microbiota.57 It should however be noted that these findings could 
not be confirmed in all studies. In addition, changes in microbial metabolic activity58 and 
a microbial signature associated with symptoms severity59 have been found. The 
microbiome perturbations can impact the intestinal epithelium and its underlying 
immune system. Growing evidence moreover supports bidirectional interactions 
between the gut microbiome and the brain.60-63 Data in support of this brain-gut-
microbiome axis originate mainly from animal studies. For example, colonization of 
germfree mice with the bowel contents of IBS patients did result in immune activation, 
increased intestinal permeability, and anxious behavior that was not related to GI 
symptoms.63,64 In recent years, evidence is also emerging from human data, such as 
brain-imaging studies, which found changes in brain activation patterns following 
administration of a probiotic.65,66 
 
Another process that was found to be altered in a subset of IBS patients is central pain 
modulation. Intestinal nociceptive signals are transduced to the central nervous system 
where they are modulated extensively. This central pain modulation is a balance 
between inhibition and facilitation of the painful stimulus and a key determinant of 
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abdominal pain perception. In the 1990s, several research groups further investigated 
the brain-gut interactions by using functional Magnetic Resonance Imaging (fMRI) and 
positron emission tomography (PET).67 These studies were important to elucidate brain 
areas and networks associated with visceral pain in healthy and disordered states, such 
as IBS. Since then, several studies have examined the complex role of the autonomic 
nervous system by applying a mechanical or thermal intestinal stimulus during fMRI. 
They demonstrated that painful rectal balloon distensions resulted in activation of 
various brain areas68; the primary and secondary somatosensory cortex, insula, cingulate 
cortex, prefrontal cortexes, and thalamus.67,69-72 In addition, it was shown that individual 
factors such as coping mechanisms, depression, anxiety, cognitions, and emotions can 
bi-directionally modulate cortical, limbic, and brainstem nuclei. This can subsequently 
result in either amplification or subordination of noxious stimuli in healthy volunteers 
and IBS patients and thereby determines whether noxious stimuli are perceived as 
painful.73 When compared to healthy controls, patients with IBS appeared to have 
different activation patterns of brain areas involved (in visceral pain processing and 
modulation).71,74 Moreover, there are indications that the vagal efferent arm exhibits 
downward modulatory properties and can even affect low grade inflammation. Several 
studies have indicated that this efferent vagal activity can be impaired in IBS.42,43 
Altogether, these findings point to increased facilitation and/or decreased inhibition of 
pain signals in IBS.73,75 In combination with peripheral alterations, this can contribute to 
abdominal pain. Further research is needed to investigate how all factors interact and 
why they lead to symptoms in some, but not all patients with IBS. 
Treatment of IBS 
Currently, there is no effective cure for IBS. Available treatment modalities merely aim 
at symptom amelioration and mostly benefit only subgroups of patients. Regardless of 
the treatment chosen, pivotal for treatment success are a good patient-physician 
relationship and a timely discussion about treatment expectations.20 Furthermore, as 
many psychiatric and extra-intestinal comorbidities interfere with patients’ symptom 
severity as well as daily functioning, constructing a multidimensional clinical profile and 
assessing all factors that impede QoL, are needed to choose a patient-centered 
approach.76 
 
Traditionally, treatment starts with reassurance and explaining the disorder. For a 
subgroup of patients with mild symptoms, this is sufficient and no further treatment is 
required.76 Given that a large proportion of patients report their symptoms to be 
triggered by meals or specific foods57, dietary and lifestyle modifications can also relief 
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symptoms and are usually suggested next if further treatment is necessary.77 General 
dietary and lifestyle modifications include less intake of e.g. alcohol, caffeine, spicy-, fat-, 
lactose containing or other foods that trigger symptoms, as well as decreasing meal 
portions and/or number of meals a day, modifying dietary fiber intake, and increasing 
physical activity.20,76 In patients with bloating and or flatulence as predominant symptoms 
that respond inadequately to general dietary modifications, a diet low in FODMAPs 
(fermentable oligosaccharides, disaccharides, monosaccharides and polyols) may be 
beneficial.78 This diet ultimately aims at a balanced intake of FODMAP containing foods 
that do not, or solely to an acceptable extent, trigger symptoms, in combination with 
low intake or avoidance of FODMAP containing foods that trigger severe symptoms. If 
dietary and lifestyle modifications provide inadequate results, psychological and/or 
pharmacological treatment should be considered. 
 
As psychosocial factors can influence GI symptoms and vice versa, various psychological 
treatments can be tried, such as cognitive behavioral therapy, gut-directed 
hypnotherapy, mindfulness-based therapy and psychodynamic therapy. When combined 
with medical and dietary therapies, gut-directed-psychotherapies collectively have a 
favorable number needed to treat of 4 and are at low risk for adverse events.79 
Nevertheless, the clinical implementation is still limited due to a lack of trained therapists 
in some geographical areas.80  
 
If pharmacological treatment is preferred and diarrhea is the main predominant 
symptom, treatment options include the antidiarrheal drug loperamide76, the antibiotic 
rifaximin81 and bile-acid binders.82 In addition, recent pharmacological advancements 
have led to the development of eluxadoline, a mixed agonist of μ-opioid and ĸ-opioid 
receptors and an antagonist of ð-opioid receptors, for the treatment of diarrhea and to 
a lesser extent abdominal pain in IBS-D patients.83 Eluxadoline treatment should, 
however, be closely monitored due to serious side effects (e.g. pancreatitis and 
sphincter of Oddi spasms).84  
 
Pharmacological treatment of constipation often begins with the osmotic laxative 
polyethylene glycol.76 Second-line options that have become available recently as a result 
of pharmacological developments include linaclotide85, and plecanatide86, and 
tenapanor.87 Linaclotide and plecanatide are guanylate-cyclase-C agonists that increase 
fluid secretion into the intestinal lumen to hydrate stools and possibly also reduce 
abdominal pain. Tenapanor is a minimally absorbed, small molecule inhibitor of the 
gastrointestinal sodium/hydrogen exchanger isoform 3 that increases fluid and sodium 
into the intestinal lumen.88 IBS patients that suffer from mixed type IBS should preferably 
Chapter 1 
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be managed by a tailored therapy that can be adapted when the predominant symptom 
switches.20  
 
Drugs that can reduce symptoms of bloating include rifaximin, some probiotics, 
eluxadoline in case of accompanying diarrhea, and linaclotide, plecanatide, or tenapanor 
in case of accompanying constipation.5,87,89 Pharmaceuticals that have shown some 
efficacy in treatment of abdominal pain, the most important hallmark of IBS, include 
tricyclic antidepressants, selective serotonin reuptake inhibitors, and antispasmodic 
drugs.76 
 
Despite the large therapeutic array and advances in the management of IBS in recent 
years, a considerable proportion of patients remain refractory to currently licensed 
pharmacological therapies. Furthermore, the therapeutic gain over placebo is a mere 8 
to 20% for most drugs available for IBS76 and treatment efficacy of the most cardinal 
symptom in particular, abdominal pain, is often unsatisfactory. Factors that further 
complicate the search for better treatments are the generally high placebo response in 
patients with IBS in clinical trials (i.e. approximately 30%)90, and the chronic relapse-
remitting and heterogeneous nature of IBS. In addition, it is difficult to capture treatment 
response since treatment effects cannot be monitored with biomarkers and end-of-day 
symptom diaries are often hindered by fake adherence.91 More research into the 
underlying pathophysiological mechanisms, appropriate symptom assessment tools, but 
also new therapeutic compounds or alternative formulations of existing drugs are 
warranted to optimize future treatment of patients with IBS. In addition, because IBS 
imposes such a significant socioeconomic burden, it is important that therapies are not 
only effective, but associated costs should also be justifiable (i.e. cost-effectiveness). A 
drug of particular interest that is low in costs and was found to have a promising number 
needed to treat of 3-4 in meta-analyses is peppermint oil.22 
 
Peppermint oil is a pharmacological compound of herbal origin that has been used to 
treat IBS for many years. Peppermint oil has an antispasmodic, smooth muscle relaxing 
effect by blocking calcium influx in the sarcolemma of the intestinal smooth muscle 
cells.92 Furthermore, menthol, the main constituent of peppermint oil, is thought to have 
direct analgesic properties through interaction with previously described intestinal 
TRPM8 and TRPA1 receptors.93 Other mechanisms of action include 5-
hydroxytryptamine antagonism94,95, antimicrobial and antifungal effects96-99, and ĸ-opioid 
receptor agonism.100 Currently, capsules that release the peppermint oil in the small 
intestine are available as an over-the-counter drug. Placebo controlled randomized trials 
using this small-intestinal release peppermint oil formulation in patients with IBS support 
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its usage and have demonstrated a reduction in abdominal pain and overall 
symptoms.101-104 Similarly, meta-analyses indicate that peppermint oil has a treatment 
effect compared to placebo of approximately 30%.105,106 Although these findings are 
highly favorable compared to other treatments107, the results are based on studies with 
methodological shortcomings, impeding the ability to draw firm conclusions about the 
effectiveness of peppermint oil in patients with IBS and limiting the incorporation in 
treatment guidelines. Therefore, there is a need for a well-designed randomized 
controlled trial conducted according to Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) guidelines on trials in IBS. Another factor hindering 
application in daily clinical practice is that conventional small-intestinal release 
peppermint oil is associated with bothersome upper GI adverse events such as 
heartburn, belching, and a peppermint oil taste101-103,108, which impair treatment 
adherence. It is likely that a colonic release and therefore more distal gastrointestinal 
exposure to peppermint oil would decrease these adverse events. This could also 
induce a more colonic anti-spasmodic effect as colonic application of peppermint oil has 
been found to inhibit colonic motor activity and peristalsis.93 Furthermore, it can be 
envisaged that an ileocolonic release of peppermint oil enhances the local exposure of 
the ileocolonic nociceptive afferents to the oil and thereby increases its analgesic effects. 
Therefore, in addition to conducting a well-designed randomized controlled trial with 
small-intestinal release peppermint oil, it is worth exploring a colonic delivery system of 
peppermint oil as this may result in fewer adverse events and increased efficacy. 
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Aims & outline of this thesis 
IBS is a highly prevalent disorder of brain-gut interaction, of which the complex and 
multifactorial pathophysiology remains poorly understood. The socioeconomic burden 
associated with IBS is substantial and is likely caused by a combination of the challenging 
diagnostic process, the chronic relapse-remitting nature of IBS, and the overall meagre 
efficacy of the current therapeutic array. Further insight into these contributing factors 
may help prevent the drainage of precious health care costs and improve patients’ 
quality of life. 
 
We studied the change in diagnostic criteria and how this affects the IBS population, and 
its impact on quality of life in part I of the current thesis. As adequate treatment of the 
most cardinal symptom, abdominal pain, is often unsatisfactory, we addressed TRP 
channels as potential therapeutic targets and investigated the efficacy and cost-
effectiveness of peppermint oil in part II of this thesis. 
 
In 2016, the Rome diagnostic criteria for IBS were revised to the more stringent Rome 
IV criteria. Until then, most studies had been based on prior criteria, such as Rome III, 
and it was unknown which Rome III IBS patients were likely to meet the Rome IV 
criteria. This however, is important to know because the Rome defined IBS population 
is the target population for randomized clinical trials to investigate treatment response 
of novel treatment strategies. It is also meaningful to assess how the change in definition 
could affect clinical practice because the criteria are pivotal in the clinical diagnostic 
process and are meant to reduce the number of diagnostic investigations (and thus 
costs) by making a positive diagnosis. Therefore, in chapter 2, we investigated 
demographic, clinical, and psychosocial differences between Rome III and Rome IV IBS 
subjects, using diary-based surrogate Rome IV criteria in a large and well-defined patient 
cohort.  
 
In most patients with IBS, symptoms fluctuate over time. Given that knowledge of 
factors affecting the natural disease course can help in the search for new patient 
tailored treatment strategies, it is pertinent to identify predictors for long-term 
symptom severity and quality of life. Therefore, we evaluated symptom evolution and 
characteristics that could predict the disease course over a five-year follow up period in 
patients participating in the Maastricht IBS cohort in chapter 3. 
 
In the search for cost-effective treatments for patients with IBS, TRP channels are 
promising targets for therapeutic interventions. Growing evidence indicates that TRP 
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channels are involved in the propagation and processing of abdominal pain signals in IBS. 
In chapter 4, we reviewed current insights regarding TRP channels and their potential 
implications for treatment in IBS. As human data on the functional relevance of the 
TRPM8 channel is exceptionally limited, we investigated neuro-immune interactions in 
the human gut to elucidate the role of TRPM8 in nociceptive processes and gut health in 
chapter 5. Peppermint oil is a potent TRPM8 agonist and has been shown to 
ameliorate abdominal pain in IBS in prior studies. Most of these studies, however, 
suffered from methodological flaws or were conducted in small populations. In 
chapter 6, we assessed the pharmacokinetic profile of a newly developed ileocolonic 
release peppermint oil capsule in healthy volunteers. This formulation was produced to 
decrease upper GI adverse events associated with conventional, small-intestinal release 
peppermint oil and to increase efficacy by the enhancement of local colonic anti-
nociception. Following the pharmacokinetic pilot study, we investigated the efficacy and 
safety of small-intestinal and ileocolonic release peppermint oil in a Rome IV IBS 
population in a randomized, placebo-controlled trial (RCT) with a highly qualitive 
experimental design. The results of this RCT have been described in chapter 7. Since 
IBS is associated with high healthcare related costs, it is increasingly important that 
therapeutic entities are also cost-effective. Therefore, in chapter 8, we determined the 
cost-effectives of peppermint oil alongside the previously mentioned RCT.  
 
Due to the lack of validated biomarkers, end-of-day symptom diaries are important to 
assess treatment response in patients with IBS. The validity and reliability of paper 
diaries, however, is impeded by fake adherence and recall bias. Given that an accurate 
assessment of treatment response in RCTs is essential in the search for better 
treatments for patients with IBS, we implemented a framework for a digitalized data 
collection in our previously mentioned peppermint oil RCT. In chapter 9, we describe 
the smartphone application that was used as a digital symptom diary in addition to the 
overall data collection method. Furthermore, we assessed patient’ adherence to the 
digital diary and investigated how patient characteristics associate with adherence. 
 
Finally, in chapter 10, we summarize the main findings of this thesis, and discuss 
implications for future research in this area and everyday clinical practice. 
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The Rome criteria for irritable bowel syndrome (IBS) have been revised and are 
expected to apply only to the subset of Rome III IBS subjects with abdominal pain as 
predominant symptom, occurring at least once a week. The aim of this study was to 
determine the percentage of Rome III IBS subjects that fulfills Rome IV criteria and to 
evaluate differences between Rome IV-positive and -negative subjects. 
 
Methods 
404 Rome III IBS subjects completed a 14-day end-of-day symptom diary, the 
gastrointestinal symptom rating scale (GSRS), hospital anxiety and depression scale 
(HADS) and rand 36-item short-form health survey (SF-36). Diary-based surrogate 
Rome IV criteria were defined as occurrence of abdominal pain at least one day each 
week with a severity of ≥2 (mild; definition 1) or ≥3 (considerable; definition 2). 
 
Results 
Using surrogate Rome IV criteria, 353 (87.4%, definition 1) and 249 (61.6%, definition 2) 
subjects were defined as Rome IV-positive. These patients were more often female, 
younger and recruited from secondary/tertiary care compared to Rome IV-negative 
subjects. They also presented with higher abdominal pain scores and gastrointestinal 
(GI) symptom severity on both end-of-day diary and GSRS, higher psychological 
symptom scores and lower quality of life compared to Rome IV-negative subjects. 
 
Conclusions 
The Rome IV IBS population likely reflects a subgroup of Rome III IBS patients with 
more severe GI symptomatology, psychological comorbidities and lower quality of life. 
This implies that results from Rome III IBS studies may not be directly comparable to 
those from Rome IV IBS populations. 
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Irritable bowel syndrome (IBS) is a functional intestinal disorder characterized by 
abdominal pain associated with altered bowel habits. IBS has traditionally been 
subcategorized into four subtypes based on predominant stool pattern: diarrhea (IBS-
D), constipation (IBS-C), a mix of diarrhea and constipation (IBS-M) or undefined 
predominant stool form (IBS-U). IBS is a prevalent disorder worldwide, with prevalence 
rates of 5-15% in the Western population.1,2 Symptoms most likely result from complex 
interactions between several biological, psychological and social factors.3,4 The exact 
underlying mechanisms of IBS pathophysiology are however not completely understood 
and as a consequence accurate non-invasive biomarkers for diagnosis, disease 
monitoring and treatment evaluation are not available.  
 
At present, the diagnosis of IBS is symptom-based, using the Rome criteria. The Rome 
Foundation, a committee of international experts in the field of functional 
gastroenterology, has been working on the development and revision of diagnostic 
criteria for IBS, amongst other functional gastrointestinal (GI) disorders, since 1994. 
Recently, Rome III criteria (2006) have been updated to Rome IV criteria (2016). Major 
adjustments include removal of the term abdominal discomfort (Rome III), leaving only 
the occurrence of abdominal pain as the key requirement for Rome IV criteria. 
Furthermore, abdominal pain should be present on average at least one day per week in 
the Rome IV criteria (see Box 2.1).5,6 This new frequency threshold was based on a 
summary report on the distribution of symptom occurrence rates for all the Rome III 
symptoms.7 Most likely, fewer patients will fulfill the new Rome criteria compared to the 
previously set criteria. Indeed, using Rome IV criteria, a lower population prevalence of 
IBS has been reported by Whitehead and colleagues.8,9 Furthermore, IBS subtype 
identification has been revised, by only taking into account symptomatic stools (i.e. 
loose/watery stools and hard/lumpy stools), which might result in a shift in IBS 
subtypes.3 
 
Studies on previous editions of the Rome criteria have demonstrated varying IBS 
prevalence rates depending on the diagnostic criteria employed. Also, differences in 
patient characteristics and symptomatology have been reported between several 
criteria.10-13 As a result of the requirement of weekly symptoms, Rome IV IBS patients 
are likely to be those with more severe symptomatology and possibly higher prevalence 
of psychiatric comorbidity and lower quality of life as compared to those fulfilling Rome 
III criteria. However, data comparing clinical features between Rome III- and Rome IV-
IBS populations are still lacking.  
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Rome III IBS 
1) Recurrent abdominal pain or discomfort* at least 3 days per month in the last 3 months and 
associated with 2 or more of the following: 
a. Improvement with defecation; 
b. Onset associated with a change in frequency of stool; 
c. Onset associated with a change in form (appearance) of stool. 
2) Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis. 
* Discomfort means an uncomfortable sensation not described as pain. 
 
Rome IV IBS 
1) Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months and associated 
with 2 or more of the following: 
a. Related to defecation; 
b. Associated with a change in frequency of stool; 
c. Associated with a change in form (appearance) of stool. 
2) Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis. 
 
Box 2.1 Definition of IBS according to Rome III and Rome IV criteria. 
 
 
Rome criteria are widely used as a cornerstone for inclusion in IBS clinical trials and 
cohort studies. It is expected that in future studies only a subset of Rome III IBS patients, 
i.e. those with more severe abdominal pain, will be eligible for study participation by 
introducing Rome IV criteria. In order to generalize current data to Rome IV 
populations and to compare results from Rome III and Rome IV studies, it is important 
to evaluate which Rome III patients are likely to meet the Rome IV criteria. Therefore, 
the aim of this study was to determine the percentage of Rome III-positive IBS subjects 
that is also highly likely to fulfill Rome IV criteria, based on end-of-day symptom diaries, 
and to evaluate whether demographical, clinical and psychosocial differences exist 
between Rome IV-positive and Rome IV-negative subjects, in a well-defined Rome III IBS 
population. 
Materials and methods 
Study design 
In the current analyses, data from a well-phenotyped Dutch cohort study, the 
Maastricht IBS (MIBS) Cohort, on the phenotypical and genotypical characterization of 
IBS patients14-16, were evaluated. The study protocol has been approved by the 
Maastricht University Medical Center + (Maastricht UMC+) Committee of Ethics in 
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February 2009 and was executed according to the revised Declaration of Helsinki (64th 
WMA General Assembly, Fortaleza, Brazil, October 2013). Furthermore, the study has 
been registered in the US National Library of Medicine (http://www.clinicaltrials.gov, 
NCT00775060). 
Study participants 
Between July 2009 and May 2016, IBS patients aged 18-75 years were included in the 
Maastricht IBS cohort at the secondary/tertiary care outpatient department of 
Gastroenterology-Hepatology at the Maastricht UMC+ in Maastricht and via general 
practitioners practices in South-Limburg, the Netherlands. All subjects fulfilled the Rome 
III criteria (see Box 2.1) for IBS and were assigned the IBS subtype based on 
predominant bowel habit, i.e. diarrhea (IBS-D), constipation (IBS-C), a mix of diarrhea 
and constipation (IBS-M) or unspecified predominant bowel habit (IBS-U).3,17 Rome III 
criteria were evaluated in a face-to-face interview by a trained clinical researcher. 
Medical history was taken by a gastroenterologist and if indicated, GI endoscopy, 
abdominal imaging and/or blood, breath or fecal analyses were performed to exclude 
organic disease. A history of abdominal surgery, except for uncomplicated 
appendectomy, cholecystectomy or hysterectomy, was reason for exclusion. All 
subjects gave their written informed consent before participation.  
Data collection 
As subject inclusion was performed since 2009, Rome IV criteria were not collected in a 
face-to-face interview at the moment of inclusion. However, all participants completed 
an end-of-day diary on symptom severity and bowel habits, during 14 days, at the time 
of inclusion. Abdominal pain, amongst other symptoms, was scored using a 5-point 
Likert scale (1=not at all; 2=mild; 3=considerable; 4=severe; 5=extremely). Using this 
information, we retrospectively determined which subjects were highly likely to fulfill the 
Rome IV criteria, based on the presence of abdominal pain on at least one day in both 
the first and the second seven days (i.e. abdominal pain at least once a week). Rome IV 
criteria do not take into account abdominal pain severity, however, as we will use 
surrogate Rome IV criteria to evaluate differences between Rome IV-positive and -
negative IBS patients, we will report on two definitions for those criteria: ‘Definition 1: 
Abdominal pain score ≥2 once a week in each week’ and ‘Definition 2: Abdominal pain 
score ≥3 once a week in each week’. Only symptom diaries that were completed for at 
least 12 of the 14 days were considered eligible for analysis. 
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Information on demographics was collected using a predefined self-report 
questionnaire. Furthermore, subjects completed the gastrointestinal symptom rating 
scale (GSRS)18, hospital anxiety and depression scale (HADS)19,20 and rand 36-item 
short-form health survey (SF-36)21,22 for GI symptom severity, co-occurrence of 
depressive and/or anxiety symptoms and general quality of life, respectively.  
 
In addition, in a subset of participants a rectal barostat procedure was performed. 
Measurement of rectal perception was performed using a standardized perception 
protocol, during which 17 pressure steps between 0 and 50 mm Hg, based on a semi-
random staircase protocol, were applied. During each pressure step pain scores were 
reported on a 100 mm visual analogue scale (VAS). The cut-off value for visceral 
hypersensitivity was defined as a pain score ≥20 at pressure ≤26 mm Hg. A detailed 
description on the rectal barostat procedure was previously reported.23  
 
The end-of-day diary data were additionally used to perform an exploratory analysis on 
whether Rome III IBS patients, that do not fulfill (surrogate) Rome IV criteria for IBS, are 
likely to fulfill Rome IV criteria for other functional bowel disorders. Definitions that 
were used for retrospective evaluation of Rome IV diagnoses for functional constipation 
(FC), functional diarrhea (FD) and functional abdominal bloating/distension (FAB/D) 
are shown in Table S2.1. Since the symptom diary was designed for IBS and not 
specifically for assessing those other disorders, not all criteria could be definitively 
checked. 
Data and statistical analyses 
All analyses were performed using IBM SPSS Statistics, version 23 (IBM Statistics for 
Macintosh, Chicago, IL, USA). 
 
The total study population is referred to as ‘total’. Depending on whether subgroups 
are highly likely to fulfill Rome IV criteria based on the end-of-day diary or not they are 
referred to as ‘Rome IV-positive’ and ‘Rome IV-negative‘, respectively. Results for 
‘Rome IV-positive’ and ‘Rome IV-negative‘ are presented separately for both definitions 
of fulfilling Rome IV criteria: ‘Definition 1: Abdominal pain score ≥2 once a week in each 
week’ and ‘Definition 2: Abdominal pain score ≥3 once a week in each week’.  
 
Categorical data are presented as proportions and differences between groups are 
tested using 2 or Fisher’s exact test. Continuous data are presented as medians and 
interquartile ranges (IQR) and groups are compared using Mann-Whitney U test, taking 
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In total, 404 subjects that completed at least 12 days of the end-of-day symptom diary 
were included in the analyses: 293 (72.5%) were women and median age was 45 [IQR: 
28-59] years. Seventy-two per cent (N=291) was recruited from secondary/tertiary 
care and IBS subtypes (based on Rome III criteria) were distributed as follows: 140 
(34.7%) IBS-D, 81 (20%) IBS-C, 159 (39.4%) IBS-M and 24 (5.9%) IBS-U. Further 
characteristics of the total study population are shown in Table 2.1.  
IBS according to Rome IV criteria – Definition 1: Abdominal pain 
score ≥2 
Of the 404 IBS subjects diagnosed by Rome III criteria, 353 (87.4%) did meet the 
surrogate Rome IV criteria when assessed using the end-of-day symptom diary and the 
cut-off for abdominal pain severity of ≥2. 
 
Rome IV-positive subjects were more often female (74.5% vs. 58.8%, P<0.05), younger 
(45 vs. 53 years, P<0.05) and recruited from secondary/tertiary care (74.4% vs. 56.9%, 
P<0.05) compared to Rome IV-negative subjects. Additionally, visceral hypersensitivity 
assessed by rectal barostat was present more often in Rome IV-positive subjects (47.5% 
vs. 11.8%, P<0.001). Subtype distribution (i.e. based on Rome III criteria) was not 
different between both groups. 
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With regards to GI symptoms, Rome IV-positive versus -negative subjects reported 
higher scores in the end-of-day diary for all symptoms assessed (i.e. abdominal pain, 
abdominal discomfort, abdominal bloating, flatulence, constipation and diarrhea) and 
higher symptom scores for all five GSRS-domains, however, this was not statistically 
significant for indigestion syndrome.  
 
Furthermore, Rome IV-positive subjects showed a higher percentage of depressive 
(21.0% vs. 5.9%, P<0.001) as well as anxiety (37.6% vs. 21.6%, P<0.05) symptoms and 
lower physical composite scores (41.67 vs. 49.92, P<0.001) with regards to quality of 
life. Mental composite scores of SF-36 did not show a significant difference between the 
groups. Results are shown in Table 2.1. 
IBS according to Rome IV criteria – Definition 2: Abdominal pain 
score ≥3 
When using the surrogate Rome IV criteria as defined by at least one day of abdominal 
pain each week using the cut-off for abdominal pain severity of ≥3, of the 404 IBS 
subjects diagnosed by Rome III criteria, 249 (61.6%) were Rome IV-positive. 
 
In line with the findings above, i.e. regarding the cut-off of abdominal pain severity of ≥2, 
Rome IV-positive subjects were more often female, younger, recruited from 
secondary/tertiary care, more often hypersensitive on rectal barostat, showed higher 
symptom severity scores for all symptoms assessed in the end-of-day symptom diary 
and showed higher percentages of depressive as well as anxiety symptoms compared to 
Rome IV-negative subjects, when using the cut-off of ≥3. Likewise, subtype distribution 
(i.e. based on Rome III criteria) did not differ between the groups.  
 
Moreover, with regard to symptom severity on GSRS, Rome IV-positive versus -
negative subjects scored significantly higher on all domains including indigestion 
syndrome when using the cut-off of ≥3. Furthermore, Rome IV-positive subjects scored 
significantly lower on both physical composite score and mental composite score of SF-
36 compared to Rome IV-negative subjects. Results are shown in Table 2.1.  
Alternative Rome IV diagnoses in Rome IV-negative (IBS) subjects 
Of the Rome IV-negative (IBS) subjects, according to the surrogate Rome IV criteria 
using the cut-off for abdominal pain severity of ≥3, 34 (23.61%) fulfilled surrogate Rome 
IV-criteria for functional constipation, 50 (34.25%) for functional diarrhea and 37 
(25.69%) for functional abdominal bloating/distension. Results are shown in Table S2.2. 




This study demonstrates that 61.6% to 87.4% of Rome III IBS patients is likely to also 
fulfill the new Rome IV criteria for IBS, depending on the cut-off for abdominal pain 
severity used, when applying surrogate Rome IV criteria based on end-of-day symptom 
diaries. Regardless of the cut-off chosen, Rome IV-positive subjects were more often 
female, younger and recruited from secondary/tertiary care than Rome IV-negative 
subjects. Not only did they present with higher abdominal pain scores, but overall 
symptom severity was higher in Rome IV-positive subjects, including a higher percentage 
of visceral hypersensitivity as assessed by rectal barostat. Additionally, higher 
percentages of comorbid psychological symptoms and lower quality of life were found 
for Rome IV-positive subjects. Taken together, the current findings imply that the Rome 
IV IBS population will likely reflect a subgroup of Rome III IBS patients with more severe 
overall gastrointestinal symptomatology, psychological comorbidities and lower quality 
of life. 
 
To date, a recent study by Bai et al. investigated the agreement between Rome III and 
Rome IV criteria for IBS in a GI outpatient population in China. They found a moderate 
consistency between Rome III and Rome IV criteria, with prevalences of 12.4% and 6.1% 
based on Rome III and Rome IV criteria, respectively.24 Similarly, Whitehead and 
colleagues reported prevalences of 10.7% and 5.7%, respectively, in a large population-
based study.8,9 Our current study confirms this decrease in prevalence by introducing 
Rome IV criteria, within a well-defined Rome III IBS population. Additionally, in line with 
these previously reported findings, our cut-off for abdominal pain severity of ≥3 may be 
most robust to define those subjects highly likely to fulfill Rome IV criteria, based on 
end-of-day diary. 
 
We observed that Rome IV-positive subjects were more often of female gender than 
Rome IV-negative subjects. These differences were not demonstrated by Bai and 
colleagues.24 Differences in symptom severity between men and women, however, have 
been reported previously, indicating possible differences in pathophysiological 
mechanisms as well as in pain perception and coping strategies. A meta-analysis by 
Adeyemo and colleagues demonstrated that women are more likely to report 
abdominal pain than men.25 Furthermore, higher overall IBS symptom severity in female 
IBS patients has been reported by Bjorkman et al.26 These previous findings could 
explain the higher percentage of women in our Rome IV-positive IBS population 
compared to the Rome IV-negative subjects.  
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With regards to clinical differences between Rome III and Rome IV IBS subjects, Bai et 
al. reported higher abdominal pain scores for Rome IV, but no differences in abdominal 
discomfort, abdominal bloating or demographic characteristics. In contrast, our study 
shows significantly higher scores for abdominal discomfort, bloating, flatulence, diarrhea 
and constipation, apart from abdominal pain. A possible explanation for the discrepancy 
between these studies is the method of data collection. Bai and colleagues 
retrospectively assessed the presence of above-mentioned symptoms at one time point, 
whereas in our study symptom severity scores were determined daily, using an end-of-
day diary during 14 days.   
 
As a study by Engsbro et al. demonstrated that IBS subtype classification differs 
depending on whether retrospective (i.e. Rome Diagnostic Questionnaire) or 
prospective methods (i.e. diary cards) are used27, we did not use the symptom diary to 
asses the IBS subtypes. However, we feel that the end-of-day diary provides an 
objective overview of present symptoms during a 14-day period and therefore can be 
used to identify patients highly likely to fulfill the Rome IV criteria. Furthermore, Rome 
IV criteria require abdominal pain to be present at least once a week on average during 
the last three months. The end-of-day symptom diary as used only provides us with 
information about the past two weeks. However, all subjects fulfilled Rome III criteria 
assessed using the Rome III Diagnostic Questionnaire, which also requires the 
abdominal complaints to be present during the previous three months. Therefore, we 
think that the surrogate Rome IV criteria are a reliable reflection of the Rome IV 
Diagnostic Questionnaire.  
 
This is the first study focusing on clinical differences between Rome III and Rome IV IBS 
subjects. In conclusion, the current study underlines a decrease of IBS prevalence when 
using (surrogate) Rome IV compared to Rome III criteria. In addition to these findings, 
the question arises how to deal with the Rome IV-negative patient population 
presenting with IBS-symptoms in both primary and secondary/tertiary care and with 
regard to future clinical and mechanistic studies.  
 
First, it might be interesting to explore whether alternative Rome IV disorders can now 
be diagnosed in these subjects, for example functional constipation, functional diarrhea 
or functional abdominal bloating/distension. An exploratory analysis in the current study 
demonstrates that 24% is likely to fulfill Rome IV-criteria for FC, 34% for FD and 26% for 
FAB/D. These results should, however, be interpreted with caution, since these 
diagnoses are based on surrogate criteria, using an IBS-specific end-of-day symptom 
diary. Nevertheless, this suggests that an additional 16% of Rome III IBS patients will 
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not fulfill any of these Rome IV diagnoses. Possibly, a small subset might be defined as 
Rome IV unspecified functional bowel disorder. However, it is very likely that patients 
reporting abdominal pain or bloating/distension less than once weekly (without 
predominant constipation or diarrhea), will not fulfill any Rome IV diagnosis due to the 
new frequency threshold.  
 
Second, as the Rome criteria are not that universally used in routine clinical practice, in 
our opinion, patients with milder functional GI symptoms seeking health care, but not 
fulfilling one of the Rome IV diagnoses, should still be managed as functional GI 
disorders. With regard to future IBS research, patient inclusion should be based on the 
Rome IV criteria, in order to aim at agreement between studies. 
 
Nevertheless, this study demonstrates that the Rome IV IBS population is represented 
by younger females with higher overall gastrointestinal symptom severity, including 
comorbid psychological symptoms and lower quality of life compared to the Rome III 
IBS population. Therefore, results from Rome III IBS studies may not be directly 
comparable to those from Rome IV IBS populations, which has implications for future 
IBS research in particular. 
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Table S2.2 Distribution of alternative Rome IV diagnoses, based on surrogate Rome IV criteria, within 
Rome IV-negative (IBS) population, i.e. assessed using end-of-day symptom diaries*. 
 Rome IV-negative 
N=155 
Functional constipation, N (%) (N=373) 34 (23.61) a 
Functional diarrhea, N (%) (N=376) 50 (34.25) b 
Functional bloating/distension, N (%) (N=370) 37 (25.69) a 
No alternative Rome IV diagnosis, N (%) (N=370) 23 (15.97) a 
a-d Number of subjects included in analyses: a144; b146. * Rome IV IBS diagnosis according to ‘Definition 2: 
Abdominal pain score ≥3 once a week in each week’. 
 







Irritable Bowel Syndrome (IBS) is a brain-gut-disorder, of which the natural course 
varies between patients and is difficult to predict. This study aimed to evaluate symptom 
evolution over a five-year follow-up period and to identify baseline predictors for 
symptom severity and quality of life (QoL) at follow-up. 
 
Methods 
Maastricht IBS Cohort participants completed questionnaires upon inclusion regarding 
demographics and lifestyle, gastrointestinal (GI) symptoms, anxiety and depression, and 
QoL. The same questionnaires, in addition to others, were completed after five years. 
Rome criteria were confirmed face-to-face at initial enrollment and through telephonic 
interviews at follow-up. 
 
Results  
At a mean follow-up of 4.7 years, 379 patients were approached of whom 203 (53.7%) 
responded. Of these, 161 were reached by telephone and analyzed; 49 (30.4%) did not 
fulfill the Rome III criteria at follow-up and had lower levels of GI symptoms and GI-
specific anxiety compared to those remaining Rome III-positive (P<0.001). However, 
Rome III-negative patients had comparable levels of QoL and life satisfaction, comorbid 
anxiety and depression, work absenteeism and impaired productivity. No baseline 
predictors were found for being Rome III-positive or -negative. However, greater age 
and lower baseline physical QoL predicted lower physical QoL at follow-up (P<0.005 
and P<0.01, respectively), while lower baseline mental QoL predicted lower mental 
QoL at follow-up (P=0.005). Additionally, higher anxiety and depression scores at 
follow-up were associated with lower QoL and life satisfaction at follow-up (P<0.001). 
 
Conclusions  
Long-term QoL and general well-being might depend on concurrent psychological 
symptoms, rather than GI symptom improvement. 
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Irritable Bowel Syndrome (IBS) is a brain-gut-disorder characterized by a chronic 
relapsing-remitting nature of symptoms, including abdominal pain and altered bowel 
habits. Global prevalence, based predominantly on the Rome III criteria, is estimated at 
5-20%1, with varying rates according to geographical area and diagnostic criteria used.2 
Recent studies using the more restrictive Rome IV criteria point to lower prevalence 
rates of 5-6%.3,4  
 
Although the exact pathophysiology of IBS remains incompletely understood, a 
multifactorial origin is generally recognized, in which dysregulation of the brain-gut-axis 
has a central role. Other factors include aberrant neuroimmune interactions, visceral 
hypersensitivity, genetic susceptibility, microbiome alterations, and psychosocial 
factors.5,6 As interference of IBS with patients’ everyday lives is extensive7 and treatment 
results are often unsatisfactory, quality of life is low and comparable to chronic somatic 
diseases.8 
 
Given the heterogeneous nature of the disorder, symptom patterns vary widely both 
between and within IBS patients and predicting individual disease courses remains 
challenging. IBS is known as a chronic, in many patients lifelong, condition with 
fluctuating gastrointestinal (GI) symptoms. Symptoms such as abdominal pain, 
constipation, and diarrhea are known to occur in episodes of several days followed by 
days without symptoms.9 In addition, transitions from one predominant bowel habit 
type to the other are common and occur in up to 75% of patients.10-12 Quality of life, on 
the other hand, has been shown to be relatively stable over a three-month period.13 
With regard to long-term symptom variability, several studies have investigated the 
disease course of IBS and have shown varying results with respect to symptom severity 
and quality of life. The majority of the prospective studies had a follow-up period of 
approximately one year, which is relatively short for a condition such as IBS. In addition, 
there is a lack of follow-up data for the Dutch population. As implications of IBS on 
quality of life have shown to vary considerably between different countries14, it is of 
added value to expand earlier findings and investigate the natural history of IBS in a 
Dutch, well-characterized population. 
 
Finally, as IBS is a symptom-based diagnosis, it is of interest to assess how symptoms 
evolve over time and how these symptoms and long-term quality of life relate to the 
Rome diagnostic criteria for IBS, in particular when they are confirmed in a telephonic 
interview rather than a purely survey-based assessment at follow-up measurements.  
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Hence, the current follow-up study, which is part of a large prospective cohort study on 
the pheno- and genotypical characterization of IBS in the Netherlands, aimed 1) to gain 
further insight into symptom evolution and long-term quality of life over a five-year 
follow-up period; 2) to identify baseline predictors for higher symptom severity and 
greater quality of life impairment at follow-up; and 3) to assess how point 1 and 2 differ 
between patients that remain Rome III-positive and those who are Rome III-negative at 
follow-up. 
Materials and methods 
Irritable bowel syndrome cohort study 
Since 2009, patients with IBS between 18 and 75 years of age who visit the outpatient 
clinic of the Gastroenterology-Hepatology division of the Maastricht University Medical 
Center+ (MUMC+), The Netherlands, are requested to enroll in the Maastricht IBS 
(MIBS) Cohort study. The MUMC+ is a university hospital with a combined secondary 
and tertiary care service in the area of South Limburg, The Netherlands. In addition, 
patients with IBS are recruited via general practitioners in the area of South Limburg. 
The MIBS Cohort is an extensively phenotyped cohort of IBS patients with a follow-up 
measurement five years after initial inclusion.15-17 The research protocol had been 
approved by the MUMC+ Committee of Ethics and all study procedures were 
performed in compliance with Good Clinical Practice Guidelines and according to the 
revised Declaration of Helsinki.18 The study had been registered in the US National 
Library of Medicine (NCT00775060). All subjects gave a written informed consent prior 
to participation.  
Subjects 
Patients who had been included at least three years (five +/- two years) before the 
current study, that is, patients included in the MIBS cohort between September 2009 
and September 2014, were eligible for participation in the current follow-up study. All 
patients fulfilled the Rome III criteria for IBS at the time of inclusion, which was 
confirmed by a trained clinical investigator in a face-to-face interview. Patients were 
assigned IBS subtypes based on their reported predominant stool-type, i.e. diarrhea 
(IBS-D), constipation (IBS-C), a mix of diarrhea and constipation (IBS-M), or unspecified 
predominant bowel habit (IBS-U). Their medical history was taken and, if any alarm 
symptoms were present or if deemed necessary by the gastroenterologist, GI 
endoscopy, abdominal imaging, and/or blood, breath and/or fecal analyses were 
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performed to exclude organic diseases. A history of abdominal surgery automatically led 
to exclusion, except for an uncomplicated appendectomy, hysterectomy, or 
cholecystectomy. 
Data collection 
At time of enrollment in the MIBS Cohort, patients completed several questionnaires, 
i.e. on demographics and lifestyle, GI symptoms, symptoms of comorbid anxiety and 
depression, and general quality of life. The data were obtained administering a 
predefined self-report questionnaire on demographics and lifestyle, an end-of-day 
14 days symptom diary, the gastrointestinal symptom rating scale (GSRS, scale 1-7, 
generates symptom scores for the following subdomains: abdominal pain, reflux, 
diarrhea, constipation, indigestion)19, the hospital anxiety and depression scale (HADS, 
scale 0-3, a screening tool for anxiety and depression)20,21, and the rand 36-item short-
form health survey (SF-36, scale 1-6, generates a physical and a mental quality of life 
component summary).22,23 
 
Approximately five years (+/- two years) after inclusion, patients were invited to 
complete several follow-up questionnaires. These included the same questionnaires that 
were filled out at baseline (with the exception of the end-of-day diary), with the addition 
of other questionnaires to further standardize the phenotyping of our population and to 
allow valid comparisons to other cohorts (i.e. international harmonization). Additional 
questionnaires included: the GSRS specific for IBS (GSRS-IBS, scale 1-7, generates 
symptom scores for the following subdomains: abdominal pain, bloating, constipation, 
diarrhea, satiety)24; the Visceral Sensitivity Index (VSI, scale 1-6, assesses GI-specific 
anxiety or, in other words, fear for GI symptoms)25; and the Satisfaction With Life Scale 
(SWLS, scale 1-6, assesses individual overall satisfaction with life).26-28 As it is known that 
IBS can affect the ability to work29, a self-report questionnaire regarding productivity 
(Productivity Cost Questionnaire (PCQ), validated for the Dutch situation) was 
included as well.30,31 Patients could opt for paper or digital web-based (invitation was 
sent via email) questionnaires to encourage participation. One reminder was sent when 
no response had been received within one month. A trained clinical investigator 
contacted all patients who did respond and confirmed the Rome III diagnostic criteria 
during a telephonic interview with them. Patients were reassigned IBS subtypes based 
on their predominant bowel habit, during the follow-up measurement. Reliable 
information on treatment history was not available for the majority of patients as this 
was not registered systematically during the follow-up period. Furthermore, many 
patients underwent self-treatment or treatment via their primary care physician, of 
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which data were not available and were therefore not included in the analysis of the 
current study.  
Statistical analysis 
All statistical analyses were carried out using IBM SPSS statistics 23.0 (Chicago IL, USA) 
and GraphPad Prism 6.0 (La Jolla, CA, USA) for Macintosh. Continuous data are 
presented as medians and interquartile ranges (IQR) and categorical data as proportions 
(%). To compare (non-parametric) continuous data between subgroups, Mann-Whitney 
U tests were used. Wilcoxon-signed-rank tests were used to evaluate differences within 
subjects over time. For categorical data, groups were compared using the Chi-square or 
Fisher’s exact test and differences over time were evaluated using the McNemar’s test. 
Correlations were assessed according to Spearman. To decrease the false discovery 
error rate induced by multiple testing, a post-hoc correction was applied using the 
Benjamini-Hochberg step-up procedure.32  
 
The patients participating in the follow-up were divided into two groups for comparison 
and further analyses, 1) Rome III-positive: patients who still fulfilled the Rome III criteria 
for IBS at follow-up; 2) Rome III-negative: patients who did not fulfill the Rome III criteria 
for IBS at follow-up. Multivariable logistic and linear regression models, respectively, 
were used to identify independent baseline predictors for 1) the presence of IBS 
according to the Rome III diagnostic criteria at follow-up; 2) quality of life at follow-up. 
We also used linear regression models to identify characteristics at follow-up that were 
associated with quality of life at follow-up. The   of the linear regression analyses signifies 
one-point change in the mental or physical quality of life component summary. 
Results 
Study population for follow-up of the Rome III irritable bowel 
syndrome cohort 
At a mean follow-up time of 4.7 (SD 1.5) years, 379 patients with IBS, Rome III-positive 
at inclusion and participating at least three (five +/- two) years in the Maastricht IBS 
cohort, were approached for participation in the follow-up measurement. A total of 203 
subjects (53.7%) responded by completing the electronic or paper questionnaires. Of 
these, 161 could be reached by telephone to confirm the Rome criteria, and these did 
not differ in demographics nor in symptom scores when compared to the 42 subjects 
that were not reached. A study flowchart is shown in Figure 3.1.  
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Follow-up – Demographics, clinical characteristics, and symptoms of 
the Rome III-positive and –negative patients  
The 161 patients in whom IBS criteria could be checked by phone were included in the 
final analysis. The majority of patients was female (74.5%) and median age was 53 years 
old (IQR=36-65).  
 
In total, 49 out of the 161 (30.4%) did no longer fulfill the Rome III criteria for IBS at 



























Figure 3.1 Flowchart of follow-up of N=379 IBS patients included in the Maastricht IBS Cohort study. N; 
number, IBS; Irritable Bowel Syndrome. 
 
Demographical and clinical characteristics at follow-up of the Rome III-negative and Rome 
III-positive patients are shown in Table 3.1. The groups did not differ significantly in age or 
gender, although the Rome III-positive group was slightly younger. As expected, Rome III-
negative patients had significantly lower GI symptom scores compared to Rome III-positive 
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patients (assessed by both the GSRS and GSRS-IBS) at follow-up, which was shown on 
each of the following subdomains: abdominal pain, bloating, diarrhea, constipation, 
indigestion (all P<0.001), and satiety (P<0.005). Despite having less GI symptoms, they did 
not have significantly higher quality of life or more satisfaction with life. Although Rome III-
negative patients had significantly less GI-specific anxiety at follow-up (P<0.001), they did 
not have less symptoms of general anxiety and depression. Moreover, levels of impaired 
work productivity and absence from work did not differ between both groups.  
 
Table 3.1 Demographical and clinical characteristics, at a five-year follow-up period, of patients who still 
fulfilled the Rome III criteria for IBS at follow-up (FU Rome III-positive) and those who did not 
(FU Rome III-negative). 
Characteristics at follow-up FU Rome III-positive FU Rome III-negative 
 N=112 N=49 
Age, median years (IQR)  52 (34-65) 57 (45-67) 
Female gender, N (%) 84 (75.00) 36 (73.47) 
BMI, median kg m-2 (IQR)  25.15 (21.88-28.70) 25.35 (21.62-28.37) 
GSRS, median (IQR) 
   Abdominal pain 
   Reflux syndrome 
   Diarrhea syndrome 
   Constipation syndrome 













GSRS-IBS, median (IQR) 
   Abdominal pain 
   Bloating 
   Constipation 
   Diarrhoea 













Comorbid-FD, N (%) 61 (55.00) 20 (41.67) 
Rome IV-positive IBS, N (%) 69 (61.61) - 
HADS, score >8, N (%) 
   Depressive symptoms 







GI-specific anxiety, median (IQR) 24.00 (13.00-37.00) 8.00 (4.00-23.00)*** 
Quality of life, median (IQR) 
   PCS 







Satisfaction with life, N (%) 
   Very unsatisfied 
   Unsatisfied 
   Below average satisfaction 
   Averagely satisfied 
   Satisfied 















Absence from work, N (%) 





N, number of patients included in the analysis; IQR, Inter Quartile Range; BMI, Body Mass Index (kg m-2); 
GSRS, gastrointestinal symptom rating scale; FD, Functional Dyspepsia; HADS, hospital anxiety and depression 
scale; PCS, physical quality of life composite summary as assessed by SF-36; MCS, mental quality of life 
composite summary as assessed by SF-36; GI, gastrointestinal. Numbers may not add up to total due to 
missing. ***P<0.001 versus Rome III-positive; **P<0.005 versus Rome III-positive. 
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Baseline - Demographics, clinical characteristics, and symptoms of 
the Rome III-positive and –negative patients 
Table 3.2 shows baseline demographics and clinical characteristics (at inclusion time into 
the cohort) of patients who were Rome III-positive and -negative at follow-up.  
 
Table 3.2 Baseline demographical and clinical characteristics, of patients still fulfilling the Rome III criteria 
for IBS at follow-up (FU Rome III-positive) and those who did not (FU Rome IV-negative). 
Characteristics at inclusion FU Rome III-positive FU Rome III-negative 
 N=112 N=49 
Age, median (IQR)  48 (29-61) 51 (39-61) 
Gender, N female (%) 84 (75.0) 36 (73.47) 
BMI, median kg m-2 (IQR) 23.70 (21.50-28.70) 24.40 (21.50-28.05) 
Secondary/tertiary care, N (%) 72 (64.29) 35 (71.43) 
IBS subtype, N (%) 
   IBS-D 
   IBS-C 
   IBS-M 











GSRS, median (IQR) 
   Abdominal pain 
   Reflux syndrome 
   Diarrhea syndrome 
   Constipation syndrome 













Diary, median score (IQR) 
   Discomfort 
   Pain 
   Constipation 
   Diarrhea 
   Bloating 
   Flatulence 
   Belching 



















HADS, score >8, N (%) 
   Depressive symptoms 





6  (5.71) 
17  (38.64) 
Quality of life, median (IQR) 
   PCS 







N, number of patients included in the analysis; IQR, Inter Quartile Range; BMI, Body Mass Index (kg m-2); 
secondary/tertiary care as compared to primary care; GSRS, gastrointestinal symptom rating scale; HADS, 
hospital anxiety and depression scale; PCS, physical quality of life composite summary as assessed by SF-36; 
MCS, mental quality of life composite summary as assessed by SF-36. Numbers may not add up to total due to 
missing. Please note that several variables shown in Table 3.1 derive from questionnaires not administered at 
baseline and could therefore not be considered in the comparison of baseline variables in Table 3.2. 
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With regard to baseline levels of GI symptom severity (assessed by the GSRS, as 
baseline GSRS-IBS data were not available), it can be noted that Rome III-negative 
patients had slightly lower baseline scores for abdominal pain. Nevertheless, after 
correction for multiple comparisons, this did not reach statistical significance nor did 
other GI symptoms differ significantly between the groups at baseline. In terms of 
general anxiety, depression, and general quality of life scores, no baseline differences 
were observed between Rome III-positive and -negative patients (Table 3.2). Moreover, 
the proportion of patients that had been recruited for the cohort from the primary care 
setting did not differ between Rome III-positive and -negative patients (Table 3.2). In 
addition, the distribution in baseline IBS-subtypes did not differ between Rome III-
positive and -negative patients (Table 3.2). 
Symptom evolution over time 
Table 3.3 shows the evolution of clinical characteristics and symptoms over time by 
pairwise comparisons between baseline and follow-up measurements. Overall, 
improvements in GI symptom severity (assessed by the GSRS, as baseline GSRS-IBS 
data were not available), general quality of life, and general anxiety and depression over 
a five-year period were small and did not reach significance in patients that still met the 
Rome III-diagnostic criteria at follow-up. Symptom severity for abdominal pain, diarrhea, 
constipation, and indigestion did improve significantly over time in the Rome III-negative 
patients, although they still had ‘low to moderate’ levels of symptoms after five years, 
with a median abdominal pain GSRS score of 2.33 (IQR=1.33-3.00), and a median 
indigestion GSRS score of 2.88 (IQR=2.25-3.94). However, similar to the Rome III-
positive patients, the Rome III-negative patients did not improve significantly in quality of 
life during the follow-up period. In addition, their comorbid depression scores were 
relatively unaltered.  
 
With regard to IBS subtype based on predominant bowel habit, Supplementary Figure 
S3.1 illustrates the proportion of IBS subtypes at baseline and at follow-up. Sixty-two 
(55.4%) out of 112 Rome III-positive patients had changed IBS-subtype during the 
follow-up period. In Supplementary Figure S3.2, the within-patient subtype changes from 
baseline to follow-up are shown. IBS-D appeared the most stable subtype (72.5% of 
Rome III-positive unchanged), whereas IBS-M and IBS-C were least stable (76,6% and 
60.9% of Rome III-positive changed respectively). 
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Table 3.3 Clinical characteristics, at baseline and at time of follow-up, of patients who still fulfilled the 
Rome III criteria for IBS at follow-up (Rome III-positive) and patients who did not (Rome III-
negative).  
 Baseline Follow-up 
FU Rome III-positive IBS patients, N=112   
BMI, median kg m-2 (IQR) 23.70 (21.45-28.70) 24.77 (21.92-28.60)** 
GSRS, median (IQR) 
   Abdominal pain 
   Reflux syndrome 
   Diarrhea syndrome 
   Constipation syndrome 













HADS, score >8, N (%) 
   Depressive symptoms 







Quality of life, median (IQR) 
   PCS 







FU Rome III-negative IBS patients, N=49  
BMI, median kg m-2 (IQR) 24.50 (21.30-28.08) 25.35 (21.68-28.73) 
GSRS, median (IQR) 
   Abdominal pain 
   Reflux syndrome 
   Diarrhea syndrome 
   Constipation syndrome 













HADS, score >8, N (%) 
   Depressive symptoms 







Quality of life, median (IQR) 
   PCS 







N, number of patients included in the analysis; IQR, Inter Quartile Range; BMI, Body Mass Index (kg m-2); 
GSRS, gastrointestinal symptom rating scale; HADS, hospital anxiety and depression scale; PCS, physical 
quality of life composite summary as assessed by SF-36; MCS, mental quality of life composite summary as 
assessed by SF-36. Numbers may not add up to total due to missing. ***P<0.001 vs. baseline; **P<0.005 vs. 
baseline; * P<0.01 vs. baseline; ∞P<0.05 vs. baseline. 
 
Multivariable regression model 
No baseline predictors for fulfilling the Rome III diagnosis for IBS at follow-up could be 
identified with regression analyses. When looking for independent baseline predictors 
concerning quality of life at follow-up for both groups taken together (N=161), the 
combined regression model that included age, gender, baseline GI symptom severity, 
and baseline anxiety and depression, showed that only younger age (  -0.16, 95% CI 
-0.26; -0.06, P=0.002) and higher physical quality of life at baseline (  0.59, 95% CI 0.41; 
0.78, P<0.001) predicted higher physical quality of life at follow-up. Likewise, only higher 
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mental quality of life at baseline (  0.46, 95% CI 0.15; 0.77, P=0.004), but not baseline 
depression or anxiety scores, predicted higher mental quality of life at follow-up. 
 
When looking for characteristics at follow-up that were associated with quality of life at 
follow-up, general anxiety (  -1.49, 95% CI -1.90; -1.07, P<0.001), and depression levels 
(  -1.00, 95% CI -1.48; -0.53, P<0.001) at follow-up were the only two parameters 
independently associated with mental quality of life at follow-up after correcting the 
model for age, gender, IBS-subtype, GI symptom severity, GI-specific anxiety, and 
general anxiety and depression. No characteristics at follow-up were found to 
independently associate with physical quality of life at follow-up. Baseline IBS-subtypes 
were not included in the models that looked for baseline predictors, as univariate 
analyses showed no significant differences in subtypes between groups, that is, the 
distribution in baseline subtypes did not differ significantly between Rome III-negative 
and -positive patients. Inclusion of these variables into the model would have decreased 
statistical validity and increased the probability of type I errors. 
Discussion 
In the current prospective study, we evaluated the natural symptom evolution of 
patients with IBS in the Maastricht IBS cohort over time.33 We demonstrated that 30.4% 
of patients did no longer fulfill the Rome III criteria after a five-year follow-up period. 
The most salient finding is that quality of life did not improve significantly in patients who 
showed a decrease in gastrointestinal symptom severity (i.e. being Rome III-negative at 
follow-up), compared to patients who had unaltered symptom severity over time 
(Rome III-positive). In addition, general wellbeing in terms of comorbid general anxiety 
and depression, work absenteeism and productivity, and life satisfaction were also 
comparable in those who still fulfilled the Rome III criteria at follow-up, when compared 
to those who did not.  
 
Several studies have investigated IBS symptom evolution in relation to diagnostic criteria 
in patient cohorts, with varying results. A study by Williams et al. using the Rome II 
criteria reported that 52% had no IBS two years after web-based diagnosis12, Ford et al. 
found that 28% did not meet the Manning criteria after 10 years34, Mearin et al. reported 
that abdominal pain frequency decreased in 26% after one year35, and more recently, 
Card et al. reported that 27% of their large study population did not fulfill the Rome III 
criteria after one year.36 Except for the study by Williams et al., the proportion of 
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patients who do not meet the diagnostic criteria after a follow-up period is thus in line 
with the findings of this follow-up study in our Dutch cohort.  
 
Given that clinical treatment decisions often rely on prognostic predictions of the 
disease course, we sought to identify baseline predictors for a less favorable disease 
course. This study, however, did not show any baseline characteristics associated with 
meeting the Rome III criteria at follow-up. As IBS is a highly heterogeneous disorder, 
larger study populations might be necessary to investigate what factors influence and 
thereby predict the natural disease course in (subgroups of) patients with IBS.  
 
Rather unexpectedly, we found that a decrease in GI symptom severity did not lead to 
an improved quality of life in our study. Clevers et al. recently evaluated longitudinal 
symptom changes over time and, in contrast to our results, found that patients with 
lower GI symptom severity had significantly higher quality of life scores.37 They also 
demonstrated that GI-specific anxiety is associated with an increase in GI symptom 
severity, which is in agreement with our results as GI-specific anxiety was significantly 
lower in the group that did not fulfill the Rome III criteria. The inconsistency between 
our data in terms of quality of life might be explained in part by the different 
questionnaires used. Clevers et al. used an IBS specific questionnaire, the IBS-QoL38, 
which assesses more disease specific changes in quality of life in contrast to generic 
quality of life instruments, such as the SF-36 that we used. Our data can therefore also 
be compared with other diseases and with the general population. Both the Rome III-
positive and -negative group showed lower mean quality of life than the mean of a 
Dutch population sample39 and of a USA based population without a functional GI 
disorder.40 Additionally, we used the validated SWLS to score overall life satisfaction. 
This has been used in healthy persons and in patients with Crohn’s disease41, but, to our 
knowledge, not in IBS patients. We found scores comparable to the ones reported by 
Crohn’s disease patients for both the Rome III-positive and -negative group.  
 
In contrast to GI symptom severity, we found that quality of life did not improve over 
time in those that were Rome III-negative at follow-up. The data reported here suggest 
that concurrent, but not baseline, psychological comorbidities are more predictive of 
this impaired long-term quality of life than GI symptom severity. Several studies in IBS 
have found similar results, in particular for the mental health related quality of life; i.e. 
Naliboff et al. reported that psychological distress had a stronger effect on health related 
quality of life than GI symptoms42, Koloski et al. reported that depression was 
independently associated with mental quality of life43, and Addante et al. reported that 
perceived stress, and anxiety and depression were significant predictors for mental 
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health related quality of life.44 This raises the question whether current treatment goals 
for IBS in daily clinical practice should be revised. Gaining insight into which symptoms 
specifically affect a patient’s quality of life can aid in reprioritizing personal treatment 
goals and increase the chance of a successful individualized treatment trajectory.45 
Currently, treatment is merely targeted towards the patient’s predominant GI 
symptoms and in many cases, this entails primary treatment of pain, constipation, or 
diarrhea. Targeting GI symptom improvement without characterizing the full extent of 
the disorder and possible psychosocial modifiers may therefore contribute to treatment 
failure concerning quality of life over time. A helpful and pragmatic framework in this 
regard has been suggested by the Rome expert panel.45 By following their five-step 
approach, clinicians can identify if and which psychological factors contribute to the 
disease burden in the individual patient and consider psychological treatments. In some 
patients, this might include the use of pharmacological neuromodulators46, but other 
therapy options include cognitive behavioral therapy (CBT), gut-directed 
hypnotherapy47, and dynamic psychotherapy.48 Due to the relative lack in therapist 
availability, clinical implementation of these therapies is still limited. Recent attempts to 
reduce resource use without compromising effectiveness may assist in making 
psychological treatment more widely available; e.g. group hypnotherapy49, internet-
delivered exposure-based CBT50, and home-based CBT.51 In that light, it will be 
interesting to explore whether these developments can affect long-term quality of life 
and well-being in patients with IBS. 
 
Several limitations of the current study should be noted. Only two time-points within 
the five-year period were assessed; no further data were available about the period in 
between the baseline and follow-up measurement, including data on treatment received 
in this period. Therefore, we can neither comment about the frequency and duration of 
IBS flares within these five years, nor about the effect of treatment on symptoms, nor on 
the causal order of the impaired quality of life and psychological comorbidities. 
Moreover, selection bias cannot be excluded. Follow-up cohort studies depend on long-
term dedication of their participants and the proportion of non-responders (loss to 
follow) in this study was 46.4%. To assess for potential selection bias, we tested for 
differences in baseline characteristics between responders and non-responders at 
follow-up. The groups did not differ in baseline demographic and lifestyle characteristics, 
nor in baseline symptom scores and subtypes (data not shown). Hence, there is no clear 
reason to assume that the non-responders would have had different outcomes at 
follow-up. Finally, a larger sample size would have been desirable. Due to a relatively 
small Rome III-negative group, small effects concerning quality of life or other 
parameters could have been missed, especially since we have corrected for multiple 
153719-Weerts_BNW.indd   62 08-09-2021   12:03153719- eerts_BN _compleet.indd   62 08-09-2021   12:06
IBS symptoms and quality of life 
63 
3 
comparisons. Although we argue that this adjustment improves the reproducibility of 
our results, an unnecessarily high false negative rate cannot be ruled out. Because of the 
small sample size, it is important that our findings are corroborated in other cohorts of 
patients with IBS. Until then, findings should be considered exploratory and appropriate 
caution should be taken when interpreting the results of the current study.  
 
Strengths of this prospective follow-up study include the heterogeneous and well-
characterized Maastricht IBS cohort population, i.e. in-depth phenotyping enables 
comparison to other large cohorts and future studies should explore possibilities of 
pooling data from different centers to cluster phenotypes and validate the robustness of 
findings such as the ones reported here. Moreover, since we have recruited patients 
from both primary and secondary/tertiary care settings (Table 3.1), our population is 
representative for the general Dutch IBS population. Another strength is the evaluation 
of the Rome criteria in a telephonic follow-up interview with patients. Due to the 
current lack of validated biomarkers, IBS remains a symptom-based diagnosis for which 
the Rome criteria are used to aid diagnostic accuracy, both in research and clinical 
settings.52 Since the Rome criteria have not been developed nor validated as a self-
administered questionnaire, asking patients to complete the Rome criteria without 
supervision by a trained researcher may lead to bias and over- or under-estimation of 
the actual diagnosis, as previously demonstrated by Lovell et al..2 In contrast to earlier 
studies on follow-up of IBS, our study method implied a complete reevaluation of the 
diagnosis in a telephonic interview and, thus, allows for a more valid and less biased 
interpretation of Rome diagnosed IBS prevalence over time.  
 
In conclusion, the current prospective study contributes to existing insight regarding 
symptom evolution over time in IBS patients and showed that 30% of patients did no 
longer fulfill the Rome III criteria after a five-year follow-up period. However, the 
decrease in GI symptom severity (i.e. being Rome III-negative at follow-up), did not 
impact quality of life nor life satisfaction. Our results indicate that long-term quality of life 
and general well-being might depend on comorbid psychological symptoms, i.e. affective 
states, rather than gastrointestinal symptom severity. 
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Figure S3.1 Proportion of patients with IBS-D, IBS-C, IBS-M, IBS-U, and No IBS (at follow-up) in the total 
population analyzed, N=161, and the proportion of patients with IBS-D, IBS-C, IBS-M, IBS-U in 
the population that was Rome III-positive at follow-up, N=112. The figure does not account for 
transitions of individual patients to different subtypes. N; number, IBS; Irritable Bowel 
Syndrome. IBS-D; Irritable Bowel Syndrome, diarrhea predominant subtype. IBS-C; Irritable 
Bowel Syndrome, constipation predominant subtype. IBS-M; Irritable Bowel Syndrome, mixed 
stool type subtype. IBS-U; Irritable Bowel Syndrome, undefined subtype. 
 













































Figure S3.2 Pie slices represent the proportion of patients with a particular IBS subtype at follow-up (please 
refer to legend for information on which subtype). The percentage depicted within the pie 
represents the proportion of patients that were diagnosed as having the same IBS subtype at 
follow-up, as at baseline. IBS-D; Irritable Bowel Syndrome, diarrhea predominant subtype. IBS-
C; Irritable Bowel Syndrome, constipation predominant subtype. IBS-M; Irritable Bowel 
Syndrome, mixed stool type subtype. IBS-U; Irritable Bowel Syndrome, undefined subtype. 
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Abdominal pain in irritable bowel syndrome (IBS) remains challenging to treat 
effectively. Researchers have attempted to elucidate visceral nociceptive processes in 
order to guide treatment development. Transient Receptor Potential (TRP) channels 
have been implied in the generation (TRPV1, TRPV4, TRPA1) and inhibition (TRPM8) of 
visceral pain signals. Pathological changes in their functioning have been demonstrated in 
inflammatory conditions, and appear to be present in IBS as well. Our aim was to 
provide a comprehensive review of the current literature on TRP channels involved in 
visceral nociception. In particular, we emphasise the clinical implications of these 
nociceptors in the treatment of IBS. 
 
Methods 
Evidence to support this review was obtained from an electronic database search via 
PubMed using the search terms “visceral nociception”, “visceral hypersensitivity”, “irritable 
bowel syndrome” and “transient receptor potential channels”. After screening the abstracts 
the articles deemed relevant were cross-referenced for additional manuscripts. 
 
Results 
Recent studies have resulted in significant advances in our understanding of TRP channel 
mediated visceral nociception. The diversity of TRP channel sensitization pathways is 
increasingly recognised. Endogenous TRP agonists, including poly-unsaturated fatty acid 
metabolites and hydrogen sulphide, have been implied in augmented visceral pain 
generation in IBS. New potential targets for treatment development have been 
identified (TRPA1 and TRPV4), and alternative means of affecting TRP channel signalling 
(partial antagonists, downstream targeting and RNA-based therapy) are currently being 
explored.   
 
Conclusions 
The improved understanding of mechanisms involved in visceral nociception provides a 
solid basis for the development of new treatment strategies for abdominal pain in IBS. 
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Irritable bowel syndrome (IBS) is a gastrointestinal disorder characterized by chronic 
recurrent abdominal pain and alterations in bowel habit. The pathophysiology of IBS is 
incompletely understood, which poses obstacles in the search for effective therapeutic 
approaches. While the defecation pattern can generally be managed adequately with 
pharmacotherapy, abdominal pain tends to be difficult to treat effectively in IBS patients. 
In the search for new therapeutic strategies, accumulating interest has been given to 
peripheral mechanisms of nociception as a key target to develop novel analgesics for 
IBS-related pain. It is now widely accepted that an altered visceral sensitivity through 
abnormal endogenous pain processing plays an important role in the pathogenesis. This 
can result both from peripheral and central sensitization processes.1 By virtue of 
peripheral sensitization of nociceptive afferents, increased nociceptive discharge can 
result in the generation of pain symptoms.2 The responsiveness of these nociceptive 
afferents or nociceptors, is determined by the expression of specific channels sensing 
noxious stimuli.3 The discovery of sensory transducer molecules, including the transient 
receptor potential (TRP) channel family has opened a new horizon in understanding 
peripheral nociceptive processes. TRP channels constitute a family of nonselective 
cation channels. Several members of this family, of which the Vanilloid 1 capsaicin 
receptor (TRPV1) has been studied most extensively, have been identified to function as 
integrators and transducers of nociceptive signals in both somatic and visceral pain. 
However, as nearly all sensory neurons and several non-neuronal cell types express 
TRPV1, its role is not limited to nociception. TRP channels indeed appear to have a 
broad spectrum of functions in the human body, a topic that has been reviewed in 
detail, elsewhere.4 This review will focus on current knowledge with regards to the 
potential role of TRP channels in the pathogenesis of pain symptoms in IBS, with 
particular emphasis on visceral nociception. Specifically, we will summarise their clinical 
implications and discuss the future of TRP channel targeted therapy. 
Methods 
Evidence to support this review was obtained from an electronic database search via 
PubMed by two of the authors (AB & ZW) using the search terms “visceral nociception”, 
“visceral hypersensitivity”, “irritable bowel syndrome” and “transient receptor potential 
channels”. The last date of the search was 21st of July 2017. After screening the abstracts 
the articles deemed relevant were cross-referenced for additional manuscripts. 
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Irritable bowel syndrome pathophysiology 
Several mechanisms have been hypothesized to play a role in the pathogenesis of IBS, 
including disturbances in microbiota, low-grade inflammation, immune activation, 
intestinal barrier dysfunction and altered bile salt absorption. Discussing these 
mechanisms separately is beyond the scope of this article. A thorough overview is 
provided in a recent review article.5 We would like to emphasise that IBS is a 
heterogeneous disease. Even identical symptoms are likely caused by different 
processes.5 Grouping IBS patients on the basis of stool pattern thus promotes 
heterogeneity, resulting in varying results with different cohorts. This aspect is also 
relevant when studying the role of TRP channels in visceral pain generation in IBS. 
Indeed, low-grade mucosal inflammation has been proposed as an important 
pathophysiological factor in IBS.6 Researchers have since demonstrated a sensitizing 
effect of inflammatory mediators on various TRP channels, as will be discussed below. It 
is important to note that inflammation does not seem to be required to maintain 
visceral sensitization, as two recent clinical studies investigating the effects of mesalazine 
in IBS failed to demonstrate any benefits.7,8 On the other hand, post-inflammatory 
sensitization can provide a theoretical explanation for IBS-like symptoms after gastro-
enteritis, known as post-infectious IBS, and after achieving endoscopic and biochemical 
remission in inflammatory bowel disease (IBD). However, it would be inadequate to 
assume inflammation as the sole driving factor of visceral hypersensitivity. Shortcomings 
of our current knowledge on TRP channel sensitization should be recognized. 
Sensory innervation of the intestine 
Nociceptive signalling from the oesophagus to the proximal colon is conducted through 
the vagal nerve. Information from mid to distal colon and rectosigmoid is carried by the 
lumbar splanchnic and sacral pelvic nerves. The vagal nerve contains the peripheral 
terminals of pseudo-unipolar neurons with their cell bodies located in the nodose 
ganglia. Visceral sensory information from the vagal nerve supply is transduced into the 
solitary nuclei located in the medulla oblongata. The splanchnic and pelvic nerves 
contain axons of pseudo-unipolar neurons arising from a dorsal root ganglion (DRG). 
Peripheral sensory information from this supply is transduced into the dorsal horn of the 
spinal cord and ascends via the spinothalamic tract.9 Peripheral nociceptive signalling is 
extensively modulated by the central nervous system, resulting in suppression or 
augmentation of the nociceptive input. These central processes determine whether 
nociceptive signalling (sensing and transmitting noxious stimuli) is perceived as pain 
(unpleasant experience).10 
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Sensory afferents of the vagal and spinal nerves have previously been divided in different 
subclasses.11 Based on their sensitivity to mechanical stimuli, afferents were divided in 
mucosal, muscular, serosal and mesenteric fibre classes.2 Mucosal afferents were defined 
as responsive to fine tactile and chemical stimuli, whereas serosal and mesenteric 
afferents respond to noxious mechanical stimuli.1 Sensing of intermediate (physiological) 
distension was attributed to muscular afferents. An additional class specific to the pelvic 
pathway, the muscular-mucosal class, responds to tactile and distension stimuli. It should 
be noted that evidence supporting the suspected anatomical distribution described 
above is currently lacking. Song et al. have attempted to morphologically identify 
specialised afferent axonal structures in the guinea pig intestine.12 They were able to 
demonstrate mechanosensitive fibres in the mesenteries and preparations of isolated 
mucosa/submucosa of the ileum and colon. However, no mechanosensitive fibres were 
observed in preparations of isolated muscle layers (with intact myenteric ganglia and 
serosa). Afferent functioning therefore appears to depend on molecular characteristics 
rather than the location within the gut wall.1,13 Functional differences in nociceptor 
transducer molecules and their divergent expression along sensory afferents determine 
the physiological role of these afferents.13 Understanding the functioning of individual 
TRP channels may provide further insights into nociceptive processes and sensitization 
mechanisms. Below we will discuss in detail the TRP channels that have been identified 
as key players in visceral nociception. These include TRPV1, TRPV4, TRPA1 and 
TRPM8. An overview of current data on these channels and their implications in IBS is 
provided in Table 4.1. 
TRP channel regulation 
In order to understand TRP channel functioning, one must be aware of the complex 
molecular modulation that these channels are subjected to. Modulatory processes can 
either result in sensitization or desensitization of the respective afferent.14 While 
desensitization prevents nociceptive signaling, sensitization of nociceptors enhances their 
discharge (i.e. potentiates the nociceptor response to a second stimulus).  
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Table 4.1 Data on TRP channels in IBS 
Channel Implications in IBS Study type Reference 
TRPV1 Sensitized and/or upregulated in colonic tissue 
samples of IBS patients, resulting in enhanced 
capsaicin sensitivity. 
 
Sensitized by inflammatory mediators. 
 
 
Expression profiles regulated epigenetically, likely 
influenced by psychological stress through 
glucocorticoids and/or catecholamines. 
 



























TRPV4 Elevated levels of endogenous agonist 5,6-EET in the 
supernatant in of colonic biopsies from IBS-D 
patients. 
 
Sensitized by inflammatory mediators.  
 


















TRPA1 Functional coupling with TRPV1. 
 
Activated by hydrogen sulphide, present in IBS-D 
patients with small bacterial overgrowth. 
 
Sensitized by inflammatory mediators. 
 
Likely to act as a directly mechanosensitive 





















TRPM8 Inhibits chemo- and mechanosensory responses of 
TRPA1 and TRPV1. 
 
Potentially protective against nociceptor sensitization 
through anti-inflammatory effects. 
 
TRPM8 polymorphisms are associated with slower 
colonic transit and an increased risk of IBS-C and IBS-

















Several mechanisms are involved in TRP channel regulation.14 First, gene expression can 
be altered through DNA methylation, resulting in gene silencing. Second, 
posttranslational modifications (e.g. phosphorylation and dephosphorylation) affect 
channel functioning. Phosphorylation cascades can be initiated by various sensitizing 
agents (discussed below). Depending on the agent, different phosphorylation pathways 
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are involved (e.g. protein kinase A, protein kinase C, calmodulin-dependent kinase).15 In 
contrast, dephosphorylation reduces TRP channel sensitivity to stimuli. Finally, TRP 
channels can be degraded by movement to intracellular lysosomes,16 or mobilized from 
intracellular pools to the cell membrane (translocation).15 All of these processes are 
kept in balance in physiological conditions, but can be disrupted in disease. Currently, 
we are only beginning to understand the role of these modulatory processes in IBS. 
Considering our growing knowledge on TRP channels in visceral pain, future studies may 
focus on this unexplored field to guide treatment development. 
TRPV1 
Of all TRP channels, TRPV1 has been studied most extensively. Studies investigating the 
expression patterns of TRPV1 in mice have demonstrated the channel’s presence along 
the entire gastrointestinal tract.17 Although human studies are more scarce, the 
expression of TRPV1 in the oesophagus and colon is now well documented, and the 
channel is suspected to be present in the human small intestine as well.18 
Immunostaining of human colon biopsies has demonstrated TRPV1-positive fibres 
throughout the mucosa, with a particular abundance in the submucosal plexus.19,20 
Activation of these fibres by noxious stimuli results in action potential generation and 
pain sensation. TRPV1 is activated by noxious heat (>42°C), protons (pH <6) and the 
vanilloid capsaicin, the pungent principle in hot peppers.20 In addition, several 
compounds have been identified as endogenous agonists. These include inflammatory 
mediators such as lipoxygenase products and prostaglandins, and endocannabinoids 
such as anandamide (see Table 4.2). Furthermore, TRPV1 seems to be involved in 
afferent signalling of mechanical stimuli,3 but its exact mechanism is still poorly 
understood. Whether the mechanosensory properties of TRPV1 are related to indirect 
effects on neuronal excitability or interactions with other TRP channels, remains to be 
established.21 
 
The use of potent chemical activators such as capsaicin has provided valuable 
information on the functioning of TRPV1-expressing afferents. Upon activation, in 
addition to the generation of an action potential, these sensory afferents release pro-
inflammatory sensory neuropeptides; calcitonin-gene related peptide (CGRP) produces 
local vasodilation and substance P (SP) increases venular and capillary permeability 
leading to plasma protein extravasation and oedema formation, collectively referred to 
as neurogenic inflammation.22 TRPV1-expressing sensory neurons can therefore 
influence GI vascular, immune and smooth muscle function, as well as sensitize 
surrounding nociceptors.3 Under physiological conditions, these effects are 
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counteracted by the anti-inflammatory effects of somatostatin, which has also been 
shown to be released by capsaicin-sensitive afferents.23 Sustained disruptions in the 
balance of these pro- and anti-inflammatory neuropeptides may result in the 
pathological sensitization of nociceptive afferents, as well as local tissue inflammation 
(see Figure 4.1). Importantly, these processes do not seem to be limited to TRPV1, but 
also apply to the other TRP channels discussed in this review.   
 
Sensitization of TRPV1-expressing afferents has been demonstrated in IBS patients by 
increased perceptive responses to capsaicin in multiple studies.20,24,25 Gonlachanvit et al. 
demonstrated that diarrhoea predominant IBS (IBS-D) patients experience greater 
abdominal burning after a single ingestion of a spicy meal or standard meal in 
combination with a capsaicin capsule, compared to healthy controls.24 As symptoms 
developed within one hour after ingestion, proximal gut hypersensitivity to capsaicin was 
suggested to exist in these patients. Schmulson et al. showed a significantly decreased 
rectal pain threshold in IBS patients after a 7-day chilli rich diet compared to a diet 
without chilli, suggesting TRPV1-induced visceral hyperalgesia.25  
 
More recently, van Wanrooij et al. studied the effects of rectal capsaicin application in 
IBS patients.20 Patients reported increased pain intensity, a similar effect lacking in 
healthy volunteers. Furthermore, the pain response appeared to be independent of 
anticipatory anxiety, suggesting a direct capsaicin effect on nociceptive mucosal 
afferents.  
 
Mechanisms underlying the increased capsaicin sensitivity in IBS patients have been 
studied extensively. Akbar et al. demonstrated upregulation in sigmoid mucosal samples 
of IBS patients.19 This increase correlated with symptom severity, suggesting that an 
increase in afferent discharge through TRPV1 activation might be directly related to pain 
symptom generation. Our earlier study corroborated these findings, demonstrating 
increased transcription of TRPV1 in IBS patients, which also strongly correlated with 
symptom severity.26 More recently, two studies confirmed the augmented expression of 
TRPV1 in colonic biopsies of IBS-D patients.27,28 It should be noted that the overall 
density of innervation has been shown to be increased in IBS patients. Increased TRPV1 
sensitivity may therefore be due to axonal sprouting rather than isolated TRPV1 
upregulation, possibly as a result of increased nerve growth factor expression.28,29 On 
the other hand, Van Wanrooij et al. were unable to objectify increased numbers of 
mucosal TRPV1 in colonic biopsies of IBS patients, as compared to healthy controls.20 
Even when the IBS patient group with visceral hypersensitivity (defined by decreased 
discomfort threshold during rectal distension) was analysed separately, no significant 
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upregulation of TRPV1 was found. The question whether increased capsaicin 
responsiveness in IBS relates to individual TRPV1 sensitivity or TRPV1 expression thus 
remains without a decisive answer. 
 
Table 4.2 Identified agonists and physical stimuli of TRP channels discussed in this paper.16,55,56,110-112 
Channel Exogenous agonists Physical 
stimuli 
Endogenous agonists 
TRPV1 Capsaicin (red pepper), polygodial 
(mountain pepper), piperine (black 
pepper), gingerol (ginger), olvanil, 
resiniferatoxin, camphor, 
diphenylboronic anhydride, double-
knot toxin (DkTx), vanillotoxin 
(tarantula toxin), phenylacetylrinvanil, 
2-aminoethoxydiphenyl borate (2-








HPETE), leukotriene B4 (LTB4), 5-(S)-
hydroxyeicosatetraenoic acid (5S-HETE)), 
reactive oxygen species (ROS), adenosine, 
ATP, lysophosphatidic acid, polyamines (e.g. 
spermine, spermidine, and putrescine) and 





hexadecanamide, and various N-acyltaurines 
and N-acylsalsolinols) 
TRPV4 Bisandrographolide A (BAA), alpha-
phorbol 12,13-didecanoate (4α-
PDD), phorbol 12-myristate 13-
acetate (4α-PDH), apigenin, 





Citric acid, dimethylallyl pyrophosphate, 
anandamide, arachidonic acids and 
epoxyeicosatrienoic acid metabolites (e.g. 
5,6-epoxyeicosatrienoic acid (5,6-EET) and 
8,9-EET, which also mediate TRPV4 
activation by cell swelling) 
TRPA1 Allyl isothiocyanate (AITC), 
cinnamaldehyde (cinnamon), allicin 
(garlic), carvacrol and thymol 
(oregano), curcumin (turmeric), 
capsiate (capsinoid), acrolein, 
menthol, icilin, nicotine, URB597, 
chlorobenzylidene malononitrile 
(tear gas), formalin, α,β-unsaturated 
aldehydes, auranofin, PF-4840154, 
cannabichromene, cannabidiol 
(CBD), tetrahydrocannabinol (THC) 
and apomorphine (agonist in low 
micromolar range and antagonist in 
higher concentration) 
Mechanical 




Prostaglandins (e.g. prostaglandin A1, 8-iso-
prostaglandin A2, and 15-deoxy-∆-
prostaglandin J2), 4-Hydroxnonenal (4-
HNE, a lipid peroxidation product), 4-
oxononenal (4-ONE), methylglyoxal, 
reactive oxygen species (ROS), cytokines 
(e.g. TNF-α and IL-6), bradykinin and 
hydrogen sulphide 
 
TRPM8 Menthol, icilin, linalool, geraniol, WS-
3, WS-12, WS-23, PMD38, 
hydroxycitronellal, FrescolatMGA, 
FrescolatML, CoolactP, Cooling 
Agent 10, cis- and trans-p-





































Figure 4.1 Schematic depiction of nociceptive afferent innervation of the intestine. Proximal (blue) neurons travel 
through the vagal nerve. These neurons transduce sensory information through the nodose ganglia 
into the solitary tract nuclei. Distal (red) neurons travel through the splanchnic and pelvic nerves 
(two distinct systems). Both the splanchnic and pelvic nerves’ somata reside in the dorsal root 
ganglia. In addition, splanchnic nerves travel through prevertebral ganglia (not shown). The 
nociceptive afferents within these neurons presumably have their nerve endings (top inset) in the 
mucosa/submucosa and mesenteries.12 Various stimuli (shown at the top) can activate the 
nociceptors, depending on the expressed TRP channels (see Table 4.2). Stimuli include exogenous 
agonists (e.g. capsaicin or menthol), physical stimuli (e.g. mechanical or thermal) and endogenous 
agonists (e.g. prostaglandins or lipoxygenase products). Activation of nociceptors by these stimuli 
results in action potential generation and pain sensation. In addition, inflammatory mediators are 
released (neurogenic inflammation), which can result in TRP channel sensitization and local tissue 
inflammation. NG= nodose ganglion, STN= solitary tract nucleus, DRG= dorsal root ganglion, S= 
splanchnic nerves, P= pelvic nerves. 
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TRPV1 functioning in (post-)inflammatory conditions 
As discussed above, the mediators of neurogenic inflammation are known to sensitize 
TRPV1. In addition, systemic inflammatory mediators have been shown to be involved in 
both sensitization and activation of TRPV1 (see Table 4.2).30 Their potential relevance to 
IBS pathophysiology is evident, as many have postulated a role for subclinical 
inflammation in IBS.5 However, inflammation has been argued to be within the 
physiological range in IBS.6 Moreover, a study measuring poly-unsaturated fatty acids in 
colon biopsy material from IBS-D patients and healthy controls, failed to demonstrate 
differences in concentrations of lipoxygenase products (TRPV1 agonists).31 It is possible 
that the role of inflammatory mediators in TRP channel sensitization is limited to post-
inflammatory hyperalgesia, as encountered in post-infectious IBS and IBD in remission. 
Animal studies have provided evidence for TRPV1 mediated post-inflammatory 
hyperalgesia, using experimental colitis models induced by dextran sodium sulphate. 
After recovery from colitis, TRPV1 deficient mice showed no pain-related behavioural 
responses or increased visceromotor responses to colorectal distension, whereas these 
responses were readily observed in wildtype mice.32  
 
Another explanation for inflammation mediated hyperalgesia in IBS could be related to 
histamine. Barbara et al. observed increased numbers of mucosal mast cells in close 
proximity to sensory nerves in colon biopsies of IBS patients,33 and these findings have 
been confirmed in a more recent study.28 Moreover, Wouters et al. demonstrated an 
increased Ca2+ response and increased number of responding neurons to capsaicin in 
histamine pre-treated biopsy specimens of healthy volunteers.34 Immunostaining showed 
co-expression of histamine receptor H1 (HRH1) and TRPV1 on submucosal neurons in 
both IBS patients and healthy controls. A functional coupling of these receptors 
therefore appears likely. In a proof-of-concept trial, the same study group demonstrated 
a significant decrease in abdominal pain scores in IBS patients after 12 weeks of 
treatment with the HRH1 antagonist ebastine, as compared to placebo. Unfortunately, 
not all patients reported pain relief, emphasising the heterogeneity of the IBS patient 
population.  
Chronic stress and epigenetics 
IBS is often described to be a disorder of the brain-gut axis. In this model, psychological 
stress is generally accepted as a key factor influencing GI symptoms and vice versa. 
Importantly, animal models have suggested both glucocorticoid- and catecholamine-
mediated TRPV1 upregulation.35,36 In addition, epigenetic mechanisms may regulate the 
effects of chronic stress on TRPV1 expression. Increased histone acetylation of the 
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TRPV1 promoter has been demonstrated in chronic stress models in rats, resulting in 
TRPV1 upregulation in DRG derived neurons.37 Furthermore, the epigenetics of visceral 
pain perception have been investigated in diarrhoea predominant IBS patients.27 Two 
miRNAs known to decrease TRPV1 expression, miR-199a and miR-199b, were found 
to be significantly downregulated and shown to correlate with pain scores. Taken 
together, these results indicate epigenetic alterations, possibly under the influence of 
psychological stress, modulate TRPV1 functioning in IBS. 
Activation of sensitized nociceptors 
Currently identified endogenous agonists of TRPV1, as well as the other TRP channels 
discussed in this review, are primarily related to inflammation (see Table 4.2). As already 
noted, (subclinical) inflammation is not the sole underlying mechanism in IBS. 
Furthermore, it is unknown whether the concentrations of endocannabinoids known to 
activate TRPV1 in vitro are high enough in vivo in order to achieve activation.38 This 
constitutes a significant gap in our knowledge of peripheral nociception in IBS, as it 
remains unclear what stimuli ultimately activate sensitized nociceptors in vivo. Although 
capsaicin is a common dietary constituent, it is unlikely to be a major factor in abdominal 
pain generation in IBS. Current understanding of intestinal signalling suggests that 
nociceptive signals are generated by exciting sensitized nociceptors as a result of 
mechanical stimulation or distension. These mechanical stimuli could be related to 
physiological motor responses of the intestine.6 High amplitude colonic contractions 
have been shown to be of a magnitude above nociceptive thresholds in visceral 
hypersensitivity. Therefore, mechanical stimuli generated by the gut itself may be 
responsible for the generation of pain symptoms through sensitized nociceptors. 
TRPV4 
Studies investigating expression patterns of Transient Receptor Potential Vanilloid 4 
(TRPV4) in the human colon have demonstrated immunoreactivity in the submucosa 
and serosa.39 Initially termed vanilloid receptor-related osmotically activated channel 
(VR-OAC), this channel has been implicated in the detection of osmolarity changes.40 In 
addition, TRPV4 is now known to sense strong acidosis, temperatures >24°C and, 
among others, the synthetic phorbol ester alpha-phorbol 12,13-didecanoate (4 PDD) 
(see Table 4.2). Currently identified endogenous agonists include anandamide and the 
poly-unsaturated fatty acid metabolites 5,6-epoxyeicosatrienoic acid (5,6-EET) and 8,9-
EET.  
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Accumulating evidence points toward a role of TRPV4 in mechanosensation.3,41 Under 
basal conditions, TRPV4 is thought to primarily sense high threshold mechanical 
stimuli.42 Comparing TRPV4 knockout and wildtype mice, responses to noxious 
distension pressures were diminished in TRPV4 knockouts. In contrast, responses did 
not differ at innocuous pressures. TRPV4 is however considered to play a major role in 
visceral hypersensitivity.42,43 Intracolonic administration of 4 PDD has been shown to 
induce hyperalgesia in mice.42 In IBS, several pathways have been proposed to result in 
visceral hypersensitivity through TRPV4 sensitization. The effects on TRPV4 of known 
mediators of visceral hypersensitivity, serotonin and histamine, were investigated in one 
study.44 Serotonin and histamine administration was demonstrated to result in 
potentiated TRPV4 responses to 4 PDD. The same research group postulated a role for 
proteases in mediating visceral hypersensitivity.45 Subsequent studies have supported 
this theory.42,43 Activation of Protease-Activated Receptor (PAR2), a channel that is also 
co-expressed with TRPV4 in afferents innervating the colon, resulted in visceral 
hyperalgesia in wildtype mice. Because hyperalgesia was lacking in TRPV4 knockout 
mice, this channel was suspected to be the downstream effector of PAR2 mediated 
visceral hypersensitivity.42 
 
Human studies on visceral TRPV4 functioning are currently limited. In one study 
researchers acquired supernatant of colonic biopsies from IBS-D patients.31 Intracolonic 
administration of the supernatant resulted in visceral hypersensitivity in mice. This was 
concluded to be TRPV4 mediated, as injection of TRPV4 targeted small interfering RNA 
prevented the effect. Subsequently, potential TRPV4 agonists in the supernatant were 
quantified. The concentration of 5,6-EET was found to be significantly elevated and 
correlated with patients’ abdominal pain severity and frequency. Interestingly, 5,6-EET 
production was linked to PAR2 activation, as PAR2 agonist peptide induced 5,6-EET 
synthesis in sensory neurons. The authors therefore suggested 5,6-EET to be an 
endogenous TRPV4 agonist with a major role in visceral hypersensitivity in IBS-D 
patients. Again, the heterogeneity of IBS should be emphasised as the above solely 
relates to IBS-D patients. No significant differences in poly-unsaturated fatty acid 
metabolite concentrations in supernatants have been observed in constipation 
predominant IBS (IBS-C) patients, mixed bowel habit IBS (IBS-M) patients and healthy 
volunteers. 
TRPA1 
To date, our knowledge on Transient Receptor Potential Ankyrin 1 (TRPA1) functions 
in visceral nociception is mostly limited to animal models. TRPA1 is thought to primarily 
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act as a chemosensor, responding to various irritants and spices, among others 
cinnamaldehyde (cinnamon) and allyl isothiocyanate (AITC), the pungent compound in 
mustard oil, horseradish and wasabi.3 Currently identified endogenous agonists include 
prostaglandins and products of oxidative stress (see Table 4.2). Furthermore, TRPA1 
has been implicated in temperature sensation, although its responsiveness has long been 
debated. Recently, a U-shaped temperature-activation curve was demonstrated using 
human TRPA1 in lipid bilayer and whole-cell patch-clamp recordings.46 This study group 
observed TRPA1 activation in temperatures below 15 degrees Celsius, as well as 
temperatures above 25 degrees, but little activation to temperatures in between.  
 
In addition to the above, TRPA1 has been studied intensively for its suspected 
mechanosensitive properties. It appears to have no role in sensing high pressure 
distension under basal conditions.47 However, TRPA1 has been demonstrated to be an 
important mediator of visceral hyperalgesia.48,49 Several animal studies have indicated 
that the mechanical stimulus threshold can be decreased upon chemical activation with 
mustard oil. These findings have recently been confirmed in an ex vivo study using 
human colonic tissue.50 Moreover, TRPA1 can be sensitized via PAR2 activation. Similar 
to TRPV4, TRPA1 may therefore be one of the effectors of protease mediated visceral 
hypersensitivity. 
 
Several characteristics of TRPA1 add to the complexity of its functioning. TRPA1 is 
almost exclusively expressed in TRPV1-positive neurons. Both channels have been 
shown to interact with each other.51 Similar to TRPV1, TRPA1 can be desensitized upon 
repeated stimulation.52 In addition, TRPA1 activation can be reduced upon repeated 
capsaicin application, a process referred to as cross-desensitization.52 Indeed, Brierley et 
al. showed that TRPA1 knockout mice were responsive to capsaicin, but lacked 
mechanical desensitization that normally follows afterwards.48 Thus, whereas TRPV1 is 
responsible for the direct response to capsaicin, the subsequently reduced 
mechanosensory function appears to be TRPA1-mediated. These results are in line with 
the general belief that TRPV1 itself is not directly mechanically gated,21 as the reduced 
response to mechanical stimuli upon chemical desensitization of TRPV1 relies on 
TRPA1. 
TRPA1 functioning in (post-)inflammatory conditions 
TRPA1 expression has previously been investigated in inflamed human colonic tissue, 
showing upregulation in IBD patients with active inflammation.51 Evidence explaining the 
role of TRPA1 in inflammation however remains contradictory, with reports of both 
pro- and anti-inflammatory effects. Although its effect on inflammation is enigmatic, 
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TRPA1 itself is undoubtedly affected by inflammatory mediators. Indeed, the 
endogenous agonists of TRPA1 are related to inflammation (see Table 4.2). 
Furthermore, studies investigating the effects of chemically induced colitis in mice 
demonstrated sensitization of visceral afferents to mechanical stimuli. These effects were 
observed in wildtype mice, but not in TRPA1 deficient mice.47,53,54  
 
Since TRPV1, TRPV4 and TRPA1 have all been shown to be involved in inflammation 
induced visceral hyperalgesia, one could assume that combined sensitization of these 
channels provides a particularly potent mechanism to induce hypersensitivity. Synergistic 
effects of TRPV1 and TRPA1 inhibition have indeed been demonstrated in the 
attenuation of colorectal distension-associated pain behaviour at high pressures in rats.54 
Unfortunately, this concept has not yet been proven in IBS. Cenac et al. have measured 
endogenous agonists of TRPA1, TRPV1 and TRPV4 (primarily inflammatory mediators) 
in the supernatant of colon biopsy material of IBS patients.31 They demonstrated 
elevated levels of endogenous agonists of TRPV4, but not TRPA1 or TRPV1. Another 
study involved peripheral blood mononuclear cell supernatants from IBS-D patients.55 
The supernatants were shown to induce mechanical hypersensitivity in vitro in colonic 
afferent neurons. Cytokine concentrations in the supernatants were subsequently 
measured, showing elevated levels of TNF- , soluble IL-2, IL-6, IL-10, IL-1  and the 
chemokines CCL3 and CCL4. Combined with the expression profiles of the receptors 
of these signalling molecules in colonic nerves, the authors proposed TNF- , IL-6, IL-10 
and IL-1  as possible mediators of mechanical hypersensitivity in IBD-D. The mechanism 
of action of TNF-  was demonstrated to be TRPA1 dependent, as its sensitizing effect 
was abolished in the presence of a TRPA1 antagonist. In contrast, the selective inhibition 
of TRPV1 using low doses of capsazepine had no effects on mechanical hypersensitivity 
induced by TNF- . In addition, a more recent study by the same group demonstrated IL-
6 mediated mechanical hypersensitivity to be TRPA1 dependent as well.56 Whether an 
interaction of sensitized TRP channels plays an important role in IBS thus remains to be 
elucidated. 
 
Future studies should include different approaches covering the diversity of potential 
pathophysiological mechanisms in IBS. For example, elevated levels of hydrogen 
sulphide, an endogenous TRPA1 agonist, were recently demonstrated in IBS-D patients 
with small bacterial overgrowth.57 These findings demonstrate that mechanisms of TRP 
channel sensitization may vary among patients.   




Transient Receptor Potential Melastatin 8 (TRPM8) appears to be one of the least 
studied TRP channels in humans. Only very recently TRPM8 polymorphisms have been 
demonstrated to be associated with slower colonic transit and an increased risk of IBS-
C and IBS-M in humans.58 However, data on TRPM8 functioning is mainly based on 
animal studies, limiting our understanding of its role in visceral pain generation. Our 
current knowledge of TRPM8 is that it has a role in thermosensation (primarily low 
temperatures).59 Several chemical compounds are able to activate TRPM8, among 
others menthol and icilin. Many will acknowledge that the sensation of mentholated 
liniments is difficult to describe. Cold and burning perceptions alternate upon 
application. Because of these opposing sensory inputs, menthol is thought to also 
activate channels other than TRPM8. Indeed, some authors have pointed to menthol-
induced TRPA1 activation in order to explain the diverse psychophysical sensations after 
topical application of menthol.60 Moreover, coupling of TRPM8 to both TRPV1 and 
TRPA1 has been demonstrated previously.61 As mentioned above, AITC is able to cause 
mechanical hypersensitivity through TRPA1 activation. This effect, however, does not 
occur after pre-treatment with icilin. In contrast, icilin-induced mechanical 
desensitization is absent in TRPA1 deficient mice, indicating that the effect was TRPA1 
mediated. Likewise, capsaicin is able to cause mechanical desensitization, but not after 
icilin pre-treatment.61 TRPM8 is therefore thought to inhibit chemo- and 
mechanosensory responses of TRPA1 and TRPV1, and thus provide antinociceptive 
effects through cross-desensitization.  
 
In addition, visceral TRPM8 is thought to have a role in inflammation. Human studies 
have revealed increased TRPM8 expression in colonic biopsy material from IBD patients 
as compared to healthy controls.62 Several experimental colitis models in mice have 
suggested protective effects of TRPM8 activation. In these studies, icilin treatment 
significantly attenuated induced colitis in wildtype mice, but not in TRPM8 deficient 
ones.62-64 The protective effects of TRPM8 activation have been linked to CGRP, which 
co-localizes with TRPM8 in the human colon.64 Although the pro-inflammatory effects of 
CGRP in neurogenic inflammation are evident, primarily consisting of vasodilation, anti-
inflammatory effects of the neuropeptide have been observed as well.65,66 De Jong et al. 
demonstrated expression of the components of the CGRP receptor, calcitonin 
receptor-like receptor (CLR) and receptor activity modifying protein-1 (RAMP1), on 
CD11c+ dendritic cells in the murine spleen.64 CGRP knockout mice were shown to 
have higher levels of pro-inflammatory cytokines (including TNF-  and IL-6) in chemically 
induced acute colitis, as compared to wildtype mice. Moreover, CD11c+ dendritic cells 
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were found to be co-localized with CGRP positive fibres in the murine colon. CGRP 
was therefore thought to exert a protective role in colitis via inhibition of the release of 
pro-inflammatory cytokines, through interaction with local dendritic cells. Indeed, 
TRPM8 deficient mice showed significant improvement in disease activity after treatment 
with recombinant CGRP, whereas no effect of treatment was observed in wildtype mice 
with induced colitis. Paradoxically, enhanced CGRP expression levels have been 
observed in mucosal fibres of TRPM8 deficient mice.62 This discrepancy has yet to be 
clarified, although it is likely that a disrupted colonic CGRP release prevents the 
neuropeptide from reaching its effector. Taken together, these results suggest that 
TRPM8 upregulation is a protective mechanism aimed at mitigating tissue inflammation. 
Therefore, TRPM8 could theoretically protect against nociceptor sensitization by 
inflammatory mediators. 
Non-neuronal TRP channel expression 
As already mentioned, TRP channels are expressed by a multitude of cell types including 
those of non-neuronal origin (both intestinal and extra-intestinal).67 Examples of non-
neuronal cells expressing TRP channels include vascular smooth muscle cells, endothelial 
cells, keratinocytes and intestinal epithelial cells. The possible involvement of the latter in 
IBS pathophysiology should not be overlooked. Increased intestinal permeability has 
been demonstrated in IBS-D patients,68 and has been associated with visceral 
hypersensitivity.69 In two studies, TRPV4 activation with 5,6-EET and 4 PDD resulted in 
increased intestinal permeability.70,71 One of the proposed mechanisms was via 
downregulation of tight junction proteins. However, conflicting results have been 
obtained for the role of TRPV1 in regulating intestinal permeability. Capsaicin has 
previously been shown to increase permeability. In contrast, the endocannabinoid-like 
compound oleoylethanolamine has been shown to be able to both increase and 
decrease intestinal permeability via TRPV1.72 Similarly, the role of TRPA1 in the 
regulation of intestinal permeability remains controversial. Fothergil et al. demonstrated 
decreased trans-mucosal resistance in colon tissue from mice after AITC and 
cinnamaldehyde administration.73 We demonstrated no effects on small intestinal 
permeability with the administration of cinnamaldehyde in twelve healthy controls.74 It 
therefore remains unclear to what extent TRP channels contribute to IBS 
pathophysiology via altering intestinal permeability. 
Motility effects of TRP channel activation 
Although we here focus on the role in visceral nociception, it should be noted that TRP 
channels are known to affect gut motor function as well.21 The effects of TRP channel 
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activation on motility are not only channel dependent, but also location dependent. For 
example, TRPV1-positive fibres located in the lower oesophageal sphincter that are 
exposed to gastric acid cause a local inhibitory reflex, lowering the intraluminal 
pressure.75 On the other hand, application of capsaicin in the distal colon and rectum in 
mice has been shown to cause fast transient colonic contractions followed by a delayed 
sustained contraction.76 These results indicate that different effector pathways are 
involved depending on the location. Suggested effectors are the tachykinin receptors 
(mainly NK1 and NK2), which respond to neuropeptides released upon TRP channel 
activation, as discussed above.77 Indeed, the contractility lowering effect in the 
oesophagus was demonstrated to be NK1 dependent via local substance P release, 
whereas NK2 activation was shown to be responsible for long lasting contractility in the 
distal colon.75,76 Additional pathways are likely to be involved however, as fast transient 
colonic contractions were shown to be inhibited by NK1 antagonists. Other TRP 
channels have also been implicated in motility. Whereas TRPV4 has previously been 
demonstrated to inhibit colonic motility in mice via reduced NO-dependent calcium 
release, TRPA1 has been implicated in both reduced and increased motor activity.39,78,79 
Taken together, the effects on gut motility emphasise the involvement of TRP channels 
in IBS pathophysiology, as they may account for both the altered defecation pattern as 
well as pain symptoms encountered in the syndrome. 
Clinical implications 
Although all of the TRP channels discussed above are suggested to have a role in visceral 
pain generation, only two (TRPV1 and TRPM8) have been implied in the treatment of 
IBS. Generally, two strategies are exploited in blocking TRP channels. One is the direct 
inhibition by administration of antagonists, the other one by repeated stimulation in 
order to desensitize the channel and its respective nerve terminal. In addition, several 
alternative techniques for TRP channel targeted therapy have been developed, that will 
be discussed hereafter. A summary of the optional therapeutic strategies related to each 
TRP channel is provided in Table 4.3. 
TRP antagonists 
The discovery of TRPV1 as a key player in nociception led to the development of 
TRPV1 antagonists as novel therapeutics in pain control. However, investigators soon 
encountered a major hurdle, as the first compounds interfered with thermoregulation. 
Several first-generation compounds were stranded in pre-clinical trials as they elicited 
marked hyperthermia.80,81 Moreover, interspecies differences in TRPV1 functioning 
further complicated research. While one TRPV1 antagonist appeared to be safe in 
153719-Weerts_BNW.indd   90 08-09-2021   12:03153719- eerts_BN _compleet.indd   90 08-09-2021   12:06
TRP channels as therapeutic targets in IBS 
91 
4 
animals, its first human clinical trial was prematurely halted as hyperthermia was 
observed in three out of four patients.82 Interestingly, while TRPV1 has been identified 
as a thermosensor, its temperature threshold is well above physiological body 
temperature. It is possible that adverse effects are not TRPV1 related and represent an 
off-target effect. Additionally, classical TRPV1 antagonists impair the noxious heat 
sensation and may therefore increase burn risk. Together, these results disfavoured the 
development of non-selective TRPV1 antagonists. Therefore, new strategies are being 
explored in order to tackle thermoregulation related adverse events in TRPV1 targeted 
therapy. Several second generation modality specific antagonists have been developed, 
as it has been observed that hyperthermia is less severe with compounds that are full 
antagonists for capsaicin, but not for protons.83 Two recent phase-I trials reported no 
side effects of two modality-selective TRPV1 antagonists.84,85 Their potency as analgesics 
however remains to be established in future studies. 
 
Table 4.3 Summary of therapeutic strategies in relation to the TRP channels discussed in this paper. 
 TRPV1 TRPV4 TRPA1 
Antagonists Potent analgesics, but 
thermoregulation interference 




currently being developed108 




Tested in neuropathies with 
good safety profiles105 
 
Several antagonists currently 
evaluated in clinical trials105 
 
 
Desensitization Six weeks of chilli treatment 
effective in IBS-D patients, but 
short-term adverse effects may 
limit adherence87 
Evidence currently lacking Repeated TRPA1 stimulation 
results in desensitization52  
Cross-
desensitization 
Inhibition of chemo- and 
mechanosensory responses 
with peppermint oil* 
 









NK1 antagonists may provide 
anti-hyperalgesic effects96 
 
Improved abdominal pain and 
stool pattern in female IBS-D 
patients with NK2 antagonist 
ibodutant94 
 




Improved abdominal pain 
scores in IBS patients with 
HRH1 antagonist ebastine34  
Evidence currently lacking Evidence currently lacking 
RNA-based 
therapy 
Plausible102  Plausible102 Plausible102 
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Desensitization 
The desensitizing properties of TRPV1 agonists such as capsaicin have been exploited 
for many years by topical preparations in the treatment of neuropathic pain.86  
 
At this moment, only one small randomized crossover study investigated the effects of 
six weeks of chilli treatment in IBS-D patients.87 At the end of treatment, patients 
reported significantly decreased post-prandial abdominal burning sensations. Similar 
positive effects have been demonstrated in epigastric pain in patients with functional 
dyspepsia.88 An important drawback of capsaicin therapy however, is its short-term 
aggravating effects, possibly limiting adherence in the clinical setting. Therefore, more 
studies are needed to evaluate efficacy and feasibility in a larger IBS population. In 
addition, it remains to be established at which dose, frequency and length of 
administration repeated capsaicin is able to, if all, induce desensitization of TRPV1-
positive nerve endings in the gut. 
 
Ultra-rapid desensitization using potent agonists offer a theoretical background for 
achieving a fast analgesic response. One of these ultra-potent TRPV1 agonists is 
resiniferatoxin, which causes sustained calcium influx, resulting in a cytotoxic intracellular 
free calcium concentration and consequent axonal damage of TRPV1-positive neurons.89 
Unfortunately, its potency also poses challenges. Similar to first generation TRPV1 
antagonists, resiniferatoxin increases the heat pain threshold. Moreover, high or 
repeated systemic doses of resiniferatoxin induce long-lasting damage to TRPV1-positive 
neurons,90 rendering it not suitable for therapeutic applications in IBS.  
Cross-desensitization 
Another mechanism aimed at analgesia is related to TRPV1 channel cross-
desensitization. As mentioned above, TRPM8 activation is thought to provide 
antinociceptive effects through subsequent inhibition of TRPV1 and TRPA1. Peppermint 
oil, containing the TRPM8 agonist menthol, exploits these beneficial effects and is 
registered for the use in IBS in several countries.91 It should be noted that the exact 
mechanism of action remains to be elucidated. Moreover, its effects appear to reach 
beyond TRP channel signalling as calcium channel mediated smooth muscle relaxation 
has been observed in vitro in human colon tissue without the involvement of TRPM8.92  
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Multiple small trials have evaluated the efficacy of peppermint oil in IBS. Side effects of 
this herbal therapy are rather mild, with heartburn being the most common.91 One 
meta-analysis reported that 75% of IBS patients experience improvement in abdominal 
pain compared with only 27% in patients receiving placebo.91 In a more recent trial, 
patients received either a sustained release peppermint oil preparation ensuring drug 
release in the small intestine, or a placebo. Patients receiving peppermint oil reported a 
significantly greater reduction in abdominal pain or discomfort compared with patients 
receiving placebo after a treatment duration of 28 days.93 New preparations have been 
developed recently ensuring peppermint oil release in the colon, trials are ongoing and 
data on the efficacy of these new formulations will be reported in the near future.  
Downstream targets of therapy 
Drugs that target molecules downstream of TRPV1 provide an attractive 
pharmacological alternative to direct TRPV1 inhibition. As TRPV1 activation is 
accompanied by the release of sensory neuropeptides inducing neurogenic inflammation 
and sensitization of surrounding nociceptors, it makes sense to target mediators (or 
their respective receptors) of this process. Indeed, antagonists of the tachykinin NK1 
and NK2 receptors of substance P and neurokinin A respectively, are being developed 
for various purposes, among others for symptom relief in IBS. For example, ibodutant, a 
neurokinin-2 receptor antagonist, has been shown to improve abdominal pain and stool 
pattern in female IBS-D patients.94 Moreover, neurokinin-1 receptor antagonists such as 
aprepitant are currently being used as anti-emetics and have been suggested as 
analgesics as well.95,96 Unfortunately, several pre-clinical studies demonstrated that NK1 
antagonists lacked analgesic effects.97 It should be noted that animal models studying the 
effects of NK1 antagonists simulated somatic pain, whereas the NK1 receptors are more 
relevant in visceral pain.96 Moreover, NK1 antagonists are thought to function as anti-
hyperalgesic agents rather than analgesics as they do not affect baseline nociception, but 
attenuate nociceptive responses sensitized through inflammation.97 Although at first sight 
this does not appear favourable, inhibiting the sensitized state rather than the normal 
resting state may actually make NK1 antagonists excellent candidates for treating 
visceral pain. The most important advantage would be that physiological functions may 
remain unaltered. In fact, similar mechanisms likely explain the beneficial effects of the 
HRH1 antagonist ebastine in IBS patients, which has been discussed above.34 As TRPV1 
sensitization after histamine pre-treatment has been shown to be HRH1 mediated, the 
effects of ebastine on abdominal pain are thought to be related to the inhibition of the 
sensitized state of TRPV1. 
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One additional mediator of neurogenic inflammation has been implicated as a potential 
target in the development of analgesic therapies. Somatostatin, originating from 
capsaicin-sensitive sensory afferents, counteracts pro-inflammatory neuropeptides 
CGRP and substance P. Indeed, the potent analgesic effects of somatostatin have long 
been recognized.98 Early studies using the somatostatin analogue octreotide have 
demonstrated increased thresholds of visceral sensory perception in IBS patients.99,100 
Moreover, anti-hyperalgesic effects of selective agonists of somatostatin receptor 1 and 
2 have been reported in induced visceral hypersensitivity in mice.101 Therefore, 
somatostatin analogues or receptor agonists may provide additional therapeutic 
strategies in visceral pain. Clinical studies will need to substantiate their applicability in 
IBS patients.  
RNA-based therapy 
The observation of decreased expression of several TRPV1 targeting miRNAs in IBS 
patients suggests an opportunity for RNA-based therapy. The therapeutic potential of 
post-transcriptional gene silencing by RNA interference is increasingly being 
recognized.102 The major benefit of synthetic siRNAs is their high target specificity, 
preventing the suppression of unrelated genes. Unfortunately, several challenges have 
yet to be overcome before RNA-based therapy can become a therapeutic option in IBS. 
The oral bioavailability of oligonucleotides is limited, confining the possible modes of 
administration to more invasive approaches. Furthermore, the effects are only transient, 
demanding repeated treatment. Therefore, there is a need for stable TRPV1 targeting 
siRNAs that are readily absorbed in the GI tract. 
Exploiting new targets 
Our current knowledge on the role of visceral TRPV4 and TRPA1 in humans is limited. 
Nonetheless, data from animal studies, discussed above, suggest that these channels are 
viable targets for IBS therapy. The previous discovery of elevated levels of the 
endogenous TRPV4 agonist 5,6-EET in IBS-D patients and the putative implication of 
TRPV4 in mechanical hypersensitivity justify the need for further research. TRPA1-
targeted therapy has been explored in animal models of visceral pain. However, 
contrasting evidence was found demonstrating attenuated visceral nociception in 
rodents with both TRPA1 antagonists as agonists.54,103,104 It is unclear whether the 
mechanism of action of the latter was based on desensitization. Arguing against such a 
mechanism is the observation that reduced abdominal contractions were observed in 
mice after a single oral dose of a TRPA1 agonist. Furthermore, one TRPA1 antagonist 
has recently shown efficacy in patients with painful diabetic neuropathy, and several 
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other TRPA1 antagonists have entered the phase of testing in clinical trials.105 Although 
the true potential of these drugs will need to be explored, their safety profile appears to 
be more favourable than that of early TRPV1 antagonists. Given this advantage, we 
expect a boost in TRPA1 targeted therapy development in the near future.  
New targets may continue to be identified. TRP channel regulatory processes in IBS 
constitute relatively unexplored terrain (see “TRP channel regulation”). Improved 
understanding of the underlying molecular processes may help identify targets that 
modulate TRP channel functioning. 
Challenges of TRP channel targeted therapy 
Although the possibilities of TRP channel targeted therapy appear endless, treatment 
development has been plagued by many challenges over the past years.16 As mentioned 
above, the first TRPV1 antagonists were associated with thermo-regulatory side effects. 
To date, the mechanisms by which these side effects arise are unknown. New selective 
agents may provide a solution to this issue. However, other challenges are to be 
expected.16 This is mainly provoked by two factors. First, TRP channels are expressed in 
a wide range of tissues (see section “Non-neuronal TRP channel expression”). Targeting 
TRP channels consequently affects systems other than nociceptors. For example, a 
systemically administered TRPV4 agonist resulted in endothelial dysfunction and 
cardiovascular collapse in one study.106 TRPV1 expressed in the central nervous system 
is thought to have a role in mood disorders. Although conflicting data exists, TRPV1 
antagonism may exacerbate depressive symptoms.38 Regulatory relations between 
organ systems further complicate the matter. TRPV1-expressing neurons are thought to 
regulate immunological functions, and interference with this function could prove 
detrimental in systemic inflammatory conditions.107 The other major issue of TRP 
targeted treatment development is related to the large diversity of possible stimuli of 
each channel. Even selective agents will not immediately overcome this hurdle. For 
example, a new TRPV1 antagonist that does not cause hyperthermia, was shown to 
potentiate proton-induced calcium influx in one study.108 This unforeseen effect could 
prove problematic in the upper gastrointestinal tract, as it may result in excessive 
TRPV1 activation by gastric acid (e.g. physiological gastro-oesophageal reflux). 
 
In addition, several limitations currently exist in the study of TRP channels and their role 
in nociception. Basic research is complicated by the lack of quality reagents. Antibodies 
used to investigate expression patterns possess poor specificity. A similar issue is 
encountered with agonists/antagonists used to investigate TRP channel functioning, 
which presents a major problem in understanding TRP biology.109 Furthermore, studies 
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regarding TRP channel involvement in visceral pain generation mostly focus on 
inflammation. Although animal colitis models have provided a wealth of information, 
alternative mechanisms of TRP channel sensitization should be explored. As discussed 
above, IBS is highly heterogeneous. Further insights in the mechanisms underlying IBS 
are needed in order to expand our knowledge of peripheral nociception and ultimately 
guide IBS treatment development. 
Conclusions 
In summary, TRPV1, TRPV4, TRPA1 and TRPM8 have been shown to play important 
roles in visceral pain generation and inhibition, making them potential targets in the 
treatment of IBS. TRPV1 antagonists have proven to be potent analgesics, but it remains 
difficult to produce compounds with an acceptable safety profile. Different strategies 
targeting TRPV1 (i.e. modality-selective antagonism) or downstream molecules (NK1 or 
NK2 antagonists or somatostatin agonists) may solve this issue. TRPV1 desensitization 
strategies may provide suitable alternatives, yet short-term adverse effects may limit 
treatment adherence. In contrast, TRPV1 cross-desensitization with peppermint oil is 
attractive because of the low prevalence of  adverse effects. The mechanism of action of 
peppermint oil however appears to reach beyond TRP channel signalling. In addition, 
TRPV4 and TRPA1 provide promising new targets. In our opinion, TRPA1 represents an 
important candidate for the development of new treatments of visceral pain. Its putative 
implication in mechanosensation in hyperalgesia but apparent lack of such function 
under basal conditions suggests a major role in IBS. Moreover, early TRPA1 antagonists 
have proven to be safe in clinical trials, rendering TRPA1 targeted therapy less of a 
pharmaceutical challenge than TRPV1 inhibition. 
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Chronic and recurring pain is a characteristic symptom in irritable bowel syndrome 
(IBS). Altered signalling between immune cells and sensory neurons within the gut may 
promote generation of pain symptoms. As transient receptor potential melastatin 8 
(TRPM8) agonists, such as L-menthol in peppermint oil, have shown to attenuate IBS 
pain symptoms, we began investigating potential molecular mechanisms. 
 
Methods 
Colonic biopsy tissues were collected from patients with IBS and controls, in two 
separate cohorts. Immunohistochemistry was performed to identify TRPM8 localization. 
Quantitative PCR was performed to measure mucosal mRNA levels of TRPM8. In 
addition, functional experiments with the TRPM8 agonist icilin were performed ex vivo 




In biopsy tissue from IBS patients, we showed that TRPM8-immunoreactivity is 
colocalized with immune cells predominantly of the dendritic cell lineage, in close 
approximation to nerve endings, and TRPM8 protein and mRNA expression was 
increased in IBS patients compared to controls (P<0.001). TRPM8 mRNA expression 
showed a significant positive association with abdominal pain scores (P=0.015). 
Treatment of IBS patient biopsies with icilin reduced release of inflammatory cytokines 
IL-1β, IL-6 and TNF-α (P<0.050). 
 
Conclusions 
These data indicate TRPM8 may have important anti-inflammatory properties and by 
this virtue can impact neuro-immune disease mechanisms in IBS. 
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Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction characterized by 
chronic recurrent pain and altered bowel habits thought to arise from disturbances in 
the neuro-immune regulatory balance of afferent signal processing.1 IBS is highly 
prevalent with an estimated prevalence in the general population of ~5%.2 In addition, 
IBS has a profound negative impact on quality of life and carries a substantial 
socioeconomic burden.3 Patients are diagnosed based on their symptoms using the 
Rome criteria.4 Importantly, these symptoms occur in the absence of gross structural 
abnormalities. The sensory symptoms of pain are the most debilitating aspects to 
patients yet are the least responsive to pharmacological treatment, highlighting the lack 
of understanding of the mediators and mechanisms involved in pain sensing of the lower 
gastrointestinal tract.  
 
We recently demonstrated that peppermint oil5, a commonly used therapeutic in IBS, 
was able to improve pain outcomes. The beneficial effects of peppermint oil have also 
been confirmed in recent meta-analyses.6,7 However, the mechanism of action remains 
somewhat obscure. Traditionally, peppermint oil is considered an anti-spasmodic due to 
the inhibition of calcium influx into the sarcolemma of the intestinal smooth muscle cells. 
On the other hand, the primary constituent of peppermint oil L-menthol, is also an 
agonist for the transient receptor potential melastatin 8 (TRPM8) channel. TRPM8 has 
an established role as an ion channel that responds to cold temperatures (<30°C), and 
the aforementioned menthol, a cyclic terpene alcohol found in mint leaves.8 Expression 
of TRPM8 has been described in a distinct population of sensory nerves including 
trigeminal ganglia (TG), dorsal root ganglia (DRGs) and in epithelial cells of the prostate 
and bladder.9 In the murine gastrointestinal tract, TRPM8 is expressed on colonic 
primary afferent neurons and activation of the channel with the agonist icilin inhibits 
chemo- and mechanosensory responses of pro-nociceptive TRP channels (TRPV1, 
TRPA1).10 The activation of these pro-nociceptive channels also leads to the release of 
pro-inflammatory mediators from afferent nerve endings, resulting in a phenomenon 
collectively referred to as neurogenic inflammation.11 Interestingly, in mouse models of 
colonic inflammation, TRPM8 knock-out mice have a more severe disease 
phenotype12,13 and treatment with TRPM8 agonist icilin attenuates colonic 
inflammation.14 Specifically, activation of TRPM8 expressed on calcitonin-gene related 
peptide (CGRP) containing sensory nerves reduces mucosal inflammation by inducing 
CGRP release, which then inhibits release of pro-inflammatory cytokines IL-6 and 
tumour necrosis factor (TNF)-α by CD11c+ dendritic cells.13 Furthermore, murine 
macrophages expressing TRPM8 regulate pro- and anti-inflammatory mechanisms via 
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modulating release of TNF-  and IL-10.12 Human data on the role of intestinal TRPM8 is 
limited to a single study showing upregulation of TRPM8 mRNA in biopsies from 
Crohn’s disease patients, in both inflamed and non-inflamed mucosa.14 In IBS, a single 
brief report describes an association of TRPM8 gene polymorphism with colonic 
transit.15 Collectively, these studies show that there is a potential role for TRPM8-
mediated reduction of gut symptoms. We sought to shed light on the putative role of 
TRPM8 in IBS. We hypothesized, in line with findings from previous animal studies, that 
TRPM8 has an anti-inflammatory effect and by this virtue represents a key factor in the 
pathophysiology of IBS. 
Materials and methods 
Patient population 
IBS patients (age 18-75 years) were recruited from 2 centres: the Maastricht University 
Medical Center+ (MUMC), The Netherlands, and The Royal London Hospital, in 
London, UK. 
 
Medical history was taken by a (trainee) gastroenterologist or research nurse, and if 
indicated, abdominal imaging and/or blood, fecal analyses were performed to exclude 
organic disease. A history of abdominal surgery, except for uncomplicated 
appendectomy, cholecystectomy, or hysterectomy, was reason for exclusion. The 
diagnosis of IBS was confirmed based on the Rome III criteria by an investigator 
independent from the treating physician.  
 
Healthy controls for the Maastricht cohort were recruited from the general population 
using advertisements. Controls from the London cohort were attending the Endoscopy 
unit for anaemia investigation and did not have macroscopic inflammation or any organic 
abnormality other than polyps and/or hemorrhoids. Controls from both the Maastricht 
and London cohort were requested to complete the Rome III questionnaire to rule out 
the presence of IBS. Demographic characteristics of all study patients are presented in 
Table 5.1. The study protocols had been approved by the respective local Ethics 
Committees, and all study procedures were performed in compliance with Good 
Clinical Practice Guidelines and according to the revised Declaration of Helsinki. All 
subjects gave a written informed consent prior to participation. 
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Table 5.1 Demographic characteristics of the study population.  
 Patients with IBS Controls 
  N=30 (Maastricht) 
+     26 (London) 
N=23 (Maastricht) 
+       6 (London) 
Age, median (IQR) 37.5 (27.0-53.8) 23.2 (20.8-30.9) 
Female, N (%) 35 (62.5) 13 (44.8) 
BMI, median (IQR) 25.2 (20.9-29.4) 22.9 (20.5-24.4)* 
GSRS, median (IQR)    
   Abdominal pain 
   Reflux syndrome 
   Diarrhea syndrome 
   Constipation syndrome 













HADS, score >8, N (%)# 
   Depressive symptoms 







IBS-subtype, N (%) 
   Diarrhea 
   Constipation 
   Mixed 







GSRS: gastrointestinal symptom reporting scale. HADS: Hospital anxiety and depression scale. #data only 
available for the Maastricht cohort. Differences between groups were analysed using Chi square and Mann-
Whitney U test. * P<0.05, ** P<0.01, *** P<0.001 versus control. 
 
Symptom diaries 
A representative subset of patients with IBS from the Maastricht cohort (N=15) filled in 
a 14-day end-of-day symptom diary 2 weeks prior to colonoscopy in order to quantify 
symptom severity. Symptoms were scored based on a 0-5 Likert scale. In addition, the 
validated questionnaires Gastrointestinal Symptom Rating Scale (GSRS) and Hospital 
Anxiety and Depression Score (HADS) were collected for characterization of the 
patient population. 
Tissue collection 
For TRPM8 IHC experiements, full thickness colon samples were obtained from 
patients undergoing surgery for colon cancer (N=3) or IBD resection (N=4) at The 
Royal London Hospital (Barts Health NHS Trust) with approval of the East London and 
The City HA Local Research Ethics Committee and after written patient consent. 
Specimens were taken following macroscopic examination and were a minimum of 
10 cm away from tumor, resection margins or lymphatic drainage field.  
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Colonic biopsies (right-sided proximal and sigmoid colon) were collected from IBS 
patients and controls in both Maastricht and London during routine colonoscopy 
examination under conscious sedation using midazolam and fentanyl or pethidine, from 
macroscopically normal mucosa. A standard biopsy forceps with a diameter of 2.8 mm 
(Boston Scientific) was used to obtain mucosal biopsies.  
 
Full thickness tissue and biopsies collected in London were placed in cold 4% 
paraformaldehyde, and fixed for 16-18h or 2h at 4ºC, respectively. Biopsies collected in 
Maastricht were directly placed in Eppendorf tubes and snap frozen in liquid nitrogen 
and stored at -80oC. Biopsy samples collected in Maastricht that were used for IHC 
were thawed and subsequently fixed in 2% PFA for 2h. 
RNA isolation and quantitative PCR 
Total RNA was isolated from the frozen biopsies using TRIzol reagent (Invitrogen, 
Carlsbad, USA) and purified with the RNeasy Plus Mini Kit (Qiagen, the Netherlands). 
Quantity and purity of the RNA samples was determined using a Nanodrop 
spectrophotometer (NanoDrop Technologies, Wilmington, USA). A concentration 
from 5 µg/µl total RNA was used. Finally, the cDNA was diluted 100× with RNAse free 
water and amplified: each reaction contained 12.5 µl iQ Sybr Green Supermix, 1µl of 
10 µM gene-specific forward and reverse primers, 4 µl diluted cDNA template and 5.5 
µl sterile water. Reactions were run on the CFX 96 Real-time qPCR Detection System 
(Bio-Rad). PCR conditions used were 3 min at 95°C, followed by 40 amplification cycles 
of 10 sec at 95°C and 45 sec at 60°C. Data were expressed as normalized expression 
ratios. 
 
Primers: GAPDH1 F: TGCACCACCAACTGCTTAGC; R: 
GGCATGGACTGTGGTCATGAG; TRPM8 F: GCTGTACAAAGCCTTCAGCAC, R: 
CTCATCACTGGCAAGGTCCA. Quantitative PCR experiments were performed in 
30 sigmoid biopsies and 24 right-sided colon biopsies from 30 IBS patients and 23 
healthy controls (all obtained from the Maastricht cohort). 
Immunofluorescent staining and tissue analysis 
Prior to analyses, biopsy samples were cryoprotected in 30% sucrose overnight, 
followed by an incubation in 50% sucrose and 50% OCT cryostat sectioning medium, 
and finally embedded in a cryomold with OCT. Tissues were stained as described.13 In 
brief, cryoprotected tissues were cut into 10 μm sections and incubated with Trident 
Universal Protein Blocking Reagent (Gene Tex, GTX30963) for 2 h before primary 
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antibody TRPM8 (1:200, Alomone: ACC-049) with either CGRP (1:400, Thermo 
Fisher, ABS026‐05‐02), CD103 (1:400, DAKO, R7188) and CD11C (1:200, Abcam, 
ab33483), CD64 (1:400, DAKO, R7129), CD68 (1:400, DAKO, M0876) and mast cell 
tryptase (1:400, DAKO,  MC052)  was applied overnight (4°C). Tissues were then 
washed and incubated (60 min, room temperature) with species-specific Alexa Fluor 
conjugated secondary antibodies (1:400, A-11001, A-21451, A-11036, Carlsbad, CA). A 
Leica DM4000 epifluorescence microscope was used to visualize TRPM8+ 
immunoreactivity (IR). Immunoreactive cells for each target were counted manually by 
two independent observers in each section and averaged over five fields of view – all 
taken at 40x magnification. Observers were blinded to the source of tissue, i.e. IBS 
subtype, as tissue was assigned a collection number until data analysis. 
Immunohistochemistry experiments were performed in biopsies from 28 IBS patients 
(5/28 obtained from the Maastricht cohort) and 7 controls (all obtained from the 
London cohort). No primary controls were performed to eliminate non-specific bind of 
secondary antibodies, and TRPM8 control antigen was used to ensure binding specificity 
(Supplementary Figure S5.4). 
Cytokine experiments 
IBS biopsies were placed in 200μL Krebs solution (control), or in icilin (treatment) 
(1 µm, Tocris, product code: 1531) in 200 μL Krebs solution, and were maintained at 
37oC with 95% CO2/5% O2 overnight (16-18 h) in 96 well plates. The supernatant was 
then removed and aliquots stored at −20°C. Quantification of cytokines the IL-1β, IL-6, 
TNF-α, IL-10, and IL-8 was performed using a customized human cytokine/ 
chemokine/growth factor assay panel (Milliplex MAP Multiplex assay, Merck Millipore, 
product codeHCYTOMAG-60K), and analyzed on Luminex MAGPIX Instrument with 
xPONENT 4.3 (Luminex Corporation). Cytokine experiments were performed using 
sigmoid biopsies from 12 IBS patients (all obtained from the London cohort). 
Statistical analysis 
Statistical analysis was performed using SPSS 26 (IBM Corporation) or GraphPad Prism, 
V.5.02. (GraphPad Software, Inc). Statistical analysis for cell counting was performed 
using the Mann-Whitney test for unpaired data. For the comparison of mRNA 
expression between IBS patients and controls, a multivariable linear regression was 
performed correcting for age and gender. Wilcoxon signed-rank test was performed to 
compare sigmoid mRNA with proximal colon mRNA levels (within subjects). Relation 
to symptoms was also assessed using multivariate linear regression correcting for age 
and gender. For cytokine release assays, paired analysis with statistical significance using 
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Wilcoxon matched-pairs signed rank test was used. Significance was defined as P<0.05. 
Considering the exploratory nature of the experiments, no formal sample size 
calculation or correction for multiple testing was applied. All data is presented as median 
and interquartile range (IQR) and P<0.05 was deemed significant. 
Results 
In human, uninflamed colonic tissue obtained from surgical resection, TRPM8 
immunoreactivity (IR) was observed to colocalize with cell bodies within the myenteric 
plexus and co-labelled with CGRP (Figure 5.1A), corroborating findings in mouse 
myenteric ganglia.10 Majority of TRPM8-IR in the inflamed mucosa (of Crohn’s disease 
patients) was found to colocalize with CD11c+ immune cells with a small population 
colocalizing with CD45+ (expressed in all differentiated haematopoietic cells) immune 
cells (Supplementary Figure S5.1), and not with CGRP-IR mucosal nerve endings as 
previously reported in mice13 (Figure 5.1B). TRPM8-IR CD11c+ cells were however, in 
close apposition to mucosal CGRP-IR nerve fibers (Figure 5.1B). As CD11c identifies a 
sub-population of dendritic cells (DC) in addition to monocytes16, we further explored 
the DC phenotype using CD103, a marker of a DC subset termed ‘conventional DC1’ 
commonly found in gastrointestinal mucosa.17 In a representative IBS patient biopsy, 
TRPM8-IR was colocalized on both CD11c+ and CD103+ cells in colonic mucosa 
(Figure 5.1C & 5.1D). We also assessed TRPM8-IR in relation to mast cells and 
macrophage/monocytes and found absence of colocalization on these cell types 
(Supplementary Figure S5.3). These findings suggested a possible pathway mediating IBS 
symptom relief following TRPM8 agonism considering the apparent colocalization of 
TRPM8-IR with dendritic cells in close proximity to CGRP-IR mucosal nerve fibers. 
 
We therefore examined TRPM8 expression in IBS patient and control biopsies from 
cohorts at Maastricht University Medical Centre+ (Netherlands) and The Royal London 
Hospital (U.K.) (56 IBS patients and 30 controls in total, demographic details in Table 
5.1). mRNA expression of TRPM8 in the sigmoid colon was significantly higher in IBS 
patients compared to healthy controls (P<0.001) (Figure 5.2A, examined in 30 IBS 
patients, 23 controls, all obtained from the Maastricht Cohort). This increased 
expression was also found when counting TRPM-IR cells within the mucosa of IBS 
patients compared to controls (P=0.045) (Figure 5.1E, examined in 28 IBS patients 
(5/28 obtained from the Maastricht Cohort) and 7 controls (all obtained from the 
London Cohort)). IBS subtype analysis showed no differences in sigmoid TRPM8 mRNA 
expression between IBS subtypes. When comparing immunoreactivity, TRPM8-IR cells 
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were increased in the IBS-D and IBS-M groups compared to IBS-C and IBS-undefined 






















Figure 5.1 TRPM8 expressed on human immune cell populations is increased in IBS patients and TRPM8 
agonism reduces inflammatory cytokine release. A: In human colon (uninflamed), TRPM8 is 
expressed on CGRP immunoreactive fibers within the myenteric plexus. B: In inflamed colonic 
mucosa (Crohn’s disease), TRPM8 (purple) is expressed on CD11c (red) positive cells that are 
in close apposition to CGRP immunoreactive nerve endings. C & D: In IBS patient biopsies, 
high levels of TRPM8 are observed in the mucosa which co-label with CD11c+ and CD103+ 
abundantly. E: IBS patients (IBS) had significantly higher levels of TRPM8-immunoreactive cells 
compared to controls (C) (N=28 IBS, N=7 C, *P=0.045). Data shown as median and IQR, with 




These results should be interpreted with caution due to the relatively small number of 
patients in each IBS-subtype. Interestingly, in IBS patients, mRNA expression of TRPM8 
in the right-sided proximal colon was comparatively higher to that of the sigmoid colon 
(N=24, P<0.001) (Figure 5.2B). In addition, sigmoid TRPM8 mRNA expression showed 
a significant positive association with abdominal pain scores as determined using a 2-
week diary ( =48.2, 95% CI 11.5;85.0, P=0.015, Figure 5.2C). 
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Based on the experiments performed on the localization of TRMP8-IR, these data 
suggested that stimulation of TRPM8 may influence cytokine release by mucosal immune 
cells. Incubation of paired IBS biopsies with TRPM8 agonist icilin (1 μM) compared to 
buffer control, significantly reduced release of cytokines IL-1β, IL-6, and TNF-α but not 













Figure 5.2 Colonic TRPM8 mRNA expression is increased in IBS patients. A: mRNA expression of TRPM8 in 
sigmoid biopsy tissue is significantly increased in IBS patients (IBS) compared to healthy controls (C) 
(N=30 IBS, N=23 C, *P<0.001). Data shown as median and IQR, corrected for age and gender, 
with P<0.05 deemed significant. B: Differential expression of TRPM8 mRNA in right-sided colon 
(proximal) vs. sigmoid (distal colon) in mucosal samples from IBS patients (N=24, * P<0.001). 
C: TRPM8 mRNA expression in sigmoid biopsies is significantly associated to pain symptom scores 

















Figure 5.3 TRPM8 agonism reduces inflammatory cytokine release from IBS patient biopsies. Stimulation of 
IBS patient biopsies (paired) with the selective TRPM8 agonist icilin (1 μM) reduced release of 
inflammatory cytokines IL-1β, IL-6, and TNFα but not IL-8 or anti-inflammatory cytokine IL-10. 
P<0.05 is deemed significant. 
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Here, we provide preliminary findings in support for TRPM8 as a potential anti-
inflammatory mediator in IBS patients. Increased TRPM8-IR on dendritic cells within the 
colonic mucosa coupled with decreased release of cytokines begins to delineate the 
potential cellular mechanisms underlying the therapeutic benefit of TRPM8 agonists, 
such as L-menthol in peppermint oil. Decreased release of cytokines IL-1β, IL-6, and 
TNF-α from DCs by TRPM8 stimulation is important as their respective receptors are 
expressed on colonic visceral afferents that mediate pain generation.18 Indeed, 
peripheral blood mononuclear cells (PBMC) isolated from IBS patients secrete increased 
levels of these same cytokines, IL-1β, IL-6, and TNF-α, compared to healthy controls.18 
In addition, TRPM8-IR CD103+ DCs may also interact with CGRP-IR sensory neurons 
that are in close apposition, possibly by neuro-immune communications where CGRP 
inhibits cytokine release from dendritic cells as demonstrated in mice.13 Considering that 
we observed increased mRNA expression and TRPM8-IR (which appears to colocalize 
with immune cells) in IBS, we postulate that this represents an inducible 
counterregulatory anti-inflammatory mechanism. This mechanism is potentially related 
to the severity of pain symptoms, as we also observed a positive association between 
TRPM8 mRNA expression and pain scores. This is supported by data demonstrating 
increased pain scores associated with elevated levels of inflammatory cytokines in IBS-
diarrhoea patients.18 There is growing (albeit inconclusive) evidence that an 
inflammatory response is likely to contribute to pain symptoms in IBS patients through 
low-grade inflammation in a similar manner to IBD patients suggesting a commonality in 
pain mechanisms via neuro-immune mechanisms, with IBS-D patients having increased 
levels of IL-8 and IL-1.19-22 In mice, colonic visceral afferents express receptors for the 
cytokines, IL-1β, IL-6, TNF-α and IL-10, and visceral hypersensitivity is induced by these 
cytokines in electrophysiology experiments.18-22 Indeed, peripheral blood mononuclear 
cells (PBMC) isolated from IBS patients secrete increased levels of these same cytokines, 
IL-1β, IL-6, and TNF-α, compared to healthy controls.18 Human visceral afferents have 
the capacity to respond to numerous inflammatory mediators23-24 and are likely similarly 
responsive directly to cytokines. This is a mechanism that requires further detailed 
exploration but is supported by the studies presented here demonstrating close 
apposition of sensory nerve endings and immune cells. In addition, the observed 
regional differences in TRPM8 mRNA expression (proximal colon higher compared to 
distal colon) may also provide an explanation for the phenomenon that the clinical 




Certain limitations apply to our findings. First, we did not have the statistical power to 
differentiate findings according to IBS-subtype. Subtype-specific changes in neuro-
immune activation have indeed been shown previously.18 Second, patients were not 
specifically matched to controls. This resulted in an older IBS population, in particular in 
the Maastricht cohort (presumably due to a bias towards older patients undergoing 
colonoscopy). There were also more females in the IBS group compared to the control 
group, which was not significantly different in the aggregate cohort. We corrected for 
these factors by using multivariate linear regression corrected for age and gender. Third, 
diary scores were only completed by a subset of patients (15/30 of the Maastricht 
cohort). Although the subset was representative for the Maastricht IBS cohort and a 
significant association was shown between pain score and TRPM8 mRNA expression, 
the found association does not necessarily reflect a causal relationship. Fourth, the 
immunoreactivity identified need not necessarily reflect the exact expression of the 
TRPM8 protein molecule. The finding of potential TRPM8 expression on immune cells is 
a novel finding and should therefore warrant the necessary conformation from future 
studies. Nevertheless, our previous experiments using this same antibody supports the 
specificity of our findings.25 Aside from the TRPM8-specific agonist, no additional 
antagonist was applied to further confirm TRPM8 specificity of the effects observed in 
the functional experiments. Therefore, future experiments with healthy controls and 
TRPM8 antagonists will need to be performed to corroborate findings. Finally, due to 
limited availability of biopsies from controls, cytokine release experiments were only 
conducted on IBS patient biopsies. Although the number of TRPM8-IR cells was 
significantly higher in IBS compared to healthy controls, release of inflammatory 
cytokines may be reduced in control biopsy tissue.  
 
The mechanism by which TRPM8 influences IBS symptom generation therefore remains 
to be established. We were not able to directly ascertain the expression and function of 
TRPM8 on dendritic cells, the presumed neuro-immune interaction is therefore 
primarily based on surrogate parameters derived from the current experimental setup 
and therefore have an exploratory rather than a confirmatory nature. As this was a 
small, preliminary study, findings will need to be substantiated in a larger IBS patient 
cohort. Nevertheless, fundamental understanding of the role of TRPM8 in the regulation 
of neuro-immune interactions, and in particular the identification of the endogenous 
agonist(s) of TRPM8, may provide further mechanistic insight and improve therapeutic 
targeting in IBS and other disorders characterized by chronic abdominal pain. 
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Figure S5.1 Expression of TRPM8 on CD45+ cells in normal, uninflamed and inflamed (Crohn's disease) 




















Figure S5.2 TRPM8-immunoreactive (IR) cells/field of view classified by IBS sub-types. Data is presented as 
median and interquartile range (N: IBS-D=6, IBS-C=4, IBS-Mixed=8, IBS (unclassified)=10 & 
Healthy controls=7). 
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Figure S5.3 TRPM8 does not co-label with monocyte/macrophage expressing CD64 and CD68, or with 















Figure S5.4 Assessment of TRPM8 antibody specificity using a) no primary control (NPC) to eliminate non-
specific secondary antibody staining and b) blocking peptide to quench TRPM8 binding sites. 
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Peppermint oil (PO) has been shown to reduce abdominal pain in patients with Irritable 
Bowel Syndrome (IBS). PO is assumed to induce intestinal smooth muscle relaxation 
and desensitization of nociceptive nerve afferents. To increase colonic PO 
concentration, an ileocolonic release peppermint oil (IC-PO) capsule has been 
developed. The aim of this study was to compare pharmacokinetic parameters of the 
currently available small-intestinal release PO (SI-PO) and the novel IC-PO. 
 
Methods 
In this randomized, double-blind, crossover study, subjects received 182 mg of either SI-
PO or IC-PO in a crossover design with a >14 days washout period. Blood samples 
were collected to determine menthol-glucuronide concentrations.  
 
Results 
Eight healthy volunteers (50% female, median age 22) were included. The time to reach 
the maximum concentration (Tmax) of IC-PO was significantly longer compared to SI-PO 
with a median (IQR) of 360 (360-405) versus 180 (120-180) min. The lag time (Tlag) was 
significantly longer with a median (IQR) of 225 (204-284) for IC-PO compared to 37 (6-
65) for SI-PO. The Area Under the menthol-glucuronide plasma concentration time 
Curves were significantly smaller with a median (IQR) of 2331μg*h/L (2006-2510) for 
IC-PO compared to 2623 μg*h/L (2471-2920) for SI-PO. No significant differences 
were found in peak concentrations and elimination half-lives.  
 
Conclusions 
IC-PO has a significantly delayed peak menthol-glucuronide concentration and Tlag, both 
pointing to the release of PO in the more distal part of the intestine. This may enhance 
therapeutic efficacy as it results in increased exposure of colonic mucosal afferents to 
the PO. A randomized controlled trial investigating the efficacy of SI and IC-PO in IBS is 
currently ongoing. 
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Irritable bowel syndrome (IBS) is a complex functional bowel disorder affecting up to 
10-20% of the population in developed countries.1,2 It is characterized by recurrent 
abdominal pain associated with changes in bowel habits.1 Of the currently available 
treatment entities, peppermint oil released in the upper small intestine has been shown 
to be effective in reducing complaints of abdominal pain and inducing global symptom 
improvement3,4 with a reported Number Needed to Treat (NNT) of 2-3.5,6  
 
The main constituent of peppermint oil is L-menthol, which is rapidly metabolized to 
menthol-glucuronide and excreted in urine when taken orally. The exact mechanism of 
how peppermint oil acts remains to be elucidated, but is most likely multifactorial.7 
What is known however, is its dose-related relaxational effect of intestinal smooth 
muscle through the inhibition of calcium influx into the sarcolemma of smooth muscle 
cells8-10 and thereby potentially decreasing abdominal cramps. Furthermore, there are 
indications that peppermint oil has a direct local anti-nociceptive effect in the colon 
through an interaction of L-menthol with transient receptor potential (TRPM8 and/or 
TRPA1) channels, channels known to play a role in visceral hypersensitivity and pain 
generation.11-14 Other studies have reported inhibition of serotonin type 3 receptors 
(5HT3) in the human colon15, antimicrobial16,17, and carminative effects.18 Capsules 
containing peppermint oil are available as an over the counter drug on the European 
market19 and capsules containing peppermint oil microspheres are available as a medical 
food product in the USA and Canada.20 All these formulations release peppermint oil in 
the small intestine.  
 
The use of small-intestinal release peppermint oil is associated with upper gastro-
intestinal side effects, such as an altered sensation in the mouth in up to 11% and 
dyspeptic symptoms including heartburn, reflux and belching in up to 24% of patients.21-
24 These burdensome symptoms negatively affect therapy adherence. To decrease these 
side effects, it could be argued that an ileocolonic release of peppermint oil is beneficial. 
In addition, a colonic release may increase efficacy in IBS patients by enhancing local 
colonic relaxation and TRP stimulation. Therefore, a new peppermint oil soft capsule 
formulation with a predominant distal ileocolonic release has been developed using a 
previously described ileocolonic delivery technology to coat existing peppermint oil 
capsules.25-27  
 
This study aimed to determine the pharmacokinetic differences and safety of both the 
small-intestinal release peppermint oil and the ileocolonic release peppermint oil in an in 
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vitro model and in healthy volunteers. Because the ileocolonic release formulation will 
release the peppermint oil in the ileocolonic region as opposed to the upper small 
intestine, we hypothesized that this will result in a delayed and possibly lower peak 
menthol-glucuronide concentration in the plasma compared to plasma concentrations 
found after administration of small-intestinal release capsules. 
Materials and methods 
In vitro GISS experiment 
The novel ileocolonic release capsules were tested in the gastro-intestinal simulation 
system (GISS). The GISS is an in vitro model based on the pharmacopoeial dissolution 
test and has been described in detail elsewhere.28 In summary, the model simulates pH 
and transit times through the human gastro-intestinal tract and enables variation of these 
and other parameters such as osmolality and agitation.28,29 Table 6.1 shows the four 
GISS test phases.  
Phase I human trial 
The research protocol was approved by the Maastricht University Medical Center+ 
Committee of Ethics and all study procedures were performed in compliance with 
Good Clinical Practice Guidelines and according to the revised Declaration of Helsinki. 
The study has been registered in the US National Library of Medicine (NCT 02291445) 
and the EudraCT database (2014-004195-32) and all subjects gave a written informed 
consent prior to participation. 
 
Table 6.1 Specifications of the four phases of the dissolution test (GISS). 








I Stomach   500 2.0 1.2 ± 0.10 150 ± 25 
II Jejunum   629 2.0 6.8 ± 0.20 250 ± 50 
III Ileum (distal)   940 0.5 7.5 ± 0.25 250 ± 50 
IV Colon (proximal) 1000 1.5 6.0 ± 0.25 250 ± 60 
GISS; gastro-intestinal simulation system. Adapted from Schellekens et al., 2007.28 
 
Subjects 
All subjects were healthy, non-smoking volunteers between 18 and 65 years old, with a 
BMI between 18 and 25 kg/m2 and no history of gastrointestinal or other chronic 
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disease (as assessed by screening in which medical history, physical examination, and 
vital signs were checked). Participants were recruited via local advertisements and a 
national recruitment website. Exclusion criteria included high intake of alcohol 
(>15 consumptions per week) or caffeine (>8 cups coffee a day). Women of fertile age 
underwent a standard pregnancy test and were instructed to continue their 
contraception throughout the study. 
 
Medication use (except for contraception) was prohibited in the 14 days prior to the 
test period and volunteers were instructed to abstain from alcohol, caffeine, grapefruit, 
and menthol- or peppermint oil containing products such as toothpaste, candy, and 
mouthwash for 48 h before each test day. Menthol-free toothpaste was provided 
beforehand.  
Study design 
This study is designed according to US Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) guidelines for bioequivalence studies30,31; a 
randomized, double blind, two-treatment, single dose, crossover pharmacokinetic study 









Figure 6.1 Study design; after screening, participants (healthy volunteers) were randomized and received 
small-intestinal release peppermint oil (PO) or ileocolonic release PO in a crossover design with 
a wash-out period of <21 days but >14 days. 
 
 
The study consisted of two identical test periods of 24 hours in which all participants 
received 182 mg of ileocolonic and small-intestinal release peppermint oil capsules. In 
line with the European Pharmacopoeia entry for peppermint oil32, both 182 mg 
formulations contained between 51 mg and 105 mg of L-menthol (normal variance 
between capsules, no differences between small-intestinal versus ileocolonic release). As 
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10 h33,34, no carry-over effects were anticipated as a result of the chosen wash-out 
period. 
 
Randomization, preparation, and labeling of the study medication were performed by an 
independent third party (Tiofarma BV, Oud Beijerland, The Netherlands). Half of the 
subjects received ileocolonic release capsules in the first test period (and small-intestinal 
release capsules in the second test period) and half of the subjects received small-
intestinal release capsules in the first test period (and ileocolonic release capsules in the 
second test period), on the basis of on a randomized pre-selection using web-based 
randomization software. All capsules were packaged in identical, sealed containers and 
subject numbers and whether it was the first or second test day were mentioned on the 
label, ensuring allocation concealment.  
 
On both test days, subjects arrived at the hospital after fasting overnight. Upon arrival, 
the subject had an intravenous catheter inserted for blood sampling. Prior to the 
administration of the peppermint oil capsule, several baseline measurements were 
taken; a venous blood sample was taken to determine baseline plasma menthol-
glucuronide, an evaluation of baseline side effects was conducted and blood 
pressure/heart rate were measured. At t=0, the study medication was administered 
with a 200 mL glass of water. Consequently, at t= 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, and 
24 h, venous blood sampling, side effect evaluation and blood pressure/heart rate 
measurements were repeated. Two hours after capsule intake, a standardized breakfast 
was provided (two sandwiches with cheese and cucumber, glass of milk, 384 calories in 
total). Lunch and dinner were subsequently provided at t=6 h and t=10 h after capsule 
intake, respectively. The last measurement before midnight took place at t=14 h, after 
which the intravenous cannula was removed and the subject was allowed to return 
home. Participants returned to the hospital for the last measurements at t=24 h. 
Throughout the complete study, volunteers were instructed to report any side effects. 
A telephonic evaluation took place between both test periods.  
Primary and secondary outcomes 
The primary outcome was Tmax: time to reach peak menthol-glucuronide concentration 
in plasma. The secondary outcomes were; Tlag, time to reach a menthol-glucuronide 
concentration of 45 μg/L; AUC, Area Under the plasma concentration Curve; Cmax, 
peak menthol-glucuronide concentrations; T1/2, elimination half-life; side effects and 
tolerability, as determined by a side effect questionnaire and blood pressure/heart rate 
measurement. 
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The pharmacokinetic profile of small-intestinal and ileocolonic release peppermint oil 
capsules was determined by menthol-glucuronide analysis in the blood. In total, 14 
venous blood samples (+/-8 mL per time point) were collected in heparinized tubes at 
the time points mentioned above. Within two hours after collection, samples were 
centrifuged at 3120 rpm for 10 min at 4°C and plasma supernatants were stored at -
80°C until assayed. Samples were analyzed for menthol-glucuronide concentration, the 
primary metabolite of L-menthol, by a 15 h incubation at 37°C with beta-glucuronidase 
and using Gas Chromatography Mass Spectrometry (GC/MS); the method has been 
described in detail elsewhere.35,36 A detection limit of 5 μg/L applied. Menthol-
glucuronide concentrations are expressed in micrograms per liter.  
Statistical analysis 
A power calculation was performed (two-sided=0.05; power=0.80; Sd=109; minimal 
detectable difference in means=150min); at least 7 subjects needed to complete the 
study to reliably demonstrate a significant difference in Time to reach peak menthol-
glucuronide concentration in the plasma (Tmax), between the small-intestinal versus the 
novel ileocolonic release peppermint oil capsules. Anticipating 1 dropout, the aim was 
to include 8 participants. 
 
Statistical analyses were carried out using IBM SPSS statistics 23.0 (Chicago IL, USA) and 
GraphPad Prism 6.0 (La Jolla, CA, USA) for Macintosh. As the sample size was small 
(N=8), data were analyzed using non-parametric tests. Tmax, Tlag, Cmax values were 
determined directly from the plasma concentration-time profiles for each subject and 
were analyzed for comparison by the Wilcoxon-signed rank test. AUCs and T1/2 were 
calculated by pharmacokinetic software MWPharm 3.80 (Mediware) using the log-linear 
trapezoidal rule (non-compartmental analysis). AUCs and Cmax were logarithmically 
transformed and a 90% CI interval was calculated of the log-transformed parameter 
ratios (small-intestinal/ileocolonic release) to assess bioequivalence. A P value of less 
than 0.05 was considered statistically significant. There were no missing data. 
Safety and tolerability analysis 
Subjects were monitored for adverse events by direct observation during the first 14 h 
after peppermint oil administration and again for 1 h after 24 h. During both test 
periods, participants completed a questionnaire regarding adverse events and 
tolerability at the 14 time points mentioned above. In addition, vital signs were reviewed 
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at these 14 time points. In between test periods and after the last test period, 
volunteers were telephoned to inquire after possible adverse events. 
Results 
In vitro GISS experiment 
In vitro analysis of the newly produced ileocolonic release peppermint oil capsules in the 
GISS showed that the actual release of the peppermint oil was postponed until the last 
phase (colon). Part of the coating remained intact and contained a small residual amount 
of peppermint oil (Table 6.2).  
 
Table 6.2 Results of ileocolonic release peppermint oil capsules in in vitro dissolution test (GISS). 
Phase  Gastrointestinal 
segment  
Capsule appearance Capsule location in 
dissolution vessel 
Oil observed on 
surface buffer 
solution 
I Stomach None 
II Jejunum Slight amount 
III Ileum (distal) Small amount 
IV Colon (proximal) 
Intact 
Intact, minor cracks in coating 
Intact, small cracks in coating  





Floating on surface 
buffer solution 
Large amount 
GISS; gastro-intestinal simulation system, PO; peppermint oil. 
Phase I human trial 
Eight healthy volunteers were screened, included, and randomly assigned to a specific 
treatment order. All participants were between 20 and 65 years old (median 22.2, IQR 
20.8-28.8). See Table 6.3 for baseline characteristics. All participants completed the 
study. 
 




PO on first test day 
Ileocolonic release 
PO on first test day 
 
N=8 N=4 N=4 
Female sex, N (%) 4 (50) 1 (25) 3 (75) * 
Age, years (median + IQR) 22.2 (20.8-28.8) 24.1 (21.2-55.0) 21.7 (20.6-27.9) 
BMI, kg/m2 (median + IQR) 21.5 (20.2-23.0) 21.7 (18.5-23.8) 21.5 (20.6-22.2) 
Height, cm (median + IQR) 177 (171-183) 181 (177-192) 173 (168-177) 
Weight, kg (median + IQR) 65.5 (64.0-72.0) 71.0 (65.3-79.8) 64.0 (61.8-66.3) 
Differences were tested using Mann-Whitney U test for non-parametric data and chi-square or Fisher’s exact 
for parametric data. * Significant difference in gender between the group receiving small-intestinal peppermint 
oil (PO) on the first test day and the group receiving ileocolonic release PO on the first test day (P<0.05). 
N=8 (total group). 
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Baseline menthol-glucuronide concentrations were all below the detection limit, except 
for one subject on the first test day who had a concentration of 5.79 μg/L. These low 
levels were considered evidence that the instructions given regarding avoidance of 
menthol-containing products were sufficient.  
 
The pharmacokinetic parameters of 182 mg small-intestinal and 182 mg ileocolonic 
release peppermint oil are shown in Table 6.4. The plasma concentration time curve is 
given in Figure 6.2. For an overview of plasma concentration time curves per individual 
subject, please see Figure S6.1 in the Supplementary Material. 
 











parameter (90% CI) 
Tmax (min) 
   Arithmetic Mean (SEM) 
   Median (IQR) 












   Arithmetic Mean (SEM) 
   Median (IQR) 











   Arithmetic Mean (SEM) 
   Median (IQR) 













   Arithmetic Mean (SEM) 
   Median (IQR) 












   Arithmetic Mean (SEM) 
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Differences between both peppermint oil capsules were tested using Wilcoxon-signed-rank test. * Significant 
difference between small-intestinal release and ileocolonic release peppermint oil (P<0.05). LN; natural log, 
CI; confidence interval, Tmax; time to reach maximum plasma concentration, SEM; standard error of the mean, 
IQR; interquartile range, Tlag; time to reach a menthol-glucuronide concentration of 45 μg/L, AUC; area under 
the concentration time curve, Cmax; maximum concentration, T1/2; Time required for the plasma 
concentration to reach half of its original value (Elimination half-life), N.A.; non-applicable. 
 
Tmax of the ileocolonic release peppermint oil capsules was significantly longer in all 
participants compared to Tmax of small-intestinal release peppermint oil with a median 
(IQR) of 360 minutes (360-405) versus 180 minutes (120-180) respectively, P<0.05 
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peppermint oil, N=8 
Ileocolonic release 
peppermint oil, N=8
(P=0.010). Median difference in Tmax between both formulations in individual participants 
was 180 minutes, (IQR 180-240, 95% CI 180-140). Tlag was significantly delayed in 
ileocolonic release peppermint oil, with a median (IQR) of 225 (204-284) versus 37 (6-
65) minutes, P<0,05 (P=0.012). In addition, AUCs0-24hrs differed significantly between the 
ileocolonic and the small-intestinal release capsules, with a median (IQR) of 2331 
μg*h/L (2006-2510) and 2623 μg*h/L (2471-2920) respectively, P<0.05 (P=0.017). No 
significant differences were found in Cmax (P=0.28) and T1/2 (P=0.16) of either capsule. 



















Figure 6.2 Concentration-time curve, menthol-glucuronide concentration was measured in 8 healthy 
volunteers (N=8) in ug/mL on 14 time points after both peppermint oil (PO) capsule 
administrations. The ileocolonic release PO has a significantly elongated time to reach the 
maximum plasma concentration. Circles and squares represent median plasma glucuronide 
levels + Interquartile Range (+IQR). 
Adverse events and tolerability 
No serious adverse events occurred during the study nor during one week follow up. 
Adverse events were reported in five subjects, but were all mild and transient. Adverse 
events are shown in Table 6.5. 
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Acid regurgitation, N (%) 1 (12.5) 0 (0) 
Fecal urgency, N (%) 1 (12.5) 0 (0) 
Headache, N (%) 
   Mild 







Altered fecal odor, N (%) 0 (0) 2 (25) 
Vital sign abnormalities, N (%) 0 (0) 0 (0) 
PO; peppermint oil, N; number. N=8 (total group). Altered fecal odor implied a peppermint oil odor. 
Discussion 
This is the first study to investigate a novel ileocolonic release peppermint oil 
formulation and to compare its pharmacokinetic parameters, safety, and tolerability with 
the small-intestinal release peppermint oil formulation currently available. Our results 
demonstrate that ileocolonic release peppermint oil soft capsules have a significantly 
delayed lag time (Tlag) and reach their peak concentration significantly later (Tmax) than 
small-intestinal release peppermint oil capsules. These findings point to the release of 
peppermint oil in a more distal part of the human gastrointestinal tract, the colon most 
presumably. Although different in release kinetics, a single dose of both formulations of 
peppermint oil can be considered bioequivalent regarding exposure in healthy 
volunteers, because the 90% confidence interval (CI) for the log-transformed parameter 
ratios (small-intestinal/ileocolonic release) is between the 80-125% confidence interval, 
the standard bioequivalence criterion as stated in the FDA and EMA guidelines on the 
investigation of bioequivalence.30,31  
 
Several authors have previously reported on the pharmacokinetic parameters of small-
intestinal release peppermint oil, often referred to as enteric-coated capsules: White et 
al. found a mean Tmax of 5 and 2.8 hours for menthol-glucuronide after three 
Colpermin® or Mintec® capsules were taken, containing 0.2 ml peppermint oil each 
and a mean L-menthol concentration of 110 mg and 117 mg respectively.19 Mascher et 
al. found a mean Tmax of 3 hours and a mean menthol Cmax of 1196 ng/ml after two 
Enteroplant® capsules were taken, containing 90 mg of peppermint oil each.34 Our 
findings for the small-intestinal release peppermint oil capsules are in line with both 
White et al. and Masher et al. in terms of Tmax found, although the Cmax differed slightly. 
A possible explanation for this modest discrepancy is that different small-intestinal 
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release formulations of peppermint oil, produced by different manufacturers, produced 
from a different harvest of mint leaves, were used. L-Menthol concentrations in 
peppermint oil are known to vary between 30% and 55%.32 When taken orally, L-
menthol is rapidly metabolized to menthol-glucuronide, which can be measured 
successfully in blood-plasma by Gas Chromatography Mass Spectrometry.35 
Consequently, the menthol-glucuronide is excreted in urine.9 
 
The menthol-glucuronide concentration was not measured directly in the small intestine 
and colon because of the practical difficulties of an ileocolonic intubation. Unlike other 
studies that have compared peppermint oil formulations, however, we think 
pharmacokinetic parameters could be compared more reliably as both formulations 
used here contained the same amount of L-menthol; the ileocolonic release peppermint 
oil capsules were created by overencapsulation of small-intestinal release peppermint oil 
capsules from the same manufacturer.19 We presume that the difference in Tmax found 
between the small-intestinal and ileocolonic release peppermint oil reflects the longer 
transit needed to reach the colon.  
 
It should be also noted that our study showed large interquartile ranges in plasma 
menthol-glucuronide levels, indicating high inter-subject variability. Measures taken to 
decrease any variability were standardized meals and snacks, an overnight fast, and the 
complete abstinence from caffeine, alcohol, smoking, and medicines affecting 
gastrointestinal function in a predefined period prior to drug administration. The 
variability found can therefore probably be explained by normal biological variation in 
gastrointestinal transit times, and polymorphic variation in cytochromes P450 (CYP) 
enzymes, which are known to facilitate L-menthol metabolism.37-40 
 
The delayed peak concentration of the novel ileocolonic release peppermint oil and, 
thus, more distal exposure to peppermint oil are not only expected to increase 
therapeutic efficacy, but it is also expected to lead to a different and possibly milder 
spectrum of adverse events, as there is less upper gastrointestinal but more distal 
gastrointestinal exposure to peppermint oil. This pilot study has examined possible 
adverse events after only a single dose of peppermint oil and was not powered to draw 
any conclusions regarding adverse events since it only included eight volunteers. In 
addition to evaluating short term adverse events, future studies should also evaluate the 
long-term adverse events occurring when peppermint oil capsules of 182 mg are taken 
three times daily, the dosage identified by previous studies as being effective in IBS 
patients and the industry norm.20,22,24,41 
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As discussed above, there are indications that peppermint oil has a direct local anti-
nociceptive effect in the intestine through an interaction with transient receptor 
potential (TRP) channels. When peppermint oil makes contact with the skin or oral 
membranes, a general cooling sensation is induced through stimulation of the TRPM8 
(transient receptor potential melastain 8) receptor.42 Interestingly, experimental 
research in murine models suggests that L-menthol, through stimulation of the TRPM8 
receptor, may be able to cross-desensitize the TRPV1 (transient receptor potential 
vanilloid 1) receptor. TRPV1 is a pro-nociceptive receptor, well-known for its 
involvement in animal models of visceral hypersensitivity and its up-regulation in the 
colon-mucosa of IBS patients13,43, indicating a role in pain generation in IBS. Together 
with its role in thermo-sensation, TRPM8 is believed to play a role in protective 
mechanisms in states of intestinal inflammation.44 Similar to the stimulation of TRPM8, 
menthol may also be able to stimulate the TRPA1 (transient receptor potential ankyrin 
1) receptor, another TRP channel suggested to contribute to visceral pain. TRPV1, 
TRPA1, and TRPM8 receptors are probably co-expressed on ileocolonic mucosal 
afferents11,45, suggesting a complex and incomprehensively understood interaction 
between these receptors that leads to the analgesic effect of peppermint oil. We 
hypothesize that the ileocolonic release of peppermint oil enhances the therapeutic 
efficacy as the application specifically results in increased exposure of the ileocolonic 
mucosal afferents described. Moreover, the anti-spasmodic effect and, thereby, 
alleviating effect of peppermint oil performs equally well, if not better, when peppermint 
oil is applied to the colon locally; it has been applied intraluminally in endoscopic 
practice to decrease pain caused by the procedure and to enhance the field of view 
during the endoscopy through the suppression of peristalsis.46-48 This pharmacokinetic 
study served as proof of concept study and we are currently conducting a randomized, 
placebo-controlled trial in IBS patients to compare the efficacy of small-intestinal and 
ileocolonic release peppermint oil in IBS patients (NCT 02716285). This study should 
confirm whether peppermint oil capsules with an ileocolonic release do indeed 
attenuate abdominal pain in IBS patients.  
 
A potential limitation of this study is that L-menthol was the only ingredient of 
peppermint oil taken into account; other constituents of peppermint oil include 
menthone, cineole, menthyl acetate, isomenthone, menthofurane, limonene, pulegone, 
carvone, and isopulegol.32,49 These could potentially contribute to clinical effects, but 
were not measured in the plasma samples. For example, in addition to the anti-
spasmodic effect, peppermint oil has been shown to inhibit serotonin type 3 receptors 
(5HT3) in the human colon.15 This inhibitory effect could only be partly accounted for by 
L-menthol in another experimental study50, suggesting the involvement of one or more 
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of the other ingredients mentioned above. Furthermore, the toxic compounds known 
to be present in peppermint oil in very low quantities – in equal dosages for ileocolonic 
release and small-intestinal release peppermint oil - were also not measured. Pulegone 
and menthofuran normally appear in peppermint oil in doses of between 1-9% and less 
than 4.0%32 and could potentially harm chronic peppermint oil users. Some animal 
studies reported toxicity due to pulegone and menthofuran; high dosages in rats were 
associated with hepatocyte vacuolization, liver necrosis, and possibly cyst-like spaces in 
the cerebellum.7 Nevertheless, when taken in the recommended dosages, the EMA and 
the FDA consider peppermint oil to be generally safe. Even if the EMA states that no 
confirmed cases of liver damage due to peppermint oil usage have been reported51, they 
do advise against the continuous use of peppermint oil for longer than three months.52 It 
remains to be elucidated whether this advice is substantiated – no studies have assessed 
the long-term effect, thus no studies have revealed damage occurring after three months 
– but further research into this topic is certainly desired. 
 
Of note is that half of the participants were male, whereas the male/female ratio in IBS 
patients is usually estimated to be 1:2.53 Ideally, future research should include IBS 
patients who may experience altered motility and/or altered transit times and should 
preferably also investigate relatively more females. Although large effects of sex on 
pharmacokinetic parameters are not expected, factors such as menstrual cycle and 
lower body weights, and thereby smaller distribution volumes, higher body fat 
percentages etc. could be of influence.54 
Conclusions 
A novel ileocolonic release peppermint oil formulation has been developed to decrease 
upper gastro-intestinal side effects associated with small-intestinal release peppermint 
oil. This study provides evidence that the ileocolonic release peppermint oil has a 
significantly delayed peak menthol-glucuronide concentration, pointing to a more 
delayed and therefore more distal intestinal release of peppermint oil. The ileocolonic 
release may enhance therapeutic efficacy as it results in increased exposure to the 
colonic mucosal afferents and decrease adverse events. A randomized placebo-
controlled trial (RCT) investigating the efficacy of small-intestinal and ileocolonic release 
peppermint oil in IBS patients has been initiated and is currently ongoing. This RCT is 
based on the pharmacokinetic data from the present study. 
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Figure S6.1 Concentration-time curve, menthol-glucuronide concentration was measured in healthy 
volunteers (N=8) in ug/mL on 14 time points after both peppermint oil (PO) capsule 
administrations. 
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Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack 
of evidence for efficacy from high-quality controlled trials. We studied the efficacy and 
safety of small-intestinal release peppermint oil in patients with IBS and explored the 
effects of targeted ileocolonic release peppermint oil. 
 
Methods  
We performed a double-blind trial of 190 patients with IBS (Rome IV criteria) at 4 
hospitals in The Netherlands from August 2016 through March 2018; 189 patients were 
included in the intent-to-treat analysis (mean age, 34.0 years; 77.8% female; 57.7% in 
primary care), and 178 completed the study. Patients were randomly assigned to groups 
given 182 mg small-intestinal release peppermint oil, 182 mg ileocolonic release 
peppermint oil, or placebo for 8 weeks. The primary endpoint was abdominal pain 
response, as defined by the US Food and Drug Administration (FDA): at least a 30% 
decrease in the weekly average of worst daily abdominal pain compared with baseline in 
at least 4 weeks. The co-primary endpoint was overall relief of IBS symptoms, as defined 
by the European Medicines Agency (EMA). Secondary endpoints included abdominal 
pain, discomfort, symptom severity, and adverse events (AEs). 
 
Results  
Abdominal pain response did not differ significantly between groups: 29 of 62 patients in 
the small-intestinal release peppermint oil group had a response (46.8%, P=0.170 vs 
placebo), 26 of 63 patients in the ileocolonic release peppermint oil group had a 
response (41.3%, P=0.385 vs placebo), and 22 of 64 patients in the placebo group had a 
response (34.4%). We did not find differences among the groups in overall relief (9.7%, 
P=0.317 and 1.6%, P=0.351 vs 4.7% for placebo). The small-intestinal peppermint oil 
did, however, produce greater improvements than placebo in secondary outcomes of 
abdominal pain (P=0.016), discomfort (P=0.020), and IBS severity (P=0.020). AEs, 
although mild, were more common in both peppermint oil groups (P<0.005). 
 
Conclusions  
We found that neither small-intestinal release nor ileocolonic release peppermint oil (8 
weeks) produced statistically significant reductions in abdominal pain response or overall 
symptom relief, when using FDA/EMA recommended endpoints. The small-intestinal 
release peppermint oil did, however, significantly reduce abdominal pain, discomfort, 
and IBS severity. These findings do not support further development of ileocolonic 
release peppermint oil for treatment of IBS. 
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Irritable bowel syndrome (IBS) is a disorder of the gut-brain axis characterized by 
recurrent chronic abdominal pain and altered bowel habits.2 IBS is highly prevalent with 
an estimated prevalence in the general population of 5-6% according to Rome IV 
criteria.3,4 IBS has a profound negative impact on quality of life and carries a substantial 
socioeconomic burden.5 Although the number of therapeutic options has grown 
recently6, treatment of abdominal pain remains challenging and is often unsatisfactory. 
One of the pharmacotherapeutic entities currently used is peppermint oil. This agent of 
herbal origin has menthol as its main constituent and is presumed to have several 
mechanisms of action including intestinal smooth muscle relaxation7, modulation of 
transient receptor potential (TRP) channel mediated visceral nociception8-10, 
5-hydroxytryptamine antagonism11, antimicrobial and antifungal effects12-14, and ĸ-opioid 
receptor agonism.15 Enteric-coated capsules that release peppermint oil in the small 
intestine are currently available as an over-the-counter (OTC) drug in Europe16 and as a 
medical food labeled product in the USA and Canada.17 
 
Guideline recommendations18 regarding the use of (small-intestinal release) peppermint 
oil in IBS treatment are currently based on prior studies showing highly favorable results 
in terms of abdominal pain reduction and global improvement of symptoms.17,19-23 Most 
of these studies, however, were hampered by significant methodological shortcomings 
that impede the ability to draw firm conclusions. Moreover, the Food and Drug 
Administration (FDA)24 and the European Medicines Agency (EMA)25 have defined 
robust, albeit provisional, endpoints for IBS trials since 2012, and the Rome diagnostic 
criteria for IBS have been updated in 2016. Taken together, there is a need for a well-
designed trial in Rome IV-defined IBS patients that investigates efficacy according to 
these stringent endpoints to refute or validate earlier findings. The primary objective of 
this multicenter, randomized, placebo-controlled study was thus to determine the 
efficacy and safety of small-intestinal release peppermint oil in a Rome IV IBS population 
according to FDA and EMA guidelines. We hypothesized that, in Rome IV IBS patients, 
conventional small-intestinal release peppermint oil would be more effective compared 
to placebo. 
 
A secondary aim was to explore the efficacy and safety of a novel soft gel peppermint oil 
capsule with a predominant distal ileocolonic release. The pharmacokinetic profile of 
this formulation has been described recently.1 The rationale for using ileocolonic release 
was based on experimental findings that peppermint oil has a direct local antinociceptive 
effect in the colon through an interaction of menthol with TRPM8 and/or TRPA1 
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channels on sensory afferents.8 We therefore hypothesized that a higher exposure of 
the colonic afferents through targeted ileocolonic delivery of peppermint oil would 
enhance antinociceptive effects and thereby improve efficacy. In addition, small-intestinal 
release peppermint oil therapy is often discontinued due to mild, but burdensome upper 
gastrointestinal (GI) adverse events (AEs) that are assumed to be related to the 
relaxation of the lower esophageal sphincter26 and can hamper therapy adherence. We 
therefore also postulated that the ileocolonic release formulation would decrease these 
AEs. 
Materials and methods 
Study design, setting, and patients 
The PEppeRmint Oil for the treatment of Irritable Bowel Syndrome: optimizing 
therapeUtic strAtegies using targeted DElivery (PERSUADE) study was a randomized, 
double-blind, placebo-controlled trial and was performed in four Dutch hospitals: one 
academic with a combined secondary and tertiary care function (Maastricht University 
Medical Center+ (MUMC+)), and three secondary care (Hospital Gelderse Vallei, Ede; 
Alrijne Hospital, Leiden; Medical Center Leeuwarden). The study protocol had been 
approved by the MUMC+ Ethics Committee (applicable to all centers). All study 
procedures were performed in compliance with Good Clinical Practice Guidelines and 
according to the revised Declaration of Helsinki. All subjects gave written informed 
consent prior to participation. All authors had access to the study data and reviewed 
and approved the final manuscript.  
 
Patients, between 18 and 75 years of age, fulfilling the Rome IV criteria for IBS, without 
alarm symptoms, were recruited via primary care, via the outpatient clinics of the 
above-mentioned hospitals, or via self-referral through public advertisements, social 
media, and the Dutch IBS patient federation. Detailed in- and exclusion criteria are given 
in the Supplementary Material. Patients were screened for eligibility in a prescreening 
(telephone interview) and a medical screening that included history taking and a physical 
examination. After the screening, eligible patients entered a 14-days pre-treatment 
period during which they scored their daily worst abdominal pain in a digital symptom 
diary (scored on an 11-point numerical-rating-scale (NRS), 0=no pain, 10=worst 
possible pain). Subsequently, those with a mean worst abdominal score of at least 3 
were then randomized to 182 mg of small-intestinal release peppermint oil (Tempocol, 
WillPharma S.A.), 182 mg of ileocolonic release peppermint oil (Tempocol, core-
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capsules, coated with a Colopulse coating layer1,27), or placebo (microcrystalline 
cellulose) intake orally. Randomization was done with ALEA (Abcoude, The 
Netherlands) Screening and Enrolment Application Software using the minimization 
method, accounted for inclusion center, IBS subtypes (diarrhea, mixed, constipation, 
undefined), sex, and age. All study medication was over-encapsulated with identical hard 
gelatin capsules and packaged in identical blisters to ensure allocation concealment by 
Tiofarma S.A. (Oud-Beijerland, the Netherlands). Patients were instructed to self-
administer three capsules daily, 30 min before breakfast, lunch, and dinner, during eight 
weeks. An eight-week treatment period was chosen as we expected the clinical effect to 
occur within this period based on previous studies.17,21 This treatment duration was also 
selected to mitigate potential hazardous effects of long-term peppermint administration 
related to certain constituents.26 Nevertheless, safety issues were later refuted by the 
EMA.28 To decrease possible AEs, in particular heartburn and belching, a gradual 
titration schedule was followed in the first week of 1-1-2-2-2-3-3 capsules per day, 
respectively. Patients, investigators and health care providers were blinded to treatment 
allocation. 
 
Patients were instructed to refrain from lifestyle changes (e.g. a change in diet or 
exercise routine) throughout the study. Rescue medication, i.e. acetaminophen alone or 
a combination with NSAIDs, PPIs, antacids, Histamine H2-receptor antagonists, 
loperamide, polyethylene glycol and psyllium, were allowed after consultation with the 
investigator (ZW). All rescue medication had to be documented in the digital diary. 
 
Study visits were conducted at the start of the pre-treatment period (screening), at 
randomization, and at the end of the treatment period (end-visit). Throughout the pre-
treatment and eight-week treatment periods, patients had to complete daily questions 
on worst abdominal pain (scored on an 11-point NRS, 0=no pain, 10=worst possible 
pain), stool evacuation frequency and consistency assessed by the Bristol Stool Form 
Scale (BSFS), and presence of AEs in a digital diary. Relief of IBS symptoms (scored on a 
7-point NRS ,1=no relief, 7=completely relieved), and abdominal discomfort, abdominal 
bloating, abdominal cramping, belching, nausea, and urgency (all scored on an 11-point 
NRS, 0=no symptoms, 10=worst possible symptoms) were assessed once weekly. In 
addition, at week 1, 2, 4, 6, and 8, and at month 3 and 6 of follow-up after the 
treatment period, patients were asked to complete several web-based questionnaires, 
including the IBS Severity Scoring System (IBS-SSS)29; the Irritable Bowel Syndrome 
Quality of Life (IBS-QoL)30, the EuroQoL-5D (EQ-5D-5L)31,32, the Generalized Anxiety 
Disorder-7 (GAD-7)33, and the Patient Health Questionnaire-9 (PHQ-9).34 At the 
beginning of week 2, 4, and 6, patients were contacted by telephone for follow-up and 
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safety assessment. The treatment period was followed by a six months follow-up period 
in which no treatment was given. An overview of the study design and timing of the 
questionnaires is given in Supplementary Figure S7.1. 
Electronic data capture and data storage 
Investigators documented all research findings in an Electronic Case Report File (eCRF). 
An electronic smartphone application was developed for the digital symptom diary in 
which entering data from previous days was impossible. The eCRF, web-based 
questionnaires, and diary all featured built-in routing, data validation, and response 
requirements to stimulate data quality and completeness. 
Primary	efficacy	endpoints 
The primary endpoint was the percentage of abdominal pain responders, according to 
FDA definition24, with a responder being a patient with at least 30% decrease in the 
weekly average of worst daily abdominal pain (scored on an 11-point NRS) compared 
to baseline, in at least 50% of the treatment period, i.e. four weeks.  
 
In line with EMA recommendations to use a global improvement outcome in trials 
treating two or more IBS-subtypes25, response to global relief of IBS symptoms was 
included as a co-primary endpoint, using a 7-point NRS. A global relief responder was 
defined as a patient with a weekly relief of threshold 6 or 7 on the NRS in at least 50% 
of the treatment period, i.e. four weeks.  
 
We expected that peppermint oil would not influence bowel habit substantially. 
Therefore, improvements in bowel movements and stool consistency were not included 
into a combined primary efficacy endpoint24, but were analyzed separately as secondary 
outcome measures. 
Secondary endpoints 
Secondary endpoints included symptom improvements of abdominal pain, abdominal 
discomfort, abdominal bloating, abdominal cramping, belching, nausea, and urgency. IBS 
symptom severity, stool frequency and consistency (based on the BSFS), use of rescue 
medication, quality of life, and comorbid anxiety and depression scores were also 
assessed. Another secondary endpoint was defined as moderate relief of IBS symptoms, 
with a patient being a responder if they had a symptom relief of threshold 5 or higher on 
the 7-point NRS in at least four of the treatment weeks. In addition, a different 
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threshold for the abdominal pain response was included, with a responder being a 
patient with at least 50% decrease in worst daily abdominal pain in at least four weeks. 
Primary efficacy outcomes were also evaluated according to IBS subtype as secondary 
outcomes. 
 
Treatment adherence was quantified by counting returned capsules at the study end-visit. 
Patients were deemed adherent if at least 80% of study medication was taken during the 
treatment period or until discontinuation of the study. Compliance rate to the digital diary 
was defined by percentage of entry days completed during the treatment period or until 
discontinuation with the study. 
Safety assessment 
Safety was assessed by the incidence, nature, and severity of AEs occurring during the 
treatment period. Researchers documented AEs during all telephone follow-up 
moments (week 2, 4, and 6) and during the end-visit at week 8. In addition, participants 
were asked to report AEs in the digital symptom diary.  
Statistical analysis 
The sample size calculation was based on the most recent meta-analysis35 available at 
the time of study design, indicating that 57% of the peppermint oil group had abdominal 
pain improvement (versus no improvement), compared with 27% in the placebo group. 
A sample size of 42 in both the placebo and the small-intestinal release peppermint oil 
group was required to detect a 30% efficacy difference between groups, with a power of 
80% at the two-sided 0.05  -level. Anticipating that ileocolonic release would increase 
efficacy, the same sample of 42 was chosen to compare this group with placebo. To 
account for heterogeneity, an inflation factor of 1.23 was applied.36 To account for a 
13% dropout, an additional 1.15 inflation factor was applied. Therefore, 60 patients per 
group were required.  
 
All analyses were based on the intention-to-treat (ITT) principle, with correction for the 
minimization variables sex, inclusion center, IBS-subtype, and age. The responder 
outcomes were analyzed using multiple logistic regression. Odds Ratios (OR), two-sided 
95% confidence intervals (CI), and corresponding P-values are reported. Patients with 
fewer than four weekly diary entries were considered “non-responders” for that week, 
regardless of their score. To account for multiple comparisons (both intervention 
groups with placebo and two primary outcomes), two-sided P-values of 
≤0.05/4=0.0125 were considered statistically significant for the primary outcomes. 
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Additionally, a per-protocol (PP) analysis was performed. The PP-population included all 
randomized patients who had at least 80% adherence to treatment and had completed 
the treatment period. A detailed description of the statistical analysis of secondary 
outcomes, for which a multiplicity correction was applied resulting in a significance level 
of  <0.025, is given in the Supplementary Material. Statistical analyses were carried out 
using IBM (Armonk, NY, USA) SPSS statistics 25.0 for Macintosh. 
Results 
Patient disposition, demographics, and baseline characteristics 
Between August 2016 and March 2018, 622 patients were screened for participation in 
this study of whom 190 were randomized (Supplementary Figure S7.2). One patient was 
erroneously randomized, i.e. without having a mean worst abdominal score of more 
than 3 during the pre-treatment period, and excluded from further analyses. Therefore, 
the modified ITT-population consisted of 189 patients. Baseline characteristics are 
shown in Table 7.1 and were balanced across treatment groups (mean overall age 
34.0 years old, standard deviation 13.3, 77.8% female, 95.8% Caucasian, 57.7% primary 
care). In total, 11 patients withdrew from the study: nine discontinued as a result of 
adverse events, one because of insufficient therapeutic response, and one for personal 
reasons.  
 
Of the small-intestinal release peppermint oil group, 90.3% was adherent to study 
treatment during the complete treatment period or until discontinuation, compared with 
92.1% of the ileocolonic release peppermint oil group, and 96.9% of the placebo group 
(P=0.330 between groups, Supplementary Table S7.1).  
 
Overall compliance to the digital diary was high and did not differ significantly between 
small-intestinal release peppermint oil, ileocolonic release peppermint oil, and placebo, 
being 88.3% (P=0.561), 85.3% (P=0.357), and 87.2% during the complete treatment 
period or until discontinuation (Supplementary Table S7.1). Compliance to the web-
based questionnaires was also high: only a single patient did not complete the 
questionnaires at the end of the treatment period. All other patients completed the 
symptom questionnaires with no missing values until the end of the study or until 
discontinuation.  
153719-Weerts_BNW.indd   148 08-09-2021   12:03153719- eerts_BN _compleet.indd   148 08-09-2021   12:06
 Efficacy and safety of peppermint oil in IBS 
149 
7 







 N=64 N=62 N=63 
Demographic data  
Age, years     
   Mean (SD) 










Sex, N (%) 
   Female 










Race, N (%) 
   Caucasian 










BMI, mean (SD) 24.6 (5.2) 25.6 (5.7) 26.5 (5.1) 
Educational level, N (%) 
   No education 
   Low  
   Moderate  
















Employment status, N (%) 
   Currently studying 
   Employed, full- or part-time 
   Unemployed 
   Incapacitated for work 
   Homemaker 






















Setting, N (%) 
   Primary care 
   Secondary care 
   Combined secondary &  













IBS-subtype, N (%)‡ 
   Diarrhea 
   Constipation 
   Mixed 
















Abdominal symptoms, mean (SD) 
   Abdominal pain§ 
   Abdominal discomfort± 
   Abdominal bloating± 
   Abdominal cramping± 
   Belching± 






















Bowel symptoms, mean (SD) 








   Mean score (SD) 
   Mild, N (%) 
   Moderate, N (%) 
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N=64 N=62 N=63 
IBS Quality of Life, mean score (SD)µ 74.0 (14.2) 72.2 (14.7) 72.8 (16.6) 
EQ-5D-5L, mean utility score (SD)♮ 0.72 (0.2) 0.74 (0.2) 0.74 (0.2) 
Psychological comorbidities# 







   Depression, mean (SD) 7.0 (4.7) 6.6 (4.4) 6.7 (4.6) 
BMI body mass index in kg/m2; IBS Irritable Bowel Syndrome. ¶ Self-reported race; placebo, N=1 mixed race 
is 1/4th Asian; small-intestinal release peppermint oil, N=1 mixed race is 1/4th Asian, and N=1 mixed race is 
1/2nd unknown; ileocolonic release peppermint oil, N=4 mixed race is 1/4th Asian, and N=1 mixed race was 
1/2nd Asian; ‡ Determined in a face-to-face interview (Rome IV); § Assessed daily during the pre-treatment 
period using an 11-point NRS in the digital diary: 0=no symptoms, 10=worst possible pain; ± Assessed weekly 
during the pre-treatment period using an 11-point NRS in the digital diary: 0=no symptoms, 10=worst 
imaginable symptoms; † The IBS-SSS consists of 5-items with a maximum score of 100, higher scores indicate 
more severe symptoms; µ The IBS-QoL consists of 34-items with a 5-point Likert scale: 1=good, 5=worse 
quality of life; ♮ The EQ-5D-5L measures 5-dimensions of QoL. Raw scores are transformed to utility scores31, 
which vary from 1 (perfect health) to 0 (death); # Anxiety, the GAD-7 consists of 7-items, and depression, 
the PHQ-9 consists of 9-items, both with a 4-point response scale, 0=not at all, 3=almost every day.  
 
Primary efficacy outcomes 
The proportion of abdominal pain responders did not differ significantly between groups: 
46.8% in small-intestinal release peppermint oil (OR1.68; 95% CI0.80, 3.51; P=0.170; 
number needed to treat (NNT) 8.1) and 41.3% in ileocolonic release peppermint oil 
(OR1.39; 95%CI 0.66, 2.90; P=0.385; NNT 14.5), compared with 34.4% in placebo (Table 
7.2, Supplementary Table S7.2, Figure 7.1).  
 
The proportion of global relief responders did also not differ significantly between 
groups: 9.7% in small-intestinal release peppermint oil (OR2.12; 95%CI 0.49, 9.17; 
P=0.317), and 1.6% in ileocolonic release peppermint oil (OR0.33; 95%CI 0.03, 3.35; 
P=0.351), compared with 4.7% in placebo (Table 7.2, Figure 7.1).  
 
In the PP-analysis, the primary endpoints did not differ significantly between groups 
(Supplementary Table S7.3). 
 
No significant differences in primary efficacy outcomes were observed for each IBS-
subtype separately (Supplementary Table S7.9). 
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Figure 7.1 Percentage of patients who were abdominal pain responders (a) and global relief responders (b) in 
the ITT-population. (a) Abdominal pain responder: a patient with at least 30% decrease in mean 
worst daily abdominal pain in at least 4 out of 8 weeks. (b) Global relief responder: a patient with at 
least a relief score of 6 or 7 (on a 7-point NRS) in at least 4 out of 8 weeks. Values are percentages, 
bars represent standard errors. 
Secondary efficacy outcomes 
Results of  exploratory secondary outcomes are presented in Table 7.2 and Supplementary 
Table S7.4. The small-intestinal release peppermint oil resulted in significantly more 
reduction in daily worst abdominal pain at week eight, with a corrected difference in 
change from baseline on an 11-point NRS, compared with placebo, of  -0.63 (95%CI, -
1.14, -0.12; P=0.016) (Supplementary Table S7.4).  
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The small-intestinal release peppermint oil was also superior over placebo with respect 
to abdominal discomfort. This effect appeared at week six of treatment, with corrected 
differences in change from baseline on an 11-point NRS, when compared with placebo, 
of -0.95 (95%CI -1.74, -0.15; P=0.020) at six weeks, -0.97 (95%CI -1.71, -0.24; 
P=0.009) at seven weeks, and -0.69 (95% CI -1.36, -0.03; P=0.041, non-significant as 




























Figure 7.2 Abdominal pain and discomfort scores in the ITT-population (N=189). Values are adjusted 
estimated marginal means derived from the linear mixed model, bars represent standard errors. 
The small-intestinal peppermint oil group had significantly more reduction in mean daily worst 
abdominal pain compared with placebo at week 8 (P=0.016). The small-intestinal peppermint oil 
group also had significantly more reduction in abdominal discomfort compared with placebo, 
(P=0.020, P=0.009, and P=0.041 at week 6, 7 and 8 of treatment, respectively). The ileocolonic 
release peppermint oil group did not differ significantly in reduction in abdominal pain and 
discomfort compared with placebo. Assessed weekly using an 11-point NRS in the digital diary. 
153719-Weerts_BNW.indd   153 08-09-2021   12:03153719- eerts_BN _compleet.indd   153 08-09-2021   12:07
Chapter 7 
154 































A significantly greater improvement in IBS symptom severity was found among those treated 
with small-intestinal release peppermint oil, with a corrected difference in change from 
baseline of -41.8 on the IBS-SSS total score (-91.5 versus -49.8 for small intestinal release 
versus placebo; 95%CI for difference -76.88, -6.70; P=0.020) at week eight (Figure 7.3, 
Supplementary Table S7.4). A greater percentage of the small-intestinal release peppermint oil 
group reported a symptom relief score of at least 5 (moderate relief) in at least four 
treatment weeks (38.7%, P=0.030, non-significant), compared with placebo (20.3%) 
(Table 7.2, Supplementary Figure S7.3). In addition, both peppermint oil groups reported 
using rescue medication for pain fewer times than the placebo group, i.e. on average 
3.71 (P=0.087), 3.16 (P=0.039), and 5.16 times for small-intestinal release, ileocolonic 
release peppermint oil, and placebo, respectively (Supplementary Table S7.8). However, 

















Figure 7.3 IBS-SSS in the ITT-population (N=189). Values are adjusted estimated marginal means derived 
from the linear mixed model, bars represent standard errors. The small-intestinal peppermint oil 
group had significantly more reduction in IBS severity at the end of the eight-week treatment 
period. *P=0.020. The absolute change from baseline in small-intestinal release peppermint oil 
was -91.53 points. The Ileocolonic release peppermint oil group did not differ significantly in 
severity reduction compared with placebo (P=0.053). Assessed using the IBS-SSS questionnaire 
consisting of 5-items with each a maximum score of 100. 
 
 
Ileocolonic release peppermint oil did not yield significantly more relief, reduction in 
abdominal discomfort or abdominal pain, nor improvement in IBS severity over placebo 
(Supplementary Table S7.4). When using a larger abdominal pain decrease threshold, i.e. 
50 instead of 30%, the proportion of abdominal pain responders did not differ 
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significantly between groups (Table 7.2). Apart from a few significant changes at single 
time-points, there were no sustained differences between groups with regard to nausea, 
abdominal bloating, urgency, or comorbid anxiety and depression (Supplementary Table 
S7.4). All treatment groups showed improvements in quality of life that persisted over 
time, without a significant difference between groups (Supplementary Table S7.4). No 
significantly different changes were observed in stool consistency and frequency across 
treatment groups apart from a single time point in stool consistency (week 6, 
Supplementary Table S7.5). When analyzing consistency and frequency for each IBS 
subtype separately, no significant changes were found apart from an increased stool 
consistency in IBS-D at a single time point (week 6 in the small intestinal peppermint oil 
group, week 3 in the ileocolonic release peppermint oil group, Supplementary Table S7.6-
7). Efficacy outcomes did not differ significantly between primary and secondary/tertiary 
care patients (Supplementary Table S7.10, Supplementary Material). 
 
Follow-up measurements until six-months after cessation of treatment also showed no 
significant differences between placebo and both forms of peppermint oil (Supplementary 
Table S7.4).  
Adverse events/safety results 
Table 7.3 summarizes the AEs reported during the treatment period. No serious 
adverse events or deaths were reported. In both peppermint oil groups, the total 
number of AEs was significantly higher compared with placebo (mean (SE) 4.26 (0.37) 
for small-intestinal release (P=0.012) and 4.54 (0.45) for ileocolonic release peppermint 
oil (P=0.001), versus 2.78 (0.34) for placebo).  
 
The most common adverse events were heartburn or GERD symptoms, belching (with 
and without a minty taste), and headache in small-intestinal release peppermint oil and 
an altered anal sensation or sensitive urethra, headache and abdominal cramps in 
ileocolonic release peppermint oil. Concerning belching, in the first two weeks of 
treatment, the small-intestinal release peppermint oil group had a larger increase in belching 
from baseline, compared to placebo (P<0.001 at week one, P=0.023, at week two). Severity 
of this symptom, however, returned to pre-treatment level after three weeks until the end of 
treatment, (Supplementary Figure S7.6). More patients on peppermint oil versus placebo 
discontinued treatment due to adverse events (three in the small-intestinal peppermint 
oil group (4.8%) and five in the ileocolonic release peppermint oil group (7.9%), 
compared with one in the placebo group (1.6%)). 
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To our knowledge, this is the first randomized, double- blind, placebo-controlled clinical 
trial of peppermint oil in patients with Rome IV-defined IBS. It showed that neither 
small-intestinal release nor ileocolonic release peppermint oil led to a statistically 
significant reduction in abdominal pain or increase in global relief based on the pre-
specified primary outcome measures as defined by FDA and EMA guidelines. Small-
intestinal release peppermint oil, but not ileocolonic, however, did yield statistically 
significant improvements in exploratory secondary outcomes of IBS symptom severity, 
abdominal pain, and abdominal discomfort. AEs occurred more often in both 
peppermint oil groups compared to placebo, but were all mild and transient. 
 
The treatment effect of small-intestinal peppermint oil was not as pronounced as 
anticipated based on the results of previous meta-analyses35,37, which indicated a 
difference in dichotomous overall abdominal pain improvement of 30% between 
placebo and peppermint oil.35 This discrepancy may relate to the more stringent criteria 
used in the current study, as our primary outcome measure required an abdominal pain 
reduction compared to baseline of at least 30% in at least four out of eight weeks 
treatment. In contrast to our study, none of the earlier trials investigating peppermint oil 
reported this endpoint. The most recent randomized trial investigated a sustained small-
intestinal release peppermint formulation (182 mg) of which the pharmacokinetics are 
comparable to the one used in the current study, in 72 IBS (Rome III) patients. They 
used the change from baseline in the Total IBS Symptom Score as a primary endpoint 
and found a significantly greater reduction of 15.7% in the peppermint oil group 
compared to placebo.17 In the current study, the placebo response rate according to the 
stringent FDA definition was 33%, which is similar to previous studies using this 
outcome measure.38-40 The therapeutic gain of small-intestinal peppermint oil over 
placebo was 12.4%, corresponding to a NNT of 8. Albeit non-significant, this difference 
in response rate is numerically comparable to the previous studies in IBS reporting 
statistically significant differences between linaclotide38, and plecanatide39 and placebo. 
Of note is that the recent ACG Monograph18 mentions a NNT of 4 for peppermint oil 
(using the data hitherto available), which is considerable better than the NNT that we 
found, but also than the NNT for linaclotide (6), plecanatide (10), or eluxadoline (12.5). 
Since we powered the study for an expected 30% difference35, it seems plausible that a 
type II error may exist and a statistical significant difference between groups would have 
been identified had we included a larger number of patients. Another reason for the 
discrepancy may be differences in baseline characteristics of our study population 
compared with populations previously investigated. In contrast with earlier work, a large 
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part of our population was recruited from primary care, patients had to fulfill the Rome 
IV diagnostic criteria for IBS2, and had to have an objectified mean worst abdominal 
score of at least 3 (on an 11-point NRS). Finally, the overall quality of evidence achieved 
thus far could explain the conflicting findings throughout the literature. Peppermint oil 
was evaluated in numerous clinical trials that were hindered by methodological 
limitations including lack of description of allocation concealment or of randomization 
method used, no description of how blinding was handled, no usage of validated 
endpoints, or treatment periods of one month or shorter.37,41 As such, treatment effects 
may have been biased or overestimated, complicating the ability to draw firm 
conclusions. 
 
Since measuring treatment response in IBS patients is based on self-reported symptoms, 
defining optimal outcome measures in IBS trials has been subject of ongoing debate. It 
has been postulated that the current recommended provisional FDA/EMA endpoints 
are limited in their ability to capture all multidimensional aspects of IBS symptoms and 
treatment response due to the over-focus on certain main symptoms and the 
dichotomization of continuous responses.42,43 It is therefore important to take into 
account various appropriate endpoints to distinguish between clinically relevant and 
non-relevant responses, in particular when these are used for clinical decision-making. 
For instance, the small-intestinal, but not ileocolonic release peppermint oil group had a 
significantly greater reduction in abdominal pain, discomfort, and IBS symptom severity 
scores, compared to placebo. Furthermore, adherence to study treatment was 
excellent and discontinuation due to headache, belching, or other AEs was low (6.4%). 
In addition, all AEs were mild and transient and the most common one, i.e. belching, 
subsided after the second week of treatment. This indicates a rather good tolerability of 
peppermint oil when administered with a gradual titration schedule for the first week. 
Thereby, the current results show, in our opinion, that small-intestinal release 
peppermint oil does have a moderate efficacy in patients with IBS and should not be 
ignored as a treatment option in everyday practice.  
 
We had hypothesized that a targeted ileocolonic release of peppermint oil would have 
led to an augmented efficacy of treatment owing to a more local colonic anti-nociceptive 
effect based on recent experimental evidence suggesting the involvement of TRP 
channels on colonic sensory afferents.8 In the current study, however, we found no 
evidence of symptomatic benefits of ileocolonic release peppermint oil over placebo. In 
addition, although upper GI adverse events were indeed diminished compared with the 
small-intestinal release peppermint oil, the novel formulation resulted in more severe 
abdominal cramping in the beginning of the treatment period. Our findings therefore, 
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taken together, do not support the use or further development of this formulation for 
treatment in patients with IBS. The reason for increased reporting of abdominal cramps 
upon administration of ileocolonic release peppermint oil is unclear and unexpected 
given the smooth muscle relaxatory effects of the agent. As far as the effects of 
peppermint oil are concerned and on the basis of these findings, however, we speculate 
that the small intestine could be of superior importance compared to the colon with 
regards to pain symptom generation and relief in IBS. In addition, considering the late 
onset of beneficial effects, we further postulate the involvement of TRP channels on 
intestinal sensory afferents rather than a primarily antispasmodic effect that is assumed 
to occur more rapidly.  
 
Currently, treatment of IBS is often tailored towards improvement of patient’s most 
predominant symptom. If initial treatment fails to achieve satisfactory results, linaclotide 
and eluxadoline are examples of recent pharmacological advancements that have led to 
novel drug development and can be used to treat constipation- and diarrheal-type IBS, 
respectively. Despite high quality evidence, their somewhat less favorable adverse event 
profile should be considered and may limit applicability.38,40 Of the therapeutic entities 
available for IBS, none has been able to cure or alter the disorder on the long-term. This 
reflects our incomplete pathophysiological understanding of IBS, which leads to the 
inability to target specific disease mechanisms. In this perspective and in view of our 
findings, peppermint oil appears to be a favorable initial treatment entity in IBS owing to 
the following reasons: 1) peppermint oil is readily available as a low-cost OTC drug; 2) 
adverse events are at most mild and transient of nature; 3) using a pharmacological 
agent of herbal origin without the risk of serious adverse events could be attractive for 
patients. In fact, in the Netherlands, peppermint oil was the most preferred treatment 
option when given the choice of ten treatment options (education on IBS, other 
antispasmodics, antidepressants, and elimination/FODMAP diet included).44 It is worth 
noting that because improvements in exploratory secondary outcomes were observed 
rather towards the end of the treatment period, and belching arises at the beginning of 
treatment, but normalizes soon after, patients should be encouraged to continue 
treatment. Finally, to avoid disappointment, providers could communicate that there is 
little evidence for long-term beneficial effects after discontinuing with peppermint oil 
treatment. Future research should investigate the safety and effect of longer treatment 
periods. 
 
This study has several limitations. First, the population was relatively young, female, and 
predominantly of Caucasian origin; therefore, data may not necessarily be generalizable 
to more diverse IBS populations. We speculate that the use of social media as a 
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recruitment strategy may have contributed to this relatively young study population. 
Nevertheless, the subtype distribution was in line with epidemiological findings in IBS.45 
Future studies are required to ascertain the effect in populations from different 
geographical regions; a current trial in the USA investigating placebo responses uses a 
peppermint oil comparator.46 However, because we have recruited IBS patients from 
primary, secondary and tertiary care, and via social media accounts of the participating 
centers, we argue that the current study population is representative for the Dutch IBS 
population seeking help for their symptoms. Caution is, however, necessary when 
applying these results to clinical practice as they might only apply to patients who have a 
certain level of pain symptoms, corresponding to both the Rome IV and the FDA pain 
entry criteria. Second, blinding of the patients may not have been entirely successful due 
to the smell and taste of peppermint oil and other recognizable adverse events. We 
tried to limit a confounding effect through the identical appearance of capsules by over-
encapsulation. Third, due to possible power limitations and increase in type I error 
(multiple testing), secondary endpoint analyses should be considered exploratory. 
Fourth, the treatment period was relatively short in comparison to other IBS trials, 
therefore potential benefits from a longer treatment period (i.e. 12-26 weeks) could not 
be ascertained. 
 
Strengths of the current study include the soundness of the experimental design with 
compliance to recent guidelines on IBS drug trials and as such, reporting on stringent 
primary outcomes according to FDA and EMA guidelines and intention-to-treat 
analyses; the meticulous use of state-of-the-art electronic data capture ensuring data 
quality and completeness; and a well-characterized patient population comprised of 
both primary and secondary/tertiary care patients diagnosed according to Rome IV 
diagnostic criteria for IBS with a low drop-out rate. 
 
In summary, peppermint oil compared to placebo was not superior in patients with IBS, 
when using the pre-specified outcome measures abdominal pain response and global 
relief of IBS symptoms based on recommendations by the FDA and EMA. We found no 
benefits of a targeted Ileocolonic release peppermint oil formulation for treatment in 
IBS. Conventional small-intestinal release peppermint oil did, however, improve 
secondary outcomes such as abdominal pain, abdominal discomfort, and IBS symptom 
severity with a minimal adverse event profile and high tolerability. Peppermint oil may 
thus be considered as a worthwhile treatment option for symptom management in IBS. 
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Detailed inclusion and exclusion criteria 
Patients had to be between 18 and 75 years of age and needed to fulfill the Rome IV 
diagnostic criteria for IBS. If alarm symptoms were present (e.g. unexplained rectal 
blood loss or weight loss), a colonoscopy or other relevant tests were performed to 
exclude organic disease. Exclusion criteria were inability to read or understand Dutch, 
history of GI disorders such as inflammatory bowel disease, celiac disease, or thyroid 
dysfunction (if not well-regulated), history of major abdominal surgery or radiotherapy 
interfering with GI function. An uncomplicated appendectomy, cholecystectomy, or 
hysterectomy were allowed unless within six months prior to screening. Other 
exclusion criteria were use of peppermint oil capsules in the three months prior to 
screening, a known allergic reaction to peppermint oil, current drug abuse, and a history 
of liver or gallbladder/biliary disease. Women had to use contraceptives and have a 
negative urine pregnancy test, or be postmenopausal for at least two years. The use of 
one antidepressant or one PPI was allowed, if a patient had been and would stay on a 
stable dose. Prohibited concomitant medications included opioids, prokinetics, stimulant 
laxatives (i.e. bisacodyl), linaclotide, prucalopride, and anti-spasmodic drugs. Regular use 
of NSAIDs, antibiotics, osmotic laxatives, and antidiarrheal drugs was prohibited. 
Treatment allocation 
Randomization was done with ALEA software using the minimization method, 
accounted for inclusion center, IBS subtypes, gender, and age. A random element was 
incorporated into each step of the minimization to ensure allocation concealment. As 
such, when an imbalance of more than two subjects per treatment group existed (in a 
specific inclusion center), there was a 10% chance that the subsequent randomization 
would overrule this already existing imbalance. 
Statistical analysis of secondary outcomes 
For secondary continuous outcomes, treatment effects were analyzed at different time-
points after correction for baseline using linear mixed models with treatment group, 
minimization variables, time, and time*group interaction as fixed-effects. A likelihood-
based approach was used to deal with missing values. Different covariance structures 
(unstructured, autoregressive moving average 1.1, heterogeneous Toeplitz, 
heterogeneous first-order-autoregressive) were explored to choose the best based on 
153719-Weerts_BNW.indd   165 08-09-2021   12:03153719- eerts_BN _compleet.indd   165 08-09-2021   12:07
Chapter 7 
166 
the Schwarz’s Bayesian Criterion (smaller values indicate a better fit). Estimated means 
(standard error, SE) per time-point, P-values, and 95% CIs are reported.  
 
A multiplicity correction was applied according to the following principle: for each 
secondary outcome measure, two comparisons are made to placebo (one for small-
intestinal release peppermint oil and one for ileocolonic release peppermint oil). 
Assuming the chance of 5% for a type 1 error for a single comparison, a two-sided P-
value ≤ 0.025 was considered statistically significant for secondary outcome analyses. 
Secondary outcomes were exploratory in nature. 
 








N=64 N=62 N=63 
Adherent to study medication¶  







Compliance rate to the digital 
symptom diary± 










¶ Adherence to study medication was quantified by counting returned capsules at the study end-visit. Patients 
were deemed adherent if at least 80% of study medication was taken during the complete treatment period or 
until discontinuation. There were no significant differences in adherence between placebo and small-intestinal, 
or ileocolonic release peppermint oil, P=0.212 and P=0.333, respectively; ± Compliance rate to the digital 
diary was defined by the percentage of entry days completed during the complete treatment period or until 
discontinuation. There were no significant differences between placebo and small-intestinal release, or 
ileocolonic release peppermint oil, P=0.405 and P=0.285, respectively. 
 
 




Peppermint oil  
N=62 N=63 
Number needed to treat 
   Based on primary abdominal response  
   outcome¶ 







Number needed to harm 





¶ A responder was defined as a patient with at least 30% decrease in mean worst daily abdominal pain in at 
least 50% of weeks in which treatment was given; § A responder was defined as a patient with at least a global 
relief score of 5, 6, or 7 (on a 7-point NRS) in at least 50% of weeks in which treatment was given. AE Adverse 
Event. 
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Figure S7.2 Flowchart of patients included in the PERSUADE study. IBS; Irritable Bowel Syndrome. 
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Figure S7.3 Percentage of patients who were moderate relief responders in the ITT-population. A 
responder was a patient with at least a relief score of 5, 6 or 7 (on a 7-point NRS) in at least 
4 weeks out of 8 weeks. Values are percentages, bars represent standard errors. P=0.030 for 
small-intestinal release peppermint oil, P=0.980 for ileocolonic release peppermint oil, both 
compared with placebo. 
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Figure S7.4 A. Stool consistency in the ITT-population (N=189), B. Stool consistency in the IBS-C 
population (N=42), C. Stool consistency in the IBS-D population (N=83). Values are adjusted 
estimated marginal means derived from the linear mixed model, bars represent standard 
errors. The small-intestinal peppermint oil group had significantly more increase in stool 
consistency at week 6 compared to placebo (P=0.018). Assessed daily using the Bristol stool 
form scale (BSFS) in the digital diary. 
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Figure S7.5 A. Stool frequency in the ITT-population (N=189), B. Stool frequency in the IBS-C 
population (N=42), C. Stool frequency in the IBS-D population (N=83). Values are adjusted 
estimated marginal means derived from the linear mixed model, bars represent standard 
errors. Assessed daily in the digital diary. 
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Figure S7.6 Belching scores in the ITT-population (N=189). Values are adjusted estimated marginal 
means derived from the linear mixed model, bars represent standard errors. The small-
intestinal peppermint oil group had significantly more increase in belching at the week 1 and 
2, *P=0.0003, and *P=0.023, respectively. The Ileocolonic release peppermint oil group did 
not differ significantly in belching compared with placebo. Assessed weekly on an 11-point 
NRS in the digital symptom diary. 
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Exploratory supplementary analyses of effect 
modification 
Effect modification gender 
To explore possible effect modifiers in a supplementary exploratory analysis, we added 
the interaction of treatment group with the possible effect modifier to the model. This 
explorative post hoc analysis showed that gender was an effect modifier of treatment 
group and the primary abdominal pain outcome, likelihood ratio (LR) test for interaction 
term: P=0.016). For men (N=42), the small-intestinal release peppermint oil did have a 
significant treatment effect on the primary outcome with 81.8% of men being a 
responder (OR9.14, 95%CI 1.36; 61.54, P=0.02), compared with 33.3% in the placebo 
group. For women (N=147), however, no significant differences were found in 
abdominal pain response rate between small-intestinal release peppermint oil, with 
39.2% of women being a responder, (OR of 1.20, 95% CI0.53; 2.76, P=0.67), compared 
with 34.7% in the placebo group. The relatively low number of included men implies 
that the effect found should be interpreted with appropriate caution. 
Effect modification primary care versus secondary/tertiary care 
We explored a potential effect modification of being a primary care patient versus 
secondary/tertiary care patient in a supplementary exploratory analysis. The proportion 
of abdominal pain responders according to FDA definition (30% decrease in worst 
abdominal pain, in at least 50% of treatment weeks) did not differ significantly between 
primary and secondary/tertiary care patients, i.e. 43/109 (39.4%) primary care patients 
were responders, compared with 34/80 (42.5%) secondary/tertiary care patients 
(P=0.793). To double-check however, we added the interaction of treatment group 
with the categorical variable of being a primary care patient (or not) to the model that 
was corrected for minimization variables age, gender, IBS-subtype, and inclusion center. 
This explorative post hoc analysis showed that being a primary care patient was not a 
significant effect modifier of treatment group and the primary abdominal pain response 
outcome (likelihood ratio (LR) test for interaction term: P=0.398). 
Effect modification baseline abdominal pain scores 
To assess potential effect modification of baseline abdominal pain on the primary 
outcome abdominal pain response, we added the interaction of treatment group with 
baseline mean worst abdominal pain to the model that was corrected for minimization 
variables age, gender, IBS-subtype, and inclusion center. This explorative post hoc 
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analysis showed that baseline mean worst abdominal pain was not a significant effect 
modifier of treatment group and the primary abdominal pain response outcome (LR test 
P=0.322). Similarly, when dividing patients into two groups based on baseline mean 
worst abdominal pain, i.e. a group with the lowest 2/3 of baseline abdominal pain and a 
group with the highest 1/3 of baseline abdominal pain, the proportion of abdominal pain 
responders did not differ significantly between groups (P=0.086). 
 
 
153719-Weerts_BNW.indd   186 08-09-2021   12:04153719- eerts_BN _compleet.indd   186 08-09-2021   12:07











Irritable Bowel Syndrome (IBS) is a prevalent, chronic gastrointestinal disorder that 
imposes a substantial socioeconomic burden. Peppermint oil is a frequently used 
treatment for IBS, but evidence about cost-effectiveness is lacking. The objective of this 
trial-based economic evaluation was to assess the cost-effectiveness of small-intestinal 
release peppermint oil versus placebo in patients with IBS.  
 
Methods 
In a multicenter randomized placebo-controlled trial, cost-effectiveness was evaluated 
from a societal perspective. The incremental cost-effectiveness ratios were expressed as 
1) incremental costs per Quality Adjusted Life Years (QALY), and 2) incremental costs 
per successfully treated patient, i.e. per abdominal pain responder (according to FDA 
definitions), both after an eight-week treatment period with placebo versus peppermint 
oil. Cost-utility and uncertainty were estimated using non-parametric bootstrapping. 
Sensitivity analyses were performed to examine parameter uncertainty. 
 
Results 
The analysis comprised 126 patients (N=64 placebo, N=62 small-intestinal release 
peppermint oil). Peppermint oil was a dominant treatment compared to placebo in 46% 
of bootstrap replications. Peppermint oil was also more effective but at higher cost in 
31% of replications. The net benefit acceptability curve showed that peppermint oil has 
a 56% probability of being cost-effective at a conservative willingness-to-pay threshold of 
€10.000 per QALY. Peppermint oil was also a dominant treatment per additional 
successfully treated patient according to FDA definitions, i.e. in 51% of the bootstrap 




In patients with IBS, small-intestinal release peppermint oil appears to be a cost-effective 
treatment although there is uncertainty surrounding the ICER. When using abdominal 
pain responder as outcome measure for the ICER, peppermint oil has a high probability 
of being cost-effective. The use of peppermint oil, which is a low-cost treatment, can be 
justified by the modest QALY gains and slightly higher proportion of abdominal pain 
responders. More research and long-term data are necessary to confirm the cost-
effectiveness of peppermint oil. NCT02716285 
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Irritable Bowel Syndrome (IBS) is a prevalent and chronic disorder of brain-gut-
interaction characterized by chronic abdominal pain and altered bowel habits.1 IBS has a 
large negative impact on quality of life (QoL)2 and is associated with considerable costs 
for patients, healthcare systems and society.3-5  
 
Regarding direct costs to healthcare systems, IBS patients are reported to have 
increased numbers of consultations, emergency room visits, hospitalizations, and 
prescribed medications, when compared to patients without IBS.2,6 Additionally, a large 
proportion of patients use over-the-counter (OTC) drugs or complementary medicine 
leading to high out of pocket costs.6 Regarding indirect costs3,4, IBS patients are more 
likely to be both absent from work (absenteeism) and impaired during work 
(presenteeism) when compared to non-IBS patients.6 Summed with the reduced QoL in 
patients, IBS leads to a high socioeconomic disease burden.2,7,8 
 
Effective therapies are therefore crucial to decrease this burden. Generally, symptom 
improvement should result in a better health-related QoL, less resource use and less 
productivity loss. Peppermint oil is a frequently used treatment for IBS and we 
previously reported the results of the largest randomized clinical trial (RCT) with 
peppermint oil to date.9 A recent meta-analysis, including data from this trial, confirmed 
the therapeutic superiority of small-intestinal peppermint oil over placebo in IBS.10 Trial 
based data on the cost-effectiveness of peppermint oil however, are lacking so far. The 
objective of this trial-based economic evaluation was therefore to assess the cost-
effectiveness of peppermint oil compared with placebo, in patients with IBS.  
Materials and methods 
This economic evaluation was performed in a multicenter, placebo-controlled, double-
blind RCT on the clinical efficacy of peppermint oil as a secondary outcome. The study 
was performed in four Dutch hospitals, one academic with a combined 
secondary/tertiary care function (Maastricht University Medical Center+, MUMC+), 
and three secondary care (Hospital Gelderse Vallei, Ede; Alrijne Hospital, Leiden; 
Medical Center Leeuwarden, Leeuwarden). The research protocol had been approved 
by the MUMC+ Committee of Ethics and has been registered in the US National Library 
of Medicine (Clinicaltrials.gov, NCT02716285). All study procedures were performed in 
compliance with GCP and the Declaration of Helsinki. All subjects had given a written 
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informed consent prior to participation. Full details of the clinical trial have been 
published elsewhere9 and are briefly summarized below. All authors had access to the 
study data and reviewed and approved the final manuscript. 
Patients, setting and interventions 
IBS patients, between 18 and 75 years of age were eligible for inclusion if they fulfilled 
the ROME IV criteria.11 Patients had to have a mean daily worst abdominal pain score 
≥3 during a two-week run-in period (on an eleven-point numerical rating scale (NRS)). 
Randomization was done with ALEA Screening and Enrollment software using the 
minimization method accounted for inclusion center, IBS subtypes, gender, and age. 
Patients were assigned to 182 mg of small-intestinal release peppermint oil in enteric-
coated soft gel capsules (Tempocol, WillPharma S.A.), ileocolonic release peppermint 
oil (Tempocol core capsules, coated with ColoPulse coating layer12), or placebo. The 
study consisted of a two-week run-in period, an eight-week treatment period, followed 
by a six-month follow-up period in which no study medication was given. Patients were 
asked to refrain from lifestyle changes and new treatments. Standard care however, 
could be continued in a stable manner. Patient inclusion took place between August 
2016 and March 2018. 
Economic evaluation 
The economic evaluation was performed in accordance with the Dutch guidelines for 
cost-calculations.13,14 the CHEERS checklist and The Professional Society for Health 
Economics and Outcomes Research (ISPOR) guidelines, based on intention-to-treat 
analysis. Costs were calculated from the societal perspective and expressed in 2017 
euros. The primary outcome of the current study is the incremental cost-effectiveness 
ratio (ICER), calculated as difference in costs between peppermint oil and placebo 
divided by the difference in QALY between peppermint oil and placebo, over the eight-
week treatment period. As the newly formulated ileocolonic release peppermint oil did 
not yield any benefits over small-intestinal release peppermint oil9, this formulation will 
not be developed further and will not be available to patients. Consequently, this 
formulation was not taken into account in this economic evaluation. 
 
Costs included all IBS-related direct costs (i.e. outpatient consultations, general practice 
consultation, dietician, and mental healthcare) and indirect costs (i.e. absenteeism, 
presenteeism, and impaired unpaid work). Additionally, cost of treatment assigned was 
included (small-intestinal release peppermint oil or placebo). An overview of treatment 
and other costs per unit is given in Table 8.1. 
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Health-related resource use was assessed using the iMTA Medical Consumption 
Questionnaire (MCQ), which is designed to measure costs in the Dutch healthcare 
system (see https://www.imta.nl). The MCQ was completed at baseline and after 
eight-weeks of treatment. As the recall-period of the MCQ is three months, the recall 
period was adjusted to eight weeks for assessment at the end of the eight-week 
treatment period. After all data had been collected, a distinction was made between 
IBS-unrelated and potentially related costs based on expert opinion; e.g. drug treatment 
for comorbid cardiovascular disease was not included, whereas visits to a 
gastroenterologist or GP, or mental healthcare were. Direct costs were calculated by 
multiplying resource use by the cost price per resource unit, adopting reference prices 
derived from the Dutch costing manual (Table 8.1). Medication costs were obtained 
from the Dutch Pharmacotherapeutic Compass (Healthcare Insurance Board, 2017). 
Additionally, for each visit to a care provider, travel expenses were calculated using a 
standard cost of €0.19 per average kilometer.  
 
Indirect health-related costs were measured using the iMTA Productivity Cost 
Questionnaire (PCQ), which was designed and validated for the Dutch situation (see 
https://www.imta.nl).15 The PCQ was completed at baseline and at four and eight-
weeks of treatment. The PCQ includes questions on productivity loss of paid work 
(absenteeism and presenteeism) and productivity loss of unpaid work (e.g. voluntary 
work, or homemaking and caregiving). Indirect costs were calculated by multiplying the 
hours absent (using self-reported dates of sick leave) or impaired (using a self-reported 
inefficiency score) by average wage rates per hour. Since the majority of costs and 
outcomes were measured within one year, no discounting was applied and all costs 
were indexed for inflation to 2017. A detailed description of the calculation of indirect 
costs is given in the Supplementary Material. 
 
Table 8.1 Overview of costs per unit of resource use. 
Resource use Unit Cost (euro) Reference 
Study treatment  
   Placebo 
















Dutch costing manual 
Dutch costing manual 
Social work consultation 





Dutch costing manual 
Dutch costing manual 






Dutch costing manual 
Dutch costing manual 
Average wage women 
Average wage men 







Dutch costing manual 
Dutch costing manual 
Dutch costing manual 
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The EuroQol-5D (EQ-5D-5L) was used to measure patients’ health-related QoL at 
baseline, four and eight weeks of treatment. The EQ-5D-5L measures five dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and has 
shown good performance in IBS patients.16 Dutch social tariffs were used to transform 
raw EQ-5D-5L scores to utility scores.17 The IBS-QoL questionnaire consists of 34 items 
with a 5-point Likert scale, and was used to determine the impact of IBS and treatment 
on QoL.18 
 
All data was collected electronically using web-based questionnaires and a smartphone-
based symptom diary. 
Statistical analysis 
Statistical analyses were performed using SPSS 25.0 (Armonk, NY, USA) and Microsoft 
Excel 16.16.7. The proportion of missing data and the missing data pattern were 
investigated using descriptives and patterns function in SPSS, and associations between 
missingness and baseline and outcome variables were investigated with logistic 
regression, to inform on the missing data mechanism. Missing values missing 
(completely) at random were handled by multivariate imputation by chained equations 
using predictive mean matching19 with gender, IBS-subtype, age, baseline IBS severity, 
baseline utility, and treatment group. QALYs were calculated by the area under the 
curve, in which the time in a certain health state was multiplied by the utility of this 
health state. The time horizon was the eight-week treatment period. For the QALY 
calculation, utility values were corrected for baseline differences between groups with 
the mean absolute difference method.20 ICER was calculated as the difference in costs 
divided by the difference in QALYs between peppermint oil and placebo. 
Nonparametric bootstrapping with 10.000 and 1.000 simulations was used to calculate 
the difference in costs between groups and to examine the uncertainty surrounding the 
ICER, respectively. This method requires resampling and derives a cost-effectiveness 
ratio from each of the generated repeated samples21-23, thereby increasing the 
robustness of the results and accounting for within and between imputation variability.19 
Results of the bootstrap analysis are presented in cost-effectiveness planes and net 
benefit acceptability curves. A cost-effectiveness plane is a scatterplot of simulated 
ICERs and presents the four situations of additional costs and additional QALY’s of 
peppermint oil compared to placebo. If the majority of the ICERs appear in the 
southeast quadrant, this indicates higher effectiveness at lower costs, i.e. peppermint oil 
dominates placebo. The northwest quadrant on the other hand indicates lower 
effectiveness at higher costs, i.e. peppermint oil is inferior compared to placebo. With 
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regard to the other two quadrants (lower effectiveness at lower costs, and higher 
effectiveness at higher costs), the choice for peppermint oil depends on the threshold 
value, i.e. the maximum amount society/decision maker is willing to pay (WTP) for a 
particular health gain. The net benefit acceptability curve shows the probability that the 
new treatment is cost-effective compared to placebo over various willingness to pay 
(WTP) values. The net monetary benefit (NMB) is calculated with the following formula: 
WTP* difference in QALY-difference in costs. Commonly used WTP thresholds per 
QALY (one additional year in perfect health) in the Netherlands are €20.000 for mild, 
€50.000 for moderately severe and €80.000 for a severe condition.24 As IBS does not 
increase mortality and our study includes a relatively short time horizon (eight weeks), a 
WTP threshold of €10.000 (estimated €65.000 per year) was chosen for the calculation 
of the net monetary benefit. Prior studies investigating cost-effectiveness in IBS have 
applied thresholds varying between £30.00025 and $80.00026 per QALY with the last 
study covering a treatment period of ten weeks. 
Sensitivity analyses 
To assess the impact of different parameters on the results, several univariate sensitivity 
analyses were performed. First, the main clinical effectiveness outcome, i.e. the 
proportion of responders instead of QALY, was used. According to the Food and Drug 
Administration (FDA) definition a responder had at least a 30% decrease in the mean 
weekly worst daily abdominal pain (measured daily, on an 11-point NRS) compared to 
baseline, in at least four (out of eight) weeks. As this endpoint does not capture a 
generic health related QoL, a lower WTP threshold was chosen to calculate the net 
monetary benefit, i.e. €5.000. For the second sensitivity analysis, unadjusted QALYs 
were used, i.e. no correction for baseline differences in QALYs between groups was 
calculated. The final sensitivity analysis was a cost-effectiveness analysis from the 
healthcare perspective, i.e. considering only direct costs. 
Results 
Overall, the intention-to-treat population of the clinical trial with three treatment arms 
consisted of 189 patients.9 Of these 189, 126 patients were included in this cost-
effectiveness study (N=64 in the placebo group, N=62 in the small-intestinal release 
peppermint), of whom 120 completed the study. Baseline characteristics are presented 
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in Table 8.2. Compliance and missing data are described in the Supplementary Material 
and Supplementary Table S8.1. 
 





Peppermint oil  
N=64 N=62 
Demographic data   
Age, years     
   Mean (SD) 







Gender, N (%) 





Setting, N (%) 
   Primary care 
   Secondary care 









Employment status, N (%) 
   Currently studying 
   Employed, full- or part-time 
   Unemployed 
   Incapacitated for work 
   Homemaker 
   Retired 

















IBS Quality of Life, mean score (SD) on IBS-QoL 74.0 (14.2) 72.2 (14.7) 
Psychological comorbidities 
   Anxiety, mean (SD) 
   Minimal anxiety, N (%) 
   Mild anxiety, N (%) 
   Moderate anxiety, N (%) 













   Depression, mean (SD) 
   Minimal depression, N (%) 
   Mild depression, N (%) 
   Moderate depression, N (%) 
   Moderately severe depression, N (%) 















Overall, a somewhat greater improvement in QoL was found in the small-intestinal 
release peppermint oil group compared to placebo, although these differences did not 
reach statistical significance (Supplementary Table S8.2).  
 
Mean costs per category are presented in Table 8.3. During the eight-week treatment 
period, direct healthcare costs differed with the peppermint oil group showing 
significantly lower costs compared to placebo. Differences were mainly caused by 
mental healthcare utilization (Table 8.3). There were no significant differences between 
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groups in indirect costs during the treatment period, except for a higher productivity 
loss in unpaid work in the small-intestinal peppermint oil group (Table 8.3). 
 






Difference in means♮ (€) 
(95% CI) 
 
N=64 N=62  
Costs, mean (SD) (€) 
Total direct costs 
   Mental healthcare 
   General practice 
   Rehabilitation 
   Outpatient consultation 
   Company doctor 
   Homeopathy 
   Medication 
   Dietician 
   Travelling-expenses 
   Treatment or diagnostics  
   Hospitalization 
   Study treatment costs 
Total indirect costs 
   Absenteeism 
   Presenteeism 










































0 (-2; 3) 
0 (-5; 6) 











Total costs, mean (SD) 1.175 (113) 1.132 (82) -40 (-226;322) 
♮ Bootstrapped differences (means and confidence intervals) between small-intestinal release peppermint oil 
and placebo. CI Confidence Interval. * significant (no zero in confidence interval). 
 
Cost-effectiveness analysis 
The incremental cost-savings of small-intestinal peppermint oil were €40.00, with an 
incremental corrected QALY gain over eight-weeks of 0.004 compared to placebo. The 
cost-effectiveness plane is presented in Figure 8.1 and shows that small-intestinal release 
peppermint oil is a dominant treatment compared to placebo in 46% of simulations 
(southeast quadrant, greater effectiveness at lower costs). Peppermint oil is more 
effective, but at a higher cost (northeast quadrant) in 31% of the simulated ratios, while 
it is inferior in 18% of simulations (northwest quadrant, less effective and higher costs). 
The net benefit acceptability curve showed that the probability of peppermint oil being 
cost-effective was 50% at a WTP-threshold of €1.000 and increased to 56% at a WTP 
threshold of €10.000 (Figure 8.2). 




































Figure 8.1 Cost-effectiveness plane of small-intestinal release compared with placebo. Each data-point 
represents 1 bootstrapped estimate of incremental costs and baseline corrected QALYs. The 
bootstrapped ICERs cover all four quadrants in both planes, indicating some uncertainty of the 
data. 46% of simulations lie in the south-east quadrant, the quadrant indicating dominance of 
peppermint oil. 31% of simulations lie in the north-east quadrant, indicating higher efficacy but at 
higher cost. The cost-effectiveness acceptability curve (Figure 8.2) shows the probability 
peppermint oil is cost-effective at different WTP-thresholds. 
 
Sensitivity analyses 
The results from the sensitivity analysis are presented in Table 8.4. When using the main 
clinical outcome instead of QALY, the proportion of abdominal pain responders did not 
differ significantly between both groups: 22/64, 29/62 in the placebo and small-
intestinal peppermint oil group, respectively.9 The cost-effectiveness plane showed that 
small-intestinal release peppermint oil is dominant in 51% of ICER simulations and more 
effective at higher cost in 41% of simulations. At a WTP-threshold of €5.000 per 
additional responder, the probability of small-intestinal release peppermint oil being 
cost-effective is 89% (Figure 8.3). 
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Figure 8.2 Cost-effectiveness acceptability curve. The line indicates the probability (y-axis) of a treatment 
being cost-effective, i.e., the proportion of replications small-intestinal release peppermint oil has 
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WTP willingness to pay; NE North-east; NW North-west; SE south-east; SW south-west; QALY quality 
adjusted life years. # The four quadrants represent four different situations of cost-effectiveness compared to 
placebo. If the majority of the bootstrapped ICERs (incremental cost-effectiveness ratio) appear in the south-
east quadrant of the figure, this indicates that treatment is dominant. If the majority of the bootstrapped ICERs 
appear in the north-west quadrant of the figure, this indicates that treatment is inferior; § The primary clinical 
endpoint was the percentage (%) of abdominal pain responders, according to FDA definition, with a 
responder being a patient with at least 30% decrease in the weekly average of worst daily abdominal pain 
(scored on an 11-point NRS) compared to baseline, in at least 50% of the treatment period, i.e. in this study 
four weeks. 




































































Figure 8.3 Cost-effectiveness acceptability curve of costs and abdominal pain responder (FDA definition). 
The line indicates the probability (y-axis) of small-intestinal release peppermint oil being cost-
effective. At a WTP-threshold of 5.000, small-intestinal release has a probability of 89% of being 




When using uncorrected (for baseline differences) QALYs, peppermint oil is dominant 
in 51% of simulations and more effective at higher cost in 40% of simulations. When 
comparing uncorrected (for baseline differences) QALYs to corrected ones, the 
probability of peppermint oil being a cost-effective treatment at a WTP-threshold of 
€10.000 increases slightly from 56% to 58%. 
 
When assessing cost-effectiveness from a healthcare perspective, small-intestinal 
peppermint oil is dominant compared to placebo in 65% of ICER simulations. 
Peppermint oil then has a 85% probability of being cost-effective at a WTP-threshold of 
€10.000. 
Discussion 
Here, we report the results of the first trial-based economic evaluation of peppermint 
oil for IBS conducted in a multicenter, placebo-controlled RCT. The results show that 
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small-intestinal release peppermint oil may be considered cost-effective compared to 
placebo during an eight-week treatment, from a societal perspective at a conservative 
WTP-threshold of €10.000 per QALY. However, there is uncertainty surrounding the 
incremental cost-effectiveness ratios (ICERs). At a lower and highly conservative WTP-
threshold of €1.000 per QALY, peppermint oil and placebo have an equal chance of 
being cost-effective. Sensitivity analyses showed similar results indicating uncertainty 
surrounding the cost-effectiveness of peppermint oil with the exception of the analyses 
using abdominal pain responder according to FDA-definition, and costs from a 
healthcare perspective. In these cases, peppermint oil has a much higher probability of 
being cost-effective compared to placebo. 
 
IBS is highly prevalent and one of the most expensive conditions in gastroenterology.27 
We recently demonstrated that peppermint oil is a moderately effective treatment in 
patients with IBS, decreasing abdominal pain, discomfort, and IBS-symptom severity.9 
Although non-significant, small-intestinal release peppermint showed an abdominal pain 
response rate (FDA-defined) of 12.4%, which is numerically comparable to studies 
reporting statistically significant differences between linaclotide,28 plecanatide29 and 
tenapanor30 versus placebo. These findings further warrant a trial-based economic 
evaluation such as the current study. 
 
Peppermint oil is available as an OTC drug without reimbursement from healthcare 
insurance in many countries. Peppermint oil capsules are relatively inexpensive and this 
study indicates that they are likely cost-effective, showing that its use can be justified by 
the (albeit modest) gains in health-related QoL and cost-savings. Moreover, in light of its 
favorable adverse event profile, and the fact that no pharmacological treatment thus far 
has been able to cure IBS or improve stringent outcomes in more than half of the 
patients investigated, small-intestinal release peppermint oil can be a worthwhile 
treatment option.  Peppermint oil seems particularly suited for primary care or as an 
initial step in therapy since more than half of patients were recruited in this setting. Our 
findings are further supported by preliminary model-based study suggesting cost-
effectiveness of peppermint oil.31 Other treatments with a high probability of being cost-
effective as a treatment for IBS are anti-depressants, the low FODMAP diet, and 
cognitive behavioral therapy.27 No direct comparisons can be made at this point due to 
different study designs and patient populations. 
 
The ICER of eight weeks of peppermint oil treatment was dominant, indicating cost 
savings with a small health related QoL gain with the bootstrap analysis showing 
uncertainty surrounding the ratio. This short-term evaluation might underestimate cost-
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effectiveness, since long-term savings and QALY gains are not taken into account. 
However, as guidelines do not currently recommend peppermint oil usage for longer 
than three months32, we did not perform any long-term analysis and did not extrapolate 
the data. Future studies should investigate the safety, effect and QALY gains of longer 
treatment periods. 
 
This economic evaluation additionally investigated cost-effectiveness based on a clinical 
parameter instead of traditional QALYs. We used the stringent abdominal pain 
response outcome (FDA-defined) at a willingness-to-pay-threshold of €5000 and 
showed that while using this outcome, peppermint oil has an 89% probability of being 
cost-effective. Currently, healthcare policymakers have not defined willingness-to-pay 
threshold values when clinical effect measures are used instead of QALYs.24 
Nevertheless, given that the FDA-endpoint is recommended by drug regulatory 
authorities33,34 and widely accepted as a primary outcome in IBS trials, we anticipate that 
more economic evaluations will present ICERs based on this endpoint in addition to 
ICERs based on more traditional QALY outcomes. This would enhance comparisons 
between treatments further.  
 
The results of the current study should be considered in light of potential limitations. 
First, for the estimation of costs, we relied on self-reported healthcare usage and 
productivity losses, which may lead to recall- and social desirability bias. However, 
studies in the UK and the Netherlands have shown good agreement between health 
registry and self-reported data.35,36 In addition, the bias would have been present in both 
groups and is therefore unlikely to have a noticeable effect. Second, a substantial part of 
the cost-savings within healthcare perspective was driven by differences in mental 
healthcare costs. This difference results in a higher probability of peppermint oil being 
cost-effective from a healthcare perspective as shown in the sensitivity analysis. It is 
questionable however, whether the difference in mental healthcare costs is a mere 
result of the treatment with peppermint oil in the relatively short period of 8 weeks. 
Baseline depression and anxiety scores were slightly higher in the placebo compared to 
the peppermint oil group. Therefore, despite using a valid randomization method 
stratified for potential effect modifiers, we cannot exclude this difference to be caused 
by chance and not treatment effect. Third, missing data regarding presenteeism 
(Supplementary Table S8.1), limits the validity of the results. Fourth, it is not always clear 
whether patients can make a distinction between IBS-related productivity loss and other 
comorbidities. Although we used expert opinion to make such distinction for the 
medical consumption questionnaire, this is not possible for the productivity 
questionnaire because of the generic questions. Fifth, since this was a trial-based cost-
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effectiveness study we only compared to peppermint oil to placebo. A valid comparison 
to other treatments such as the low-FODMAP diet or cognitive behavioral therapy 
would require a model-based study. Sixth, patients were relatively young, female, and 
predominantly white. In addition, half of the population was recruited from primary 
care. Results may therefore not reflect cost-effectiveness in other populations. 
Nevertheless, the patient inclusion led to a population highly representative for IBS 
patients seeking treatment in daily routine clinical practice. Thereby our results are 
applicable to everyday practice and informative for both healthcare policy makers and 
providers. 
 
In summary, treatment of IBS with small-intestinal release peppermint oil appears to be 
cost-effective, both from a societal and healthcare perspective, although there is 
uncertainty surrounding the ICER. When using abdominal pain responder instead of 
QALY as an outcome measure, peppermint oil has a very high probability of being cost-
effective. The use of peppermint oil, which is a low-cost treatment, can be justified by 
the modest QALY gains and the slightly higher proportion of abdominal pain 
responders. More research and long-term data are necessary to confirm the cost-
effectiveness of peppermint oil. 
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Patients had to be between 18 and 75 years of age and needed to fulfill the Rome IV 
diagnostic criteria for IBS. If alarm symptoms were present (e.g. unexplained rectal 
blood loss or weight loss), a colonoscopy or other relevant tests were performed to 
exclude organic disease. Exclusion criteria were inability to read or understand Dutch, 
history of GI disorders such as inflammatory bowel disease, celiac disease, or thyroid 
dysfunction (if not well-regulated), history of major abdominal surgery or radiotherapy 
interfering with GI function. An uncomplicated appendectomy, cholecystectomy, or 
hysterectomy were allowed unless within six months prior to screening. Other 
exclusion criteria were use of peppermint oil capsules in the three months prior to 
screening, a known allergic reaction to peppermint oil, current drug abuse, and a history 
of liver or gallbladder/biliary disease. Women had to use contraceptives and have a 
negative urine pregnancy test, or be postmenopausal for at least two years. The use of 
one antidepressant or one PPI was allowed, if a patient had been and would stay on a 
stable dose. Prohibited concomitant medications included opioids, prokinetics, stimulant 
laxatives (i.e. bisacodyl), linaclotide, prucalopride, and anti-spasmodic drugs. Regular use 
of NSAIDs, antibiotics, osmotic laxatives, and antidiarrheal drugs was prohibited.  
Determination of indirect costs 
For the determination of absenteeism costs, self-reported dates of sick leave were used 
to determine the period for which absenteeism needed to be valued. Costs were 
calculated by multiplying the hours absent by average wage rates per hour (reference 
average wage rates used in this study can be found in Table 8.1).  
 
For the determination of presenteeism costs, productivity losses were valued by 
multiplying hours in which work was impaired with average wage rates per hour. The 
number of hours in which work productivity was impaired, was determined using a self-
reported inefficiency score. Productivity losses in unpaid work were valued by 
multiplying the hours lost in productivity with the average wage for domestic help (Table 
8.1, main manuscript), as recommended by the Dutch costing manual.13 For all other 
indirect costs, we used general average wage rates per hour instead of job-specific 
wages, as recommended by the Dutch costing manual, as this leads to less bias in favor 
of high-income earners. Because of general disparities in wages as a result of gender, 
different averages were used for women versus men (Table 8.1, main manuscript).   




Compliance and missing data 
Compliance to the web-based questionnaires was high: only a single patient did not 
complete the questionnaires at the end of the treatment period. All other patients 
completed all questionnaires until the end of the study or until discontinuation. 
However, due to a routing error, a single question regarding presenteeism was not 
presented to all patients at all time points. This led to missingness of this particular item 
in up to 50% of patients. Missingness on this topic was well balanced between treatment 
groups and the missing values were MCAR. Missing values regarding costs and utilities 
from the patients that discontinued the study (N=6) were MAR. No other missing 
values occurred. An overview of the proportion of patients with missing data per cost 
component is given in Supplementary Table S8.1. 
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Treatment effect is the corrected difference in change from baseline between small-intestinal release 
peppermint oil and placebo, obtained from linear mixed modelling. P-value is level of significance of 
comparison between small-intestinal release peppermint oil and placebo. The treatment period consisted of 












End-of-day symptom diaries are recommended by drug regulatory authorities to assess 
treatment response in patients with irritable bowel syndrome (IBS). We developed a 
smartphone application to measure treatment response. Because the employment of an 
application to measure treatment response in IBS is relatively new, we aimed to explore 
patients’ adherence to the diary and characteristics associated with adherence.  
 
Methods 
A smartphone application was developed to serve as a symptom diary. IBS patients 
(based on Rome IV criteria) were instructed to fill out end-of-day diary questionnaires 
during the eight-week treatment. Additional online questionnaires assessed 
demographics, IBS symptom severity, and psychosocial comorbidities. Adherence rate 
to the diary was defined as the percentage of days completed out of total days. 
Adherence to the additional web-based questionnaires was also assessed.  
 
Results 
Overall, 189 patients were analyzed (mean age 34.0±13.3 years, 77.8% female). The 
mean adherence rate to the diary was 87.9±9.4%. However, adherence to the diary 
decreased over time (P<0.001). No significant association was found between 
adherence and age, gender, or educational level, while higher anxiety scores were 
associated with lower adherence (P=0.03). Adherence to the online questionnaires was 
also high (>99%). Missing data due to technical issues was limited. 
 
Conclusions 
The use of a smartphone application as a symptom diary to assess treatment response 
resulted in high patient adherence. The data-collection framework described led to 
standardized data-collection with excellent completeness and can be used for future 
RCTs. Due to the slight decrease in adherence to the diary use throughout the study, 
this method might be less suitable for longer trials. 
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Irritable Bowel Syndrome (IBS) is a highly prevalent chronic disorder of brain-gut-
interaction characterized by recurrent abdominal pain and altered bowel habits.1 Since 
well-defined organic causes and validated biomarkers for IBS are lacking, patient 
reported outcome measures (PROMs) are crucial to assess treatment response. In 
accordance, drug regulatory authorities currently recommend using end-of-day 
symptom scores in IBS trials to measure drug efficacy.2,3 Diaries are generally considered 
suitable to measure these end-of-day gastro-intestinal (GI) symptom scores and have 
the ability to capture symptom variability over time.4 The validity and reliability of paper 
diaries, however, may be impeded by fake adherence5, i.e. falsifying or backfilling written 
answers outside of the proposed time-window to forge good adherence.6 The gap 
between reported and actual adherence to paper diaries has shown to be as large as 
80% in some studies.7 Because backfilling introduces considerable recall and ecological 
bias8, using paper diaries can distort trial results, which can ultimately lead to incorrect 
conclusions about treatments. Efficacy endpoints in clinical trials should therefore, 
preferably not be assessed by paper diaries.  
  
Recent technological advancements and the widespread availability of smartphones have 
given rise to numerous health-related applications and electronic diaries in the last 
decade9-12, both in clinical and research settings. A digitalized data-collection provides 
several advantages over a paper-based data-collection as it results in higher data entry 
quality and more efficient data handling.13 For example, responses can be verified 
automatically by built-in response requirements, routing, and data validation, and manual 
data transcription can be omitted. More importantly, data entry of previous days can be 
prevented and all entries can be given a date- and time-stamp, generating more valid 
(momentary) results and allowing assessment of actual adherence to the diary. Studies 
in (non-IBS) patients that have implemented electronic diaries have reported excellent 
adherence, ranging from 76%-100%.5,14,15 
 
These advantages encouraged our group to implement a digital data-collection 
framework and develop a smartphone application that can be used as a digital symptom 
diary. This diary was used to collect Food and Drug Administration (FDA) 
recommended efficacy outcomes in our randomized placebo-controlled clinical trial 
(RCT) on the efficacy of peppermint oil in IBS, the PERSUADE study.16 The current 
study describes the development and evaluates the performance of the overall digital 
framework used for data-collection in that clinical trial. Within the realms of IBS trials, 
the use of a digital symptom diary is relatively new; most previous studies did not report 
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the adherence to the assessment method used, and data on adherence in other 
populations can not necessarily be extrapolated to IBS. Therefore, our primary aim was 
to evaluate the performance of a custom-made digital symptom diary in patients with 
IBS, in particular by assessing patients’ adherence. Since patient characteristics can 
impact adherence17,18, our secondary aim was to identify sociodemographic and clinical 
patient characteristics associated with adherence rate. 
Materials and methods 
The present study was based on data from the PERSUADE study.16 This was a 
randomized, double-blind, placebo-controlled trial conducted in four hospitals located 
throughout the Netherlands (Supplementary Figure S9.1). The study protocol was 
approved by the Maastricht University Medical Center+ (MUMC+) Ethics Committee 
and was registered in the US National Library of Medicine (Clinicaltrials.gov; 
NCT02716285). All study procedures were performed in compliance with Good 
Clinical Practice Guidelines and according to the revised Declaration of Helsinki.19 All 
participants gave written informed consent prior to participation.  
 
The study design of the PERSUADE study has been described in detail elsewhere.16 In 
brief, the primary aim was to investigate the efficacy of peppermint oil, a conventional 
small-intestinal and a novel ileocolonic release formulation, in patients with IBS. To this 
end, patients between 18-75 years of age, who fulfilled the Rome IV-criteria for IBS and 
had a mean worst abdominal pain score at least 3 on an 11-point numerical rating scale 
(NRS, 0=no pain, 10=worst possible pain) during a 14-days pre-treatment period were 
included. Participants were randomized to placebo, small-intestinal release peppermint 
oil, or ileocolonic release peppermint oil for an eight-week treatment period.  
 
Data-collection was performed using a customized framework for digital data-collection, 
specifically designed and developed for the trial, consisting of 1) a digital symptom diary 
(smartphone application); 2) an electronic Case Report File (eCRF, Castor EDC); 3) 
web-based patient questionnaires (Castor EDC); and 4) a planning tool (Ldot). During 
the 14-days pre-treatment and the eight-week treatment period, patients were 
instructed to register symptoms daily in the digital symptom diary. Study visits and 
telephone follow-up telephone interviews were documented in the eCRF. Patients were 
requested to complete several web-based questionnaires at different time-points within 
the study duration. The complete list of inclusion criteria and study overview with timing 
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of the questionnaires is given in the Supplementary Material. Primary efficacy results of 
the PERSUADE study have been described elsewhere.16 
Digital symptom diary: smartphone application 
For the digital symptom diary, an electronic smartphone application was developed by 
the center for data and information management at Maastricht University (MEMIC), in 
close collaboration with the investigators. The app was programmed using Xamarin, a 
framework to develop cross-platform applications by using programming language C 
sharp (C#). The PERSUADE app supports Android and iOS devices. A Maastricht 
University industrial designer designed the visual content. A MEMIC team of data-
managers and researchers of the MUMC+ Neurogastroenterology group tested the 
application and provided feedback throughout several phases of development. 
Additionally, a patient was asked to use the diary and provide feedback regarding its 
user-friendliness. Patient inclusion could commence once a version was reached that all 
agreed on. 
 
The application’s home screen consisted of three main elements, the daily end-of-day 
symptom questionnaire, a medication list, and the Bristol stool chart questionnaire 
(Figure 9.1). The end-of-day symptom questionnaire included one main question to 
assess the primary outcome (in accordance with FDA guidelines): “How would you rate 
your abdominal pain today? Think about the worst abdominal pain today” (0=no pain, 
10=worst possible pain) (Figure 9.2). The daily symptom questionnaire was accessible 
between 6 and 12pm and was unavailable outside this time window, to avoid premature 
completion. Other daily questions were related to ‘need of rescue medication’, and 
‘adverse events experienced’. If a patient had not completed the daily entry before 
10 pm of that particular day, one push notification was given. At the end of each week, 
the end-of-day questionnaire consisted of additional questions regarding abdominal 
discomfort, abdominal bloating, abdominal cramping, belching, nausea, and urgency 
during the last week (on an 11-point NRS, 0=no symptoms, 10=worst possible 
symptoms). There was no possibility to enter data from previous days and participants 
could not review prior entries. Automated routing, response requirements, and real-
time data verification were built in to increase data-quality and completeness. 
 
The medication list was used once to register all regular medication use. Patients were 
asked to keep their concomitant medication use as stable as possible. However, if 
alterations were needed, they were able to delete, add, or change dosage of (non GI-) 
drugs.  
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The Bristol stool form scale was used to register all bowel movements (Figure 9.3). 















Figure 9.1 Home screen, i.e. main menu, of the PERSUADE smartphone application. In Dutch, 
Medicijnenlijst means Medication list, Ontlasting rapportage means registration of Bowel habit, 
and Vragenlijst means questionnaire. Note that the questionnaire icon is grey, denoting that the 
end-of-day daily symptom questionnaire is disabled. The questionnaire was accessible and could 






















Figure 9.2 Question in the PERSUADE smartphone application assessing the primary endpoint. Patients 
were requested to answer this question each night during the pre-treatment and treatment 
period. In Dutch, Hoe erg was vandaag de pijn in uw buik? means How would you rate your 
abdominal pain today? Denk hierbij aan de ergste pijn vandaag means Think about the worst 
pain today. Annuleren means cancel, and volgende means next. 
153719-Weerts_BNW.indd   216 08-09-2021   12:04153719- eerts_BN _compleet.indd   216 08-09-2021   12:07























Figure 9.3 The Bristol Stool Chart questionnaire. Patients were requested to register each bowel 
movement by selecting the stool type most resembling theirs. In Dutch, ontlasting means 
defecation, kleine harde keutels, moeizame passage means small hard lumps, difficult to pass. 
Hoofdscherm means home screen, opslaan means save.  
 
 
All patients received extensive verbal and written instructions during the screenings visit 
on how to use the application and were encouraged to contact the researchers if the 
application crashed or otherwise did not function properly. A personalized username 
and password were provided for access to the application. Patients were instructed to 
enable automatic updates of the application to ensure the most recent version was 
used. If a patient did not own a smartphone or tablet, a device was provided. During the 
complete pre-treatment and treatment periods, an alert system in the planning tool 
notified the investigators when a patient had failed to submit three or more daily entries. 
In addition, the development (IT) team received automated notifications of application 
crashes. 
Web-based patient questionnaires 
At randomization, two, four, six, and eight weeks of treatment, and at three and six 
months of follow-up after treatment had ended, patients were requested to fill out web-
based questionnaires. We chose not to implement these into the digital diary because of 
the large number of questions to be answered. Included were a questionnaire regarding 
demographics and lifestyle, and validated questionnaires regarding symptom severity 
(IBS Symptom Severity System), quality of life (IBS Quality of Life, EuroQoL EQ-5D-5L), 
comorbid symptoms of anxiety and depression (General Anxiety Disorder 7, Patient 
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Health Questionnaire 9), and healthcare utilization and productivity loss (Medical 
Consumption Questionnaire, Productivity Cost Questionnaire). Patients received 
invitations via email containing a HTML-link to the electronic environment (Castor 
EDC). If a patient had not completed the questionnaire within two days, two automatic 
reminders were sent via email. Automated routing, response requirements, and real-
time data verification were built in to increase data-quality and completeness. 
Electronic Case Report File (eCRF) 
During the study visits and telephone follow-up calls, investigators documented all 
findings in a cloud-based eCRF (Castor EDC). The eCRF forms were built by the first 
author with input from the other authors and contained items regarding e.g. 
demographics, Rome IV diagnostic criteria for IBS, history and physical examination, 
adverse events, and general wellbeing. Investigators were given unique usernames and 
passwords to view and add data for their respective inclusion centers. To achieve 
registration uniformity, the investigators were trained on how to enter data and 
additional step-by-step instructions were given in standard operating procedure 
documents. Real time automated data verification and corresponding pop-up 
notifications were built in to prevent typing errors or other erroneous entries. 
Automated routing of questions and response requirements ensured that correct items 
were displayed and filled in. An audit trail enabled tracking of all data changes. 
 
Information on the eCRF, the web-based tool used by investigators to monitor study 
logistics, and privacy and data storage are given in the Supplementary Material. 
Planning tool – Ldot 
Ldot is a web-based tool developed by MEMIC and was used to monitor study logistics. 
All personal patient data were entered into Ldot and the application supported the 
study workflow by indicating when each study event, e.g. randomization, follow-up call, 
etc., needed to take place per patient. Ldot was able to communicate with the digital 
diary and the web-based questionnaires (Castor EDC). For example, all email invitations 
for the questionnaires were sent automatically via Ldot. Patients’ adherence to the diary 
and web-based questionnaires could be monitored within Ldot and investigators were 
notified if patients failed to complete three consecutive days in the diary. Investigators 
were also notified if patients failed to complete a web-based questionnaire after a 
reminder was given. To guarantee the anonymity and quality of research data, no 
research data could be entered into Ldot. Investigators could view and add personal 
data for their respective inclusion centers. There was no possibility of viewing data from 
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other inclusion centers, except for the coordinating investigator (first author) who had 
access to all data. An audit layer of the application tracked and stored information of all 
changes. 
Storage, servers, and privacy 
All software and data storage complied with international ISO27001, ISO9001, and 
Good Clinical Practice guidelines, and Dutch NEN7510 guidelines. Electronic diary data, 
web-based-questionnaire and eCRF data, and privacy sensitive personal data (Ldot) 
were all stored on different (non-connected) servers. Several back-ups were made per 
day. Access to the servers was and will be restricted, with 24-hour on-site surveillance. 
Data will be stored for 15 years after study completion. 
Outcome measures 
The primary outcome of the current study was patients’ adherence to the digital 
symptom diary, defined as the mean percentage of entries and calculated by dividing the 
number of actually completed entries by the number of minimal requested entries (total 
number of days in study). Patients were instructed to complete a diary entry on all 
consecutive days during the 14-day pre-treatment and 56-day treatment period, or all 
days until discontinuation with the study. 
 
Secondary outcomes were change in mean adherence per week over time, 
sociodemographic and clinical patient characteristics associated with adherence rate, 
mean time of diary completion, and difference in adherence between patients who were 
defined as responders to treatment versus non-responders. Potential data-loss and 
critical evaluation points were considered to explore the overall feasibility of a 
smartphone application as a primary data-collection tool in a RCT. Other secondary 
outcomes were patients’ adherence to and completeness of the additional web-based 
questionnaires, and investigators’ adherence to and completeness of the electronic case 
report file (eCRF). 
Statistical analysis 
Statistical analyses were carried out using IBM SPSS statistics 25.0 for Macintosh 
(Armonk, NY, USA). Data are expressed as mean and standard deviation or as number 
plus percentage of total. Multivariable linear regression analysis was used to investigate 
the association between baseline patient characteristics and adherence to the digital 
diary, adjusting for minimization variables (age, gender, IBS-subtype, inclusion center and 
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treatment group). A repeated measures ANOVA was performed to assess the influence 
of time (weeks) on adherence. If the Mauchly’s test indicated that the sphericity 
assumption was not met, the Greenhouse-Geisser corrected results were reported. A 
two-sided P<0.050 (2-sided) was considered statistically significant. 
Results 
Overall, 190 patients were randomized. One patient was randomized erroneously, i.e. 
without fulfilling all inclusion criteria. Therefore, 189 patients were analyzed (N=64 in 
the placebo group, N=62 in the small intestinal release peppermint group, N=63 in the 
ileocolonic release peppermint oil group: mean (SD) age 34.0 (13.3) years, 77.8% 
female, 95.8% Caucasian, 57.7% primary care). Eleven patients withdrew from the study 
during the treatment period (data until discontinuation were included in the analyses). 
Baseline characteristics are presented in Table 9.1. During recruitment, only a single 
patient stated the digital data-collection as a reason not to participate. 
Patients’ adherence to the digital symptom diary 
Most patients used their own smartphones, but four out of 189 patients needed a 
device provided by the investigators. Patient’s adherence to the daily digital symptom 
diary was excellent during the entire study period, reflected by a mean (SD) completion 
rate of 87.9% (9.4), 91.5% (9.2) and 86.9% (10.8), during all 70 days of study duration, 
the 14-day pre-treatment period, and the eight-week treatment period, respectively. 
Adherence during the treatment period did not differ significantly between treatment 
groups being 87.2% for placebo, 88.3% for the small-intestinal release (P=0.67 versus 
placebo), and 87.2% for the ileocolonic release peppermint oil (P=0.33 versus placebo). 
Adherence did not differ between patients that were clinical responders to treatment 
versus patients that were non-responders, i.e. 88.0% and 86.2%, respectively. Over the 
complete study period of 70 days, a significant decrease in mean weekly patient’ 
adherence to the end-of-day questionnaire was found, i.e. F (5.9, 1114.9)=15.5, 
P<0.001 (Figure 9.4). Nevertheless, mean (SD) adherence was still good at the end of 
the study, i.e. 79.6% (26.61) (Figure 9.4). 
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Table 9.1 Summary of patient demographic and baseline characteristics. 
 N=189 
Demographic data  
Age, years     
   Mean (SD) 




Gender, N (%) 
   Female 
 
147 (77.8) 
Educational level, N (%) 
  No education 
   Low  
   Moderate  






Setting, N (%) 
   Primary care 
   Secondary care 





IBS-subtype, N (%)a 
   Diarrhea 
   Constipation 
   Mixed 







   Mean score (SD) 
   Mild, N (%) 
   Moderate, N (%) 






IBS Quality of Life, mean score (SD)c 73.0 (15.1) 
EQ-5D-5L, mean utility score (SD)d 0.7 (0.2) 
Psychological comorbiditiese 
   Anxiety, mean (SD) 
 
5.4 (4.3) 
   Depression, mean (SD) 6.8 (4.5) 
a Determined in a face-to-face interview (according to Rome IV criteria); b The IBS Symptom Severity System 
consists of 5-items with a maximum score of 100, higher scores indicate more severe symptoms; c The IBS-
Quality of Life questionnaire consists of 34-items with a 5-point Likert scale: 1=good, 5=worse quality of life; d 
The EuroQol-5D-5L measures 5-dimensions of QoL. Raw scores are transformed to utility scores20, which 
vary from 1 (perfect health) to 0 (death); e Anxiety; the GAD-7 consists of 7-items with a 4-point response 
scale: 0=not at all, 3=almost every day. Depression; the PHQ-9 consists of 9-items with a 4-point response 
scale: 0=not at all, 3=almost every day. 
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Figure 9.4 Adherence rate per week to the digital symptom diary in the PERSUADE study, which was 
defined as the mean percentage of entries and calculated by dividing the number of actually 
completed entries over the number of minimal requested entries. Dots represent mean 
adherence rate (%) plus standard deviations. N=189. The decrease in adherence throughout the 
pre-treatment and treatment period is statistically significant, F(5.9, 1114.9)=15.5, P<0.001. 
 
 
When exploring independent baseline predictors for adherence, the combined 
regression model that included all minimization variables (age, gender, IBS-subtype, 
inclusion center), treatment group, baseline IBS symptom severity, anxiety and 
depression scores, and educational level, showed that one of the four inclusion centers, 
i.e. center C (Supplementary Figure S9.2), (regression coefficient B -10.04, 95% CI -19.51; 
-0.56, P=0.04) and anxiety scores at baseline (B -0.59, 95% CI -1.12; -0.06, P=0.03) 
were negatively associated with adherence throughout the study. Indeed, when 
comparing adherence between the different inclusion centers, mean (SD) adherence in 
center C was lowest, i.e. 82.3% (12.5), compared with 88.3% (9.2), 84.7 (14.0), and 
91.4% (7.7), in centers A, B, and D, respectively. Mean time of completing the end-of-
day symptom diary was 9:46 pm, i.e. 14 minutes before receiving the push notification. 
Feasibility of a smartphone application as primary data-collection 
method 
Several technical issues were noted by the investigators or reported by patients. In most 
cases, the cause was found and the issue was resolved by the app development team 
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without data-loss. Encountered hurdles included difficulties installing the application 
during the screening visit due to connectivity failure, not receiving reminder notifications, 
inaccurate visual scaling of questionnaires on smaller smartphone screens, updates of 
Android or iOS operating systems that interfered with prior processes, and connectivity 
failure due to server maintenance. All (documented) technical issues and their (short-
term) consequences are presented in Table 9.2. 
Web-based questionnaires: patients’ adherence and completeness 
Adherence to the web-based questionnaires was also excellent. One patient did not 
complete the questionnaires at the end of the treatment period; all others completed all 
questionnaires until the end of the study or until discontinuation (N=11 discontinued 
with the study). Halfway through the study duration, however, a routing error in one 
questionnaire became apparent. Although this mistake was corrected immediately, the 
error had already led to missing data for that (one) particular question in 23.3%-54.0% 
of all patients, depending on measurement moment (Supplementary Table S9.1). No 
missing items were found in other questionnaire items. 
Investigators’ adherence to the eCRF 
Adherence of the investigators to the eCRF was excellent with a completion rate of 
more than 99%. In total, there were 27 patients with at least one missing variable in the 
case report file, 11 of whom discontinued with the study during the treatment period 
(the missing values comprehend follow-up calls that were not conducted). The 
remaining 17 cases with missing data were because of missed follow-up calls (in 11 
cases, one out of three follow-ups was missed), not registering if additional information 
about the six-months follow-up period was given, not registering the date of the last 
menstruation, not registering if the GP was informed about participation in the study, or 
not registering the number of capsules that were reported not to be taken during one of 
the follow-up calls. 
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Table 9.2 Technical difficulties and consequences with regard to the digital symptom diary. 
Description of technical issue N patients 
affected 
Consequence and if applicable, solution. 
Low internet connectivity hindered 
installation of the application during the 
screening visit 
15 In most cases, the problem was solved by moving 
to a location with better internet connectivity, or 
by postponing the installation to a later time. 
Not receiving push-notifications as a 
reminder to complete the end-of-day 
questionnaires 
12 In many cases, patients would complete the 
questionnaire regardless of receiving the 
notification. However, the exact effect is unknown 
and it may have negatively impacted adherence 
during days no notification was received. In most 
cases, the problem could be resolved by changing 
the telephone settings, e.g. by ignoring battery 
optimizations. In two cases in which the issue could 
not be resolved, reminders were given during the 
study period by setting the alarm of the device at 
10pm. In the short period during which it was 
unknown how many devices were affected, 
additional text-messages were sent as a reminder. 
Incomplete views of the questions due to 
a too large scaling on smaller 
smartphone screens. 
8 The issue was resolved by adjusting the scaling in 
the application during updates. Because only a few 
letters were not depicted correctly and because all 
participants had received a manual that included the 
actual questions asked, the negative effect of short-
term scaling issues is estimated to be negligible.  
iOS or Android updates that interfered 
with prior settings of the applications 
 
 
- The issue did not lead to missing data because the 
small bugs did not shut down the application. The 
development team would provide updates that 
resolved the issues as soon as possible.  
Maintenance of the hosting server 21 The issue led to missing data of one complete day, 
i.e. the day at which the maintenance took place, in 




The results of the current study demonstrate that patients’ adherence to the end-of-day 
questionnaire in the digital symptom diary was excellent, with a mean completion rate of 
87.9% over 70 days of study duration. The total proportion of missing data and data-loss 
due to technical issues of the application was small, indicating that it is safe and realistic 
to use the application as a primary data-collection method. Furthermore, patients’ 
adherence to the web-based questionnaires and investigators’ adherence to the eCRF 
were also outstanding with completion rates of more than 99%. 
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In terms of electronic diary usage in clinical trials, the adherence rate found in this IBS 
study is at least comparable to or even higher than rates previously reported rates.5,14,15 
Most people in the Netherlands own a mobile phone, i.e. 90.3% (Statistics 
Netherlands).21 Only few patients (N=4) needed a device from the investigator team to 
participate in the study and only a single patient stated the digital data-collection as a 
reason not to participate. Mean adherence to the digital symptom diary decreased with 
+/-11% from the first week of the pre-treatment period, to the last week of the eight-
week treatment period (Figure 9.4). A slight decrease in adherence to the diary during a 
study period, i.e. logging fatigability, is not uncommon and has also been observed in 
other studies investigating digital diaries.5,22 Regarding the usage of digital diaries in RCTs 
to assess treatment response (according to FDA-recommended definitions) in IBS 
patients specifically, we are aware of one recent IBS study that applied an electronic 
diary to assess treatment effect. However, a direct comparison with this study was not 
possible, as details on the type of device, application, or adherence to the diary were 
not provided.23  
 
With regard to sociodemographic and clinical patient characteristics associated with 
completing the daily entries in the diary, we found no evidence for a statistically 
significant effect of gender, age, or educational level on adherence. This differs from the 
results of some prior studies and meta-analysis, which observed for example a 
statistically significant positive effect of age on adherence.15,17 Our interpretation is that 
this may be caused by the relatively young patient population in the current study. We 
observed that patients with higher anxiety scores had lower adherence to the digital 
symptom diary. These data are in line with those of Aaron et al., showing that 
participants with higher stress levels may have lower completion rates.24 Interestingly, a 
negative association was found between one inclusion center and adherence. All four 
inclusion centers were located in urban areas, but with a wide geographical spread 
throughout the Netherlands as shown in Supplementary Figure S9.2. The center with the 
negative association (C) was the center in the most urban and populated area, i.e. the 
Amsterdam-The Hague-Rotterdam-Utrecht urban agglomeration. No obvious 
demographical or baseline differences were observed between study populations in 
different inclusion centers. No significant association was found between the lower 
adherence and the investigator by whom the instructions were given. Although the 
reason for a lower adherence of patients included in this center is unclear, religious and 
cultural backgrounds of inhabitants of this agglomeration may have differed from those 
of the inhabitants of other geographical areas.25-27 Nevertheless, overall mean (SD) 
adherence during the treatment period in this inclusion center was still good, i.e. 82.3% 
(12.5). 
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In terms of technical issues arising during the study, minor bugs occurring as a 
consequence of ever evolving smartphones and operating systems are practically 
inevitable. It is our experience therefore that continuous maintenance and software 
updating by a development (IT) team is crucial to avoid data-loss and potential agitation 
of the study participant due to application malfunctioning. Consequently, the feasibility 
of using a smartphone application as a primary data-collection method depends to a 
large extent on skills and availability of development team staff and research groups 
should check if appropriate support is available before opting for such methods. 
 
Many high-quality IBS trials have used Interactive Voice Response Systems (IVRS) as the 
primary data-collection method.28-31 In spite of this frequent use, the IVRS used in IBS 
trials have not been described in detail, thereby hampering replication and 
implementation of the used methodology in other trials. For comparison to our 
methodology, we therefore depended on what is known about IVRS in general. Akin to 
a digital symptom diary, the IVRS method allows control of time-windows in which 
surveys should be completed, provides automated time-stamps to answers, performs 
data verification and validation, follows a predefined routing schema, enables automatic 
reminders, collects and stores data “real-time”, and leads to an overall consistent survey 
administration. In addition, both methods equally depend on telephone- or internet-
service, and require staff to program and maintain the software. A potential advantage 
of the IVRS over the digital diary is that it does not depend on literacy skills of the 
participant. An IVRS may also need fewer software updates than required by 
smartphone applications due to the high paced updates of operating systems. Potential 
disadvantages of the IVRS compared to a digital symptom diary are e.g. 1) the inability to 
get clarification during the survey, whereas a digital symptom diary can have built-in 
optional clarification of questions; 2) not all IVRS are equipped with speech-recognition, 
open-ended questions then require transcription by a data-manager; 3) the quality of 
open-ended question recordings is dependable on enunciation, background noise, and 
connection; and 4) usage of the IVRS requires extensive participant training and could be 
less user-friendly.32 As for patient adherence to the IVRS, this was reported by only one 
recent IBS trial. They reported a mean adherence rate of 71% and 73% in the two 
groups examined, when adherence was defined as completing at least 80% of the 
scheduled calls to the IVRS.30 The adherence to the IVRS in that study was thus notably 
lower than the adherence to the digital symptom diary found in the current study. 
 
The current study described the overall framework for digitalized data-collection used in 
the PERSUADE study. In addition to the digital symptom diary, the electronic 
framework used in this drug trial consisted of web-based patient questionnaires and an 
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electronic CRF to collect additional secondary outcomes. A troublesome issue that 
occurred was a routing error in one of the questionnaires that was discovered too late 
and had already led to a high proportion of missing data (Supplementary Table S9.1). This 
applied to only a single question, but routing errors can have potentially disastrous 
consequences. As such, investigators and data-managers should take appropriate care 
and time when testing questionnaires. Data-exports should furthermore be examined in 
an early testing phase and preferably by more than one investigator and data-manager. 
Similar to the diary, the web-based questionnaires and the eCRF featured built-in 
routing of questions, data validation, and response requirements to stimulate data-
quality and completeness. Overall, these steps allowed for guaranteed standardized 
data-collection with a completeness of more than 99% for the web-based questionnaire 
and eCRF items.  
 
Additional advantages of the combined framework for digitalized data-collection are: 1) 
the ability to monitor patients and their adherence; 2) a reduction in paperwork and 
physical archiving, e.g. in this study the paperwork was reduced to one single informed 
consent file; 3) manual data transcription can be omitted as research data enter the 
database immediately; 4) the possibility to adjust and individualize the smartphone 
application, eCRF, and web-based questionnaires according to the needs of each 
particular study and 5) more accurate and standardized data reporting as no error-
prone re-entry necessary as compared to paper diaries. The described framework for 
digitalized data-collection can therefore be employed across different disease entities.  
 
Our findings should be interpreted in light of some potential limitations. First, the study 
was not primarily designed for the analysis of adherence to the digital symptom diary, 
but for measuring the main clinical outcome.16 However, since almost 200 patients were 
included, the sample size is sufficiently large to estimate adherence with enough 
precision. Second, adherence rate was not assessed within a controlled trial with a more 
traditional method of data collection (i.e. paper-and-pencil diaries, IVRS) as a 
comparison. However, the rapid diffusion toward digitalized approaches in healthcare 
and clinical research renders such comparison less meaningful from a practical point of 
view as the use of such techniques become inevitably ubiquitous. In addition, it is 
unlikely that these traditional approaches to data collection would result in even higher 
adherence than those observed here. Another limitation was that patient satisfaction 
with the digital diary or web-based questionnaires was not quantified by means of a 
questionnaire. In the current study, the feasibility of the used framework was evaluated 
primarily on the basis of patients’ and investigators’ adherence and the proportion of 
complete data, whereas quantified patient satisfaction was not taken into account. 
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However, a low patient satisfaction would have likely led to a lower adherence and 
thereby a higher proportion of missing data. Therefore, it is unlikely that applying such a 
questionnaire would have altered our main findings.  
 
In conclusion, in this IBS drug trial, the use of a smartphone application as a digital 
symptom diary to assess treatment response was found to be highly feasible and 
resulted in high quality data-collection with an excellent patient adherence of more than 
86% during the complete study period. The combination of the digital diary with the 
eCRF, planning tool and web-based-questionnaires in this study led to an overall 
standardized state-of-the art data-collection with excellent completeness and can be 
used as a framework for future RCTs. Due to the slight decrease in patient adherence 
to the digital diary throughout the study, caution is needed when using such methods in 
long-term studies. Although this framework was designed for IBS clinical trials, the 
results reported here are of added value for a far broader range of disorders for which 
the collection of PROMs is required. Future studies should preferably include a control 
group, for example a group using the IVRS or a group using the app without receiving 
reminding notifications, to compare adherence and to ascertain specific factors driving 
high adherence. 
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In- and exclusion criteria 
Eligibility criteria for pre-treatment period 
In order to be eligible to participate in the run-in period of this study, subjects must 
meet all the following criteria: 
1. Age between 18 and 75 years; 
2. Diagnosed with Irritable Bowel Syndrome according to the Rome IV criteria26:  
 Recurrent abdominal pain, at least 1day/week for the last 3 months; 
 Symptom onset at least 6 months prior to diagnosis 
 Associated with two or more of the following: 
1. Pain related to defecation; 
2. Pain associated with a change in frequency of stool; 
3. Pain associated with a change in form (appearance/consistency) of stool; 
3. Based on the medical history and previous examination, no other causes for the 
abdominal complaints can be defined. Especially no history of: 
a. Inflammatory Bowel Disease; 
b. Celiac Disease; 
c. Thyroid dysfunction (if not well-regulated); 
If alarm symptoms (including unexplained rectal blood loss or weight loss) are 
present, a colonoscopy has been performed and was negative for other causes. 
4. Women in fertile age (<55 years old) must use contraception or be 
postmenopausal for at least two years. 
 
Exclusion criteria for pre-treatment period 
A potential subject who meets any of the following criteria will be excluded from 
participation in this study: 
1. Insufficient fluency of the Dutch language; 
2. Any previous use (also incidental use) of peppermint oil capsules in the last 3 months 
prior to inclusion (the use of peppermint tea, menthol candy etc. is allowed); 
3. The inability to stop regular use of medication affecting the gastro-intestinal system 
(such as Non Steroidal Anti Inflammatory Drugs (NSAID), laxatives, prokinetics, 
opioids, smasmolytics and anti-diarrhoeal drugs). This use should be halted at least 1 
week before enrollment into the run-in period; 
a. The use of 1 antidepressant drug is allowed, providing dosing has been stable for 
>6 weeks before enrollment; 
b. The use of 1 proton pump inhibitor (PPI) is allowed, providing dosing has been 
stable >6 weeks before enrollment; 
4. Previous major abdominal surgery or radiotherapy interfering with gastrointestinal 
function:  
a. Uncomplicated appendectomy, cholecystectomy and hysterectomy allowed 
unless within the past 6 months;  
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b. Other surgery upon judgment of the principle investigator; 
5. History of liver disease, cholangitis, achlorhydria, gallstones or other diseases of the 
gallbladder/biliary system; 
6. Pregnancy, lactation; 
7. Using drugs of abuse; 
8. Known allergic reaction to peppermint. 
 
Inclusion criteria for the actual treatment period 
In order to be eligible to participate in this study, subjects must meet all of the following 
criteria: 
1. No changes in in- and exclusion criteria for the run-in period have occurred; 




Table S9.1 Proportion of patients with missing data in web-based questionnaires. 
 N=189 
Missingness of all questionnaires due to discontinuation or non-response, N (%) 
   Baseline 
   T = 4 weeks 
   T = 8 weeks 
   T = 3 months 







Missingness in question regarding presenteeism due to a routing error, N (%) 
   Baseline 
   T = 4 weeks 
   T = 8 weeks 
   T = 3 months 
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In this thesis, we have focused on the diagnostic criteria, targeted treatment, and 
socioeconomic burden of irritable bowel syndrome (IBS). We showed that patients 
who fulfill the updated and more restrictive Rome IV criteria are more likely to be 
younger women, with more severe gastrointestinal (GI) symptomatology, more severe 
psychological comorbidities, and lower quality of life, compared to patients with similar 
symptoms who do did not fulfill the Rome IV criteria (chapter 2). In chapter 3, we 
found that 30% of patients did no longer fulfill the Rome III criteria for IBS after a follow-
up period of five years. However, this reduction in GI symptoms was not paralleled by 
improvement in quality of life or life satisfaction. Our data suggest that quality of life and 
general well-being are more related to concurrent anxiety and depression scores than 
to GI symptom severity. To further improve patient outcome and quality in life in IBS, 
better and possibly more targeted treatments are needed. 
 
In chapter 4, we provided a comprehensive overview of transient receptor potential 
channels as novel treatment strategies in patients with IBS. Transient receptor potential 
melastatin 8 (TRPM8) is of particular interest because menthol, the primary constituent 
of peppermint oil, is an agonist for the TRPM8 receptor. Peppermint oil itself is a 
commonly used therapeutic agent in IBS. In chapter 5, we therefore focused more 
specifically on the TRPM8 channel and explored neuro-immune interactions possibly 
underlying symptom generation in IBS. By using various experimental techniques, we 
shed light on the potential anti-inflammatory function of TRPM8 in IBS. Because of a 
relative lack in high-quality evidence for efficacy of peppermint oil, we went on to 
further evaluate the clinical performance of peppermint oil in IBS. First, in chapter 6, 
we demonstrated that a newly developed ileocolonic release peppermint oil formulation 
had a significantly later mean peak menthol concentration in the blood, in comparison 
with the conventional small-intestinal release peppermint oil. This finding points to a 
more distal, presumably ileocolonic, release of peppermint oil in the intestine when 
given in the ileocolonic release peppermint oil formulation. Thereafter, in chapter 7, 
we investigated the efficacy and safety of small-intestinal and ileocolonic release 
peppermint oil in patients with IBS in a large multicenter randomized controlled trial, the 
PERSUADE study. We found that peppermint oil, in both formulations, was not 
superior compared to placebo when using the FDA recommended primary outcome of 
abdominal pain response. Small-intestinal release peppermint oil, however, showed 
significant improvements in secondary outcomes of IBS symptoms. We also showed 
that small-intestinal peppermint oil appears to be cost-effective in patients with IBS 
during an eight-week treatment period (chapter 8). In the final chapter, chapter 9, 
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we described the custom-made framework for digitalized data collection in which we 
used a smartphone application as a digital end-of-day symptom diary. We found that 
our method led to high patient and investigator compliance and an overall state-of-the 
art standardized data collection with excellent completeness. 
Diagnostic criteria 
As IBS is a disorder of gut-brain interaction without a clear organic cause, the diagnosis 
is currently based on the presence of typical symptoms. The Manning criteria, published 
in 1978, were the first criteria described to aid the diagnosis of IBS1, followed by the 
Rome diagnostic criteria for FGIDs.2 Generally, the symptom-based Rome diagnostic 
criteria have benefited IBS research as they have provided a clear definition of criteria 
patients should fulfill in IBS studies. This increases the reproducibility of research 
findings. Nevertheless, applicability of the criteria in daily clinical practice is limited3, as 
was also shown by a study of our group. Using a survey across 11 European countries, 
our colleagues found that only about one third of general practitioners (GP) use the 
Rome diagnostic criteria to diagnose IBS in daily practice.4 This may reflect that the 
diagnostic process in IBS is challenging, despite the fact that diagnostic criteria have been 
defined and generally accepted. Reasons for this include: 1) IBS symptoms can resemble 
those of other organic disorders, e.g. inflammatory bowel disease or microscopic colitis, 
and the criteria do not provide clear leads to differentiate between these and IBS5; 2) 
IBS symptoms vary considerably both between and within patients; 3) underlying 
pathophysiological mechanisms may differ between subgroups of IBS patients6; 
4) precise, objective and non-invasive biomarkers are currently not available, hence, 
there is no simple test that can accurately diagnose the disorder7; and 5) clinicians are 
not aware of the symptom-based diagnostic criteria or may not be confident enough to 
employ them. A new problem arose when in 2016 the previous Rome III criteria were 
updated to the more restrictive Rome IV criteria: what to do with patients who do no 
longer fulfill the diagnostic criteria for IBS? These patients remain to have the same 
symptoms and unfulfilled needs. Using end-of-day symptom diary based surrogate 
markers, we investigated how the change to more stringent criteria would impact IBS 
prevalence (chapter 2). We found that 12.6% to 38.4% of Rome III-positive patients 
would no longer fulfill the updated Rome IV criteria for IBS, depending on definitions 
used. Our results were corroborated by another study, in which the investigators found 
that 15% did no longer fulfill the updated IBS criteria.8 More recent population-based 
studies have also confirmed the decrease in IBS prevalence when using the Rome IV 
criteria: Van Houte et al. and Jossan et al. found prevalence rates of 5.5% in the general 
Belgian population and 5.1% in a Canada-UK-US population, respectively.9,10 This is a 
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decrease of approximately 6% compared to population prevalence rates on the basis of 
the Rome III criteria.11 Consequently, clinicians need to be aware of the fact that a 
significant percentage of patients presenting with IBS symptoms, does not fulfill the more 
restrictive Rome IV criteria, though they are in need for therapy, similar to patients 
fulfilling the criteria. Under the new Rome IV criteria, the majority of patients would 
rather be categorized as having functional constipation, functional diarrhea, functional 
abdominal bloating/distention or unspecified bowel disorder. The diagnostic confusion 
may lead to delay or lack of appropriate treatment. Furthermore, patients who are 
Rome IV negative are excluded from participation in clinical trials on novel therapeutic 
strategies that may otherwise benefit them. Although this is directly related to the 
update in criteria, we showed that even patients who did no longer fulfill the preceding 
Rome III criteria for IBS after a 5-year follow-up period still presented with moderate GI 
symptoms and had comparable scores of impaired quality of life and general well-being 
as those who still fulfilled the criteria (chapter 3). Failing to treat symptoms that 
hamper quality of life and affect patients’ everyday functioning may eventually result in 
increased health-associated costs. We therefore pragmatically advise that patients who 
present with functional GI symptoms, but do not fulfill the diagnostic Rome IV criteria, 
should still be managed as having a functional GI disorder. 
 
Diagnosing IBS in daily practice is complicated by it often being a diagnosis by 
exclusion.12 As a consequence, a large proportion of patients undergo numerous 
diagnostic investigations to exclude organic disorders, even though studies have shown 
that the yield of these is rather low and not substantiated or evidence-based.12,13 The 
diagnostic work-up of IBS often is redundant, with significant costs and challenges to the 
financially restrictive healthcare system. The high prevalence of IBS, the associated 
frequent usage of healthcare resources and loss in work productivity (i.e. absenteeism 
and presenteeism) result in a considerable global impact on society and associated 
economic burden.14  
The challenging (re)search for better therapies 
Another major contributing factor to the substantial socioeconomic burden is the 
limited efficacy of most therapeutic modalities for IBS. Neither low-cost traditional, nor 
new and more costly pharmacological agents for IBS have been able to provide more 
than 8-20% therapeutic gain over placebo.15 Novel therapeutic strategies that not only 
provide more global relief, but are also cost-effective are therefore urgently needed.  
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Peppermint oil is a promising low-cost drug for IBS, but evidence from high quality 
randomized controlled trials was still limited. We investigated its efficacy in a well-
designed trial according to FDA and European Medicines Agency (EMA) guidelines 
(chapter 7). In addition to the conventional enteric-coated peppermint oil with small-
intestinal release, a newly developed ileocolonic release peppermint oil (chapter 6) 
was studied. We hypothesized that both formulations would be superior compared to 
placebo, but no statistically significant differences were found when using the pre-
specified strict FDA and EMA recommended endpoints. In this regard, the first clinical 
trial with peppermint oil in a Rome IV-defined IBS population of both primary and 
secondary care patients showed a negative primary outcome when using these robust 
stringent endpoints. However, the difference in primary abdominal pain response rate 
(FDA recommended endpoint) between placebo and small-intestinal release 
peppermint oil in our study, i.e. 12.4%, is comparable to differences in response rate of 
other IBS therapeutic trials; e.g. using linaclotide16, or plecanatide.17 It should be noted 
that in these studies much larger patient populations were studied compared to our 
study. Although the PERSUADE study is the largest peppermint oil RCT in patients with 
IBS up to date, we cannot exclude that our study was underpowered to detect 
statistically significant effects when using these pre-specified stringent endpoints. A type-
II error may have occurred since we powered the study for an expected 30% difference 
that had previously been reported by a meta-analysis.18  
The importance of appropriate outcome measures 
In general, clinical trials investigating treatment for IBS are hindered by high placebo 
response rates estimated at around 40%19, the chronic relapse-remitting nature, and 
potentially elusive outcome measures. With regard to the latter, there has been ongoing 
debate about whether current instruments are able to fully evaluate the complex and 
heterogeneous IBS condition and represent all relevant dimensions of health for patients 
with IBS.20 Both the FDA and EMA recommended endpoints for IBS trials treating more 
than one IBS-subtype, are dichotomous endpoints of being an abdominal pain- or global 
relief responder or non-responder, respectively. It has been argued that these 
dichotomous endpoints provide an incomplete clinical understanding and fail to 
represent smaller benefits that are clinically important.21 Therefore, trial results in IBS 
may reflect a lack of efficacy of treatments given, but could also reflect a lack of 
appropriate outcome measures. In case of the PERSUADE study, conflicting findings 
were found across different outcome measures. On the one hand, no statistically 
significant differences were found between groups in primary outcomes recommended 
by the FDA and EMA, nor in health-related quality of life scores. This may seem at odds 
with previous meta-analyses that reported higher efficacy rates.22 On the other hand, 
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small-intestinal release peppermint oil did show statistically significant improvements in 
secondary outcomes of IBS symptoms that indicate clinically meaningful differences, such 
as IBS symptom severity, abdominal discomfort, and more relief of IBS symptoms 
(chapter 7). The difference in efficacy rates might therefore not be at odds with prior 
work, but merely a consequence of reporting the rigorous and stringent outcome 
measures predefined by the FDA/EMA for the first time in peppermint oil research. 
Inclusion of our study data and thus a broader array of outcome measures in the meta-
analysis subsequently led to widening of the uncertainty around the estimate of 
efficacy.23,24 Future research is needed to clarify the role of these different outcome 
measures on efficacy results. 
The importance of an appropriate target population  
Another reason for the general low level of efficacy in IBS trials may be related to the 
definition of the target population. The Rome criteria recommend to include only the 
Rome IV-defined IBS population in clinical trials to increase standardization and increase 
reproducibility of study findings. We did not find any association between baseline 
abdominal pain and being an abdominal pain responder in our study (chapter 7). 
Neither do we know whether inclusion of additional Rome-III positive Rome IV-negative 
patients with ‘milder’ IBS symptoms might have resulted in better efficacy of peppermint 
oil compared to inclusion of Rome IV-positive patients only. It should be noted that we 
included patients from both primary and secondary/tertiary care and this may have led 
to a higher applicability of trial results to the general population. Nevertheless, one 
could speculate on the outcome of efficacy of peppermint oil when a pragmatic trial in 
real-world setting would have been conducted. In such a trial, all patients in routine care 
with IBS-like symptoms and without an organic cause that have IBS according to their 
doctor’s opinion (without Rome IV criteria confirmation necessarily). To date, only very 
few pragmatic trials have been performed in IBS, e.g. one investigating the efficacy of 
acupuncture25 and one investigating on-demand usage of antispasmodics.26 Further 
insight into pathophysiological mechanisms underlying IBS can also aid selection of the 
best treatment for a specific patient. Subsequently, this may lead to more cost-effective 
treatment of patients with IBS. Our group previously performed a trial with probiotics 
selected to affect visceroperception in a subgroup of patients with visceral 
hypersensitivity. Unfortunately, preselection of patients did not lead to a better 
outcome.27 IBS is generally considered a complex multifactorial disorder. For tailored 
treatment strategies, better insight in single or combined factors contributing to 
predominant symptoms in subgroups of patients is needed. 
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The importance of appropriate measurement tools 
Use of inappropriate symptom measurement tools is another factor that may impede 
clinical trial design, the measurement of treatment response, and therefore the 
development of novel (cost-effective) therapies. In the PERSUADE study, we used a 
custom-made smartphone application as a digital symptom diary, web-based patient 
questionnaires, and an electronic case report file, collectively resulting in standardized 
data collection with high patient and investigator compliance (chapter 9). Compared 
to traditional paper diaries and questionnaires, this digital approach has led to a 
reduction in recall- and ecological bias, shows a higher adherence and provides more 
real time data, contributing to the methodological soundness of our RCT. Optimal 
symptom measurement tools may diminish biased trial results and enable clinicians and 
policy makers to draw more valid conclusions about treatment efficacy. Another 
example of a more real time registration of IBS symptoms, is the Experience Sampling 
Method (ESM). Akin to the digital end-of-day symptom diary used in the PERSUADE 
trial, the ESM is an electronic questioning method. In contrast to end-of-day symptom 
questionnaires, the ESM applies random and repeated measurements in the subject’s 
natural environment for several consecutive days. Our research group is in the process 
of validating an ESM patient reported outcome measure (PROM) specifically for IBS and 
this will help to gain further insight into fluctuations in IBS symptoms and potential 
triggers.28 This more detailed insight will further enable a more personalized medicine 
approach (that may also be more cost-effective). In addition, validated multi-item ESM-
PROMs developed according to FDA guidelines can also be used in clinical trials to 
evaluate treatment response. Future studies should assess whether this would alter 
findings of efficacy endpoints, and if yes – to what extent, in comparison to digital end-
of-day questionnaires or Interactive Voice Response (IVR) systems.  
Targeted treatment with peppermint oil 
Regardless of whether we had selected the appropriate outcome measures in our RCT, 
assessed them with the most optimal measurement tool, or included the correct target 
population, we had anticipated greater treatment efficacy of peppermint oil in patients 
with IBS. In contrast to the highly favorable number needed to treat of 2-3 that had 
been found in prior (less well designed) studies, we showed a number needed to treat 
of 8.  
 
Advantages of small-intestinal release peppermint oil as an initial treatment compared to 
other pharmacological options for IBS are its availability as a low-cost over the counter 
(OTC) drug and the general mild and transient adverse event profile without the risk of 
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serious adverse events. As treatment effects emerged towards the end of the eight-
week treatment period, future studies should evaluate the efficacy and safety of longer 
treatment with small-intestinal release peppermint oil. It would also be of value to assess 
if longer treatment periods will be cost-effective, since we found that small-intestinal 
release peppermint oil is likely cost-effective on the short term. In addition, it may be 
interesting to explore the presence of pharmacogenetic effects on treatment response, 
as part of the mechanism of action of peppermint oil is via TRPM8 stimulation through 
its main constituent menthol.29 Mutations in transient receptor potential channels are 
known from genetics analyses in pain research30 and may affect treatment response.  
 
In chapter 5, we investigated TRPM8 as the potential mechanism of action of 
peppermint oil, and postulated that activation of this receptor results in diminished 
release of inflammatory mediators which contribute to pain symptom generation. As 
this mechanistical study was small and preliminary, future research will need to elucidate 
these mechanisms further to optimize targeted treatments such as peppermint oil for 
IBS.  
 
We had hypothesized that the ileocolonic release would further increase efficacy, but 
this was not shown by our results. While reducing upper GI side effects, the ileocolonic 
release peppermint oil unexpectedly showed an increase in abdominal cramping. As 
ileocolonic-release peppermint oil also showed lower efficacy than small-intestinal 
release peppermint oil, we do not recommend its further development in the current 
form. Further insight into the differential intestinal expression of the receptor, i.e. 
expressional differences between duodenum, proximal colon and sigmoid, may lead to 
better understanding of the small-intestinal versus the ileocolonic release peppermint oil 
performance.  
Integrating mental health care 
In chapter 3, we showed that a reduction in IBS symptom severity was not paralleled 
by improvement in quality of life and general life satisfaction in patients with IBS. Our 
data suggested that quality of life and general well-being were related to concurrent 
anxiety and depression risk scores, rather than GI symptom severity. Moreover, in the 
cost-effectiveness analysis of the PERSUADE study, we found that a large proportion of 
the total associated socioeconomic costs was driven by mental healthcare usage 
(chapter 8). In patients with IBS, the prevalence of psychological co-morbidities is high 
and there is long-standing appreciation for a connection of anxiety and depression and 
altered stress responses and IBS. In view of the generally unsatisfactory results of 
153719-Weerts_BNW.indd   245 08-09-2021   12:04153719- eerts_BN _compleet.indd   245 08-09-2021   12:07
Chapter 10 
246 
pharmacological treatment and our findings of chapter 3 and 8, it can be argued that 
future models of care and novel treatment strategies should preferably integrate the 
management of psychological comorbidities. A multidisciplinary and multidimensional 
approach likely leads to better treatment outcomes than standard care given by GPs 
and gastroenterologists. Treatment guidelines are indeed increasingly incorporating the 
promising biopsychosocial model of care, which simultaneously addresses both mood 
disorders and GI symptoms in patients with IBS.31 The efficacy of psychological therapies 
alone, e.g. cognitive behavioral therapy32,33 and hypnotherapy34 has also been 
demonstrated in high quality studies. Nevertheless, therapist-led interventions are 
generally time consuming, relatively costly and the availability may be limited in some 
geographical areas due to a limited number of trained therapists. Psychological 
treatments that require less resources may increase cost-effectiveness, patient-
satisfaction, and availability. Such treatments include 1) group hypnotherapy that has 
been shown to be non-inferior to individual hypnotherapy35; 2) internet-delivered 
exposure-based cognitive behavioral therapy (CBT) that has been shown to reduce IBS 
symptoms36; and 3) a primarily home-based CBT that has been shown to be at least as 
effective as standard CBT.32 In that light, our group recently started a study to explore 
whether online hypnotherapy is non-inferior compared to individual face-to-face 
hypnotherapy in treatment of IBS symptoms (NCT03899779). It is hypothesized that 
such approaches can decrease treatment-associated costs, while simultaneously 
increasing general well-being and quality of life in patients with IBS.  
General conclusions 
This thesis has assessed the redefinition of diagnostic criteria and how this impacts the 
clinical diagnostic process in IBS. The potential effect on study populations in research 
has been described. Furthermore, this thesis has given an overview of current 
knowledge on TRP channels in IBS and provided the first in vivo data on the TRPM8 
channel in IBS. Study findings described in this thesis are key in paving the way to 
develop novel TRP targeted therapies for IBS.  
 
At the center of this thesis is the PERSUADE study, the largest RCT with peppermint oil 
in IBS to date. This trial not only contributed to knowledge on peppermint oil, but also 
assessed efficacy using both strict endpoints according to regulatory guidelines and other 
clinically relevant but less robust endpoints. Findings in this thesis showed that 
peppermint oil is not only moderately effective, but also appears to be cost-effective. 
Trial data were collected using a digital data-collection method which is detailed further 
in this thesis and led to excellent adherence.  
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This chapter has addressed some of the major challenges of IBS research, such as 
selecting the appropriate study outcomes and patient population, and employing a more 
digital and daily-life approach to data-collection.  
 
Although this thesis provides new insights in the broader sense of IBS research and 
treatment, the high prevalence, substantial socioeconomic burden, and impact on quality 
of life of IBS will continue to necessitate extensive future research into the field of 
disorders of gut-brain interaction and particularly IBS. 




1. Manning AP, Thompson WG, Heaton KW, et 
al. Towards positive diagnosis of the irritable 
bowel. Br Med J 1978;2:653-654. 
2. Longstreth GF, Thompson WG, Chey WD, et 
al. Functional bowel disorders. 
Gastroenterology 2006;130:1480-1491. 
3. Lea R, Hopkins V, Hastleton J, et al. 
Diagnostic criteria for irritable bowel 
syndrome: utility and applicability in clinical 
practice. Digestion 2004;70:210-213. 
4. Mujagic Z, Jonkers D, Hungin APS, et al. Use 
of Rome criteria for the diagnosis of irritable 
bowel syndrome in primary care: a survey 
among European countries. Eur J 
Gastroenterol Hepatol 2017;29:651-656. 
5. Camilleri M. Do the Symptom-Based, Rome 
Criteria of Irritable Bowel Syndrome Lead to 
Better Diagnosis and Treatment Outcomes? 
The Con Argument. Clin Gastroenterol 
Hepatol 2009;8:129. 
6. Holtmann GJ, Ford AC, Talley NJ. 
Pathophysiology of irritable bowel syndrome. 
Lancet Gastroenterol Hepatol 2016:1:133-
146. 
7. Chang L, Di Lorenzo C, Farrugia G, et al. 
Functional Bowel Disorders: A Roadmap to 
Guide the Next Generation of Research. 
Gastroenterology 2018;154:723-735. 
8. Aziz I, Tornblom H, Palsson OS, et al. How 
the Change in IBS Criteria From Rome III to 
Rome IV Impacts on Clinical Characteristics 
and Key Pathophysiological Factors. Am J 
Gastroenterol 2018;DOI 10.1038/s41395-
018-0074-z. 
9. Van den Houte K, Carbone F, Pannemans J, et 
al. Prevalence and impact of self-reported 
irritable bowel symptoms in the general 
population. United Eur Gastroenterol J 
2018;7:307-315. 
10. Jossan N, Simren M, Sperber A, et al. Health 
Care Utilization for Rome IV Irritable Bowel 
Syndrome; A Three-Country Survey in the 
General Population. Gastroenterology 
2017;152:S68. 
11. Hungin AP, Whorwell PJ, Tack J, et al. The 
prevalence, patterns and impact of irritable 
bowel syndrome: an international survey of 
40,000 subjects. Aliment Pharmacol Ther 
2003;17:643-650. 
12. Spiegel BM, Farid M, Esrailian E, et al. Is 
irritable bowel syndrome a diagnosis of 
exclusion?: a survey of primary care providers, 
gastroenterologists, and IBS experts. Am J 
Gastroenterol 2010;105:848-858. 
13. Vanner SJ, Depew WT, Paterson WG, et al. 
Predictive value of the Rome criteria for 
diagnosing the irritable bowel syndrome. Am J 
Gastroenterol 1999;94:2912-2917. 
14. Corsetti M, Whorwell P. The global impact of 
IBS: time to think about IBS-specific models of 
care? Therap Adv Gastroenterol 2017;10:727-
736. 
15. Simren M, Tornblom H, Palsson OS, et al. 
Management of the multiple symptoms of 
irritable bowel syndrome. Lancet 
Gastroenterol Hepatol 2017:2:112-122. 
16. Rao S, Lembo A, Shiff S, et al. A 12-week, 
randomized, controlled trial with a 4-week 
randomized withdrawal period to evaluate the 
efficacy and safety of linaclotide in irritable 
bowel syndrome with constipation. Am J 
Gastroenterol 2012;107:1714-1724. 
17. Brenner D, Fogel R, Dorn S, et al. Efficacy, 
safety, and tolerability of plecanatide in 
patients with irritable bowel syndrome with 
constipation: results of two phase 3 
randomized clinical trials. Am J Gastroenterol 
2018;113:735-745. 
18. Khanna R, MacDonald J, Levesque B. 
Peppermint oil for the treatment of irritable 
bowel syndrome: a systematic review and 
meta-analysis. J Clin Gastroenterol 
2014;48:505-512. 
19. Ballou S, Beath A, Kaptchuk TJ, et al. Factors 
Associated With Response to Placebo in 
Patients With Irritable Bowel Syndrome and 
Constipation. Clin Gastroenterol Hepatol 
2018;16:1738-1744 e1731. 
20. Shah E, Pimentel M. Placebo effect in clinical 
trial design for irritable bowel syndrome. J 
Neurogastroenterol Motil 2014;20:163-170. 
21. Lacy B, Lembo A, Macdougall J, et al. 
Responders vs clinical response: a critical 
analysis of data from linaclotide phase 3 clinical 
trials in IBS-C. Neurogastroenterol Motil 
2014;26:326-333. 
22. Black CJ, Moayyedi P, Quigley EMM, et al. 
Peppermint Oil in Irritable Bowel Syndrome. 
Gastroenterology 2020;159:395-396. 
153719-Weerts_BNW.indd   248 08-09-2021   12:04153719- eerts_BN _compleet.indd   248 08-09-2021   12:07
 General discussion 
249 
10 
23. Weerts Z, Masclee AAM, Jonkers D, et al. 
REPLY to GASTRO-D-19-02037. 
Gastroenterology 2020;DOI 
10.1053/j.gastro.2020.04.010. 
24. Black C, Yuan Y, Selinger C, et al. Efficacy of 
soluble fibre, antispasmodic drugs, and gut-
brain neuromodulators in irritable bowel 
syndrome: a systematic review and network 
meta-analysis. Lancet Gastroenterol Hepatol 
2020;5: 117-131. 
25. MacPherson H, Tilbrook H, Bland JM, et al. 
Acupuncture for irritable bowel syndrome: 
primary care based pragmatic randomised 
controlled trial. BMC Gastroenterology 
2012;12:150. 
26. Ducrotte P, Grimaud JC, Dapoigny M, et al. 
On-demand treatment with alverine 
citrate/simeticone compared with standard 
treatments for irritable bowel syndrome: 
results of a randomised pragmatic study. Int J 
Clin Pract 2014;68:245-254. 
27. Ludidi S, Mujagic Z, Jonkers D, et al. Markers 
for visceral hypersensitivity in patients with 
irritable bowel syndrome. Neurogastroenterol 
Motil 2014;26:1104-1111. 
28. Vork L, Keszthelyi D, Mujagic Z, et al. 
Development, content validity, and cross-
cultural adaptation of a patient-reported 
outcome measure for real-time symptom 
assessment in irritable bowel syndrome. 
Neurogastroenterol Motil 2018;30. 
29. Henstrom M, Hadizadeh F, Beyder A, et al. 
TRPM8 polymorphisms associated with 
increased risk of IBS-C and IBS-M. Gut 
2017;66:1725-1727. 
30. Lotsch J, Geisslinger G. Pharmacogenetics of 
new analgesics. Br J Pharmacol 2011;163:447-
460. 
31. Tanaka Y, Kanazawa M, Fukudo S, et al. 
Biopsychosocial model of irritable bowel 
syndrome. J Neurogastroentero Motil 
2011;17:131-139. 
32. Lackner JM, Jaccard J, Keefer L, et al. 
Improvement in Gastrointestinal Symptoms 
After Cognitive Behavior Therapy for 
Refractory Irritable Bowel Syndrome. 
Gastroenterology 2018;155: 47-57. 
33. Ljotsson B, Andersson G, Andersson E, et al. 
Acceptability, effectiveness, and cost-
effectiveness of internet-based exposure 
treatment for irritable bowel syndrome in a 
clinical sample: a randomized controlled trial. 
BMC Gastroenterol 2011;11:110. 
34. Miller V, Carruthers HR, Morris J, et al. 
Hypnotherapy for irritable bowel syndrome: 
an audit of one thousand adult patients. 
Aliment Pharmacol Ther 2015; 41:844-855. 
35. Flik CE, Laan W, Zuithoff NPA, et al. Efficacy 
of individual and group hypnotherapy in 
irritable bowel syndrome (IMAGINE): a 
multicentre randomised controlled trial. 
Lancet Gastroenterol Hepatol 2019;4:20-31. 
36. Ljotsson B, Hedman E, Andersson E, et al. 
Internet-delivered exposure-based treatment 
vs. stress management for irritable bowel 
syndrome: a randomized trial. Am J 
Gastroenterol 2011;106(8): 1481-1491. 
 
 
153719-Weerts_BNW.indd   249 08-09-2021   12:04153719- eerts_BN _compleet.indd   249 08-09-2021   12:07
Hoofdstuk spreads proefschrift IBS Zsa Zsa Weerts 170x240mm V9.indd   25 07/09/2021   10:19








Hoofdstuk spreads proefschrift IBS Zsa Zsa Weerts 170x240mm V9.indd   26 07/09/2021   10:19









Irritable bowel syndrome (IBS) is disorder of gut-brain interaction, previously known as 
a functional gastrointestinal disorder and is characterized by chronic recurrent 
abdominal pain and altered bowel habits. It is highly prevalent affecting 5-15% of the 
population depending on the criteria used and is associated with a pronounced impact 
on quality of life. The underlying pathophysiology of IBS is multifactorial, complex and 
incompletely understood and as a consequence, reliable biomarkers to diagnose IBS are 
currently lacking. This makes IBS a diagnosis which is, according to current consensus, 
merely based on symptoms. Symptoms vary widely both within and between patients, 
reflecting the complex and heterogeneous phenotype of IBS. Despite its prevalence and 
substantial negative impact on patients, treatment options are currently limited and are 
moderately effective at best. The relative lack of effective therapies adds further to the 
large associated socioeconomic burden. 
 
This thesis covers several aspects concerning IBS, from the diagnostic Rome criteria and 
symptom evolution over time (part I), to the investigation of therapeutic targets, with a 
special focus on treatment with peppermint oil, its potential mechanisms of action and 
its cost-effectiveness (part II).  
Part I - Epidemiological aspects and clinical manifestations of 
Irritable Bowel Syndrome 
Currently, diagnosis of IBS is made based on the presence of typical clinical symptoms 
which are incorporated in the Rome criteria and include abdominal pain and aberrant 
defecation such as constipation, diarrhea or a combination of the two. The Rome 
criteria have been modified every few years, which has led to some variation in IBS 
patient populations over time, depending on which criteria were used to diagnose IBS. 
The most recent version of the criteria is the Rome IV, published in 2016, which was 
expected to be more stringent than the prior Rome III due to the requirement of 
abdominal pain at least once a week instead of three days per month. In addition, the 
presence of pain instead of discomfort alone is a necessity. In chapter 2, we compared 
the prevalence of IBS according to the Rome III and IV criteria in the well characterized 
Maastricht IBS Cohort. Of 404 patients that were diagnosed with IBS using the Rome III 
criteria, between 87% and 62% was likely to also fulfill the Rome IV criteria. When 
comparing clinical characteristics between Rome III IBS patients and those also fulfilling 
the Rome IV criteria, we found that the Rome IV IBS population reflected a subgroup of 
Rome III IBS patients that was more often female, with more severe GI 
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symptomatology, psychological comorbidities and lower quality of life. This implies that 
results from Rome III IBS studies may not be directly transferable to Rome IV IBS 
populations. In clinic however, both groups should be considered as having IBS. 
 
Besides variations in population characteristics due to different diagnostic criteria used, 
symptoms within patients are also know to vary over time. Given that insight in factors 
affecting the natural disease course can help in the search for new patient-tailored 
targeted treatment strategies, we evaluated symptom evolution and characteristics that 
could predict the disease course over a five-year follow up period in chapter 3. Of 161 
Rome III IBS patients of the Maastricht IBS cohort, 30% did not fulfill the Rome III criteria 
any longer and had significantly lower levels of GI symptoms and GI-specific anxiety after 
five years follow-up. Nevertheless, comorbid anxiety and depression and quality of life 
were comparable between patients that did and did no longer fulfill the diagnostic 
criteria at follow-up. No baseline predictors for being Rome-IV positive at follow-up 
were found. These results suggest that long-term quality of life and general wellbeing 
might depend on concurrent psychological symptoms, rather than GI symptom 
improvement over time. Therefore, therapeutic efforts should also be aimed at 
addressing mental health issues. 
Part II - Transient receptor potential channels as therapeutic target 
Although the number of therapeutic options for IBS has grown in the last decades, 
treatment of abdominal pain in particular remains challenging and is often unsatisfactory. 
In the search for cost-effective treatments, Transient Receptor Potential (TRP) channels 
are promising targets for therapeutic interventions. TRP channels are known to have 
temperature-sensing properties, among many other functions. Growing evidence 
indicates that TRP channels in the GI tract are involved in the propagation and 
processing of abdominal pain signals in IBS.  
 
To gain an overview of current knowledge on the role of various TRP channels in 
visceral nociceptive processes in IBS, we first performed an extensive literature search 
and summarized the findings in chapter 4.  An extensive overview of knowledge on 
TRPV1, TRPV4, TRPA1, TRPM8 and their potential implications for treatment in IBS 
was given. Of these, TRPV1 is most widely-studied and its stimulation is associated with 
increased visceral nociception, hypersensitivity and increased neurogenic inflammation. 
Although direct antagonism of TRPV1 led to excellent analgesia, safety issues impair its 
clinical use. Knowledge regarding another important channel, the TRPM8 channel, is 
mostly derived from animal studies. These have shown that TRPM8 appears to have an 




anti-nociceptive and possibly anti-inflammatory effect. Peppermint oil, which has been 
used for decades to treat abdominal pain in IBS, has menthol as its main constituent. 
Interestingly, menthol is a TRPM8 agonist suggesting a possible effect through this TRP 
channel.  
 
In chapter 5, we then investigated molecular mechanisms underlying the potential 
beneficial effect of TRPM8 agonism in IBS. As human data on intestinal TRPM8 was 
limited to a single study in Crohn’s disease and a brief report on polymorphisms in IBS, 
this was the first study investigating TRPM8 in intestinal tissue of IBS patients. In biopsies 
from both a London and Maastricht IBS cohort, we showed that TRPM8-
immunoreactivity was colocalized with immune cells being predominantly of the 
dendritic cell lineage and in close approximation to nerve endings. In addition, we 
demonstrated that TRPM8 immunoreactivity and mRNA expression was increased in 
IBS patients as compared to controls. Ex vivo treatment of IBS patient biopsies with 
TRPM8 agonist icilin reduced the release of pro-inflammatory cytokines. These data 
indicate that TRPM8 may have important anti-inflammatory properties and by this virtue 
can impact neuro-immune disease mechanisms in IBS. 
 
Peppermint oil is one of the pharmacotherapeutic entities currently used for IBS and is 
also an agonist for TRPM8. Enteric-coated capsules that release peppermint oil in the 
small intestine are currently available as an over-the-counter drug in Europe. However, 
studies investigating the clinical efficacy of peppermint oil in IBS are hampered by 
methodological shortcomings that impede the ability to draw firm conclusions. In 
addition, the Rome diagnostic criteria have been updated and the European Medicines 
Agency (EMA) and Food and Drug Administration (FDA) have defined robust endpoints 
for clinical trials in IBS since then. Together, a methodologically well-designed trial to 
assess efficacy of peppermint oil in Rome IV diagnosed IBS patients was warranted. 
 
Although the mechanism of action of peppermint oil is multifactorial (e.g. intestinal 
smooth muscle relaxation, inhibition of serotonin receptors, anti-microbial and anti-
fungal), part of its effect is likely effectuated through TRPM8 stimulation via its main 
constituent, menthol. We hypothesized that an increased local colonic peppermint oil 
concentration would perhaps increase therapeutic efficacy and decrease burdensome 
upper GI adverse events from small-intestinal release peppermint oil, such as heartburn 
and belching, due to the more distal release. Therefore, an ileo-colonic release 
peppermint oil capsule was developed and its pharmacokinetic performance was 
assessed and compared to the already existing small-intestinal peppermint oil capsule in 
a crossover study, described in chapter 6. We showed in eight healthy volunteers, that 
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the time to reach the maximum concentration of the menthol metabolite, menthol-
glucuronide, was significantly longer for ileocolonic release compared to small-intestinal 
release peppermint oil, i.e. 360 versus 180 min. The lag time – time to reach a systemic 
concentration - was also significantly longer, i.e. 225 compared to 37 min, respectively. 
These results point to the likely release of peppermint oil in the more distal part of the 
intestine, the ileocolonic region.  
 
We then investigated both formulations of peppermint oil in the PERSUADE trial, 
described in chapter 7. The primary objective of this multicenter, randomized, 
placebo-controlled study was to determine the efficacy of small-intestinal release 
peppermint oil according to FDA and EMA guidelines. Moreover, we aimed to explore 
efficacy of the novel ileocolonic release peppermint oil. In 189 Rome IV diagnosed IBS 
patients, both formulations of peppermint oil did not result in statistically significant 
abdominal pain reduction or global symptom relief, when using stringent FDA and EMA 
recommended endpoints. The small-intestinal peppermint oil did, however, show greater 
improvements versus placebo in secondary outcomes, i.e. abdominal discomfort, IBS 
severity, and moderate relief. Adverse events were mild but more common in both 
peppermint oil groups as compared to placebo. As our results did not show benefits of 
ileocolonic release peppermint oil, i.e. upper GI adverse events were indeed reduced 
but abdominal cramping was increased in some patients, findings did not support the 
further development of ileocolonic release peppermint oil for IBS. Small-intestinal 
release peppermint oil, however, can be considered a moderately effective treatment 
based on the results of our study being the largest RCT with peppermint oil to date. 
 
Ideally, treatments should not only be effective, but also cost-effective. It is known that 
IBS not only has a large negative impact on quality of life, but is also associated with 
increased direct healthcare costs (e.g. consultations, emergency room visits) and indirect 
healthcare related costs (e.g. sick leave, decreased productivity at work). In chapter 8, 
we described a cost-effectiveness study of the small-intestinal release peppermint oil 
compared to placebo that was performed alongside the clinical RCT (PERSUADE 
study). The peppermint oil group had a slightly higher increase in utility scores (quality 
adjusted life years) than placebo during treatment. In addition, the peppermint oil group 
appeared to incur fewer total costs during treatment. Results of the cost-effectiveness 
analysis showed that peppermint oil is likely cost-effective with a probability varying 
between 56% and 89%, depending on the outcome measure and willingness to pay 
threshold used. Data analyses showed some uncertainty surrounding these results.  
 




Summarizing, we demonstrated a moderately positive effect of peppermint oil on IBS 
symptoms (chapter 7). Peppermint oil is inexpensive, widely available and has few 
adverse events. Taken together with the modest gains in quality of life adjusted years 
and the results of chapter 8 where we show that peppermint is likely cost-effective, 
we conclude that peppermint oil seems an appropriate first-line treatment for patients 
with IBS. More research and long-term data are necessary to confirm the effectiveness 
and cost-effectiveness of peppermint oil. 
 
Since there are no reliable biomarkers in IBS, end-of-day symptom diaries are 
considered the gold standard to assess treatment response. For the PERSUADE study, 
we used a custom-made digital framework for data-collection consisting of a daily digital 
symptom diary (custom smartphone application), web-based patient questionnaires 
(regarding e.g. demographics and life style, IBS symptom severity, and anxiety and 
depression), and an electronic case report file (eCRF) for investigators to report in. This 
digital framework and the results of the study investigating the feasibility of this digital 
data collection method is described in chapter 9. We showed that the mean overall 
compliance rate to the symptom diary was 88%. Patients’ compliance to the additional 
web-based questionnaires and investigators’ compliance to the eCRF were also very 
high, i.e. both more than 99%. Missingness due to technical issues was limited to one 
question. The data collection framework thereby was shown to lead to a standardized 
state-of-the art data collection with excellent completeness and can be used for future 
RCTs. Due to a slight decrease in patient compliance to the digital diary throughout the 
study, this method might be less suitable for trials of longer duration.  
 
Finally, in chapter 10, we provide an overview of the major findings presented in this 
thesis, integrated the different topics that were discussed in the different chapters, tried 
to place results in the broader scope of IBS research and discussed new insights and 
future perspectives. 
 
Although this thesis provides new insights in different aspects of IBS research and 
treatment, its high prevalence, associated substantial socioeconomic burden, and impact 
on quality of life on patients affected will continue to necessitate extensive future 
research into the field of disorders of gut-brain interaction and particularly IBS. 
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Het Prikkelbare Darm Syndroom (PDS), oftewel Irritable Bowel Syndrome (IBS) in het 
Engels, is een aandoening die gekenmerkt wordt door een verstoorde functie van de 
hersen-darm as, voorheen een functionele maagdarmaandoening genoemd. PDS wordt 
gekarakteriseerd door chronisch terugkerende buikpijn en een veranderd ontlastings-
patroon. Het is een veelvoorkomende aandoening die bij 5-15% van de bevolking 
voorkomt, afhankelijk van de gebruikte criteria voor diagnose. De onderliggende 
pathofysiologie van PDS is nog niet volledig opgehelderd, maar is complex en 
multifactorieel bepaald. Als gevolg daarvan ontbreken momenteel betrouwbare 
biologische markers om PDS te diagnosticeren. Dit maakt PDS een diagnose die, 
volgens de huidige consensus, louter is gebaseerd op klachten die door patiënten 
gerapporteerd worden. Deze klachten, oftewel symptomen, kunnen sterk verschillen 
per patiënt en over de tijd waardoor PDS gekenmerkt wordt door een heterogene 
patiëntenpopulatie. Ondanks de hoge prevalentie en de aanzienlijke vermindering in 
kwaliteit van leven waarmee PDS gepaard gaat, zijn behandelopties op dit moment 
beperkt en op zijn best matig effectief. Het ontbreken van effectieve therapieën draagt 
bij aan de grote sociaaleconomische last van PDS. 
  
Dit proefschrift richt zich op meerdere aspecten van PDS. Deel I richt zich op de Rome 
criteria om PDS te diagnosticeren en verandering van symptomen over de tijd. Deel II 
richt zich op onderzoek naar gerichte aangrijpingspunten voor therapie, met een 
bijzondere nadruk op de behandeling van PDS met pepermuntolie, potentiele 
werkingsmechanismen, en de kosteneffectiviteit van deze behandeling. 
Deel I - Epidemiologische aspecten en klinische manifestaties van 
het Prikkelbare Darm Syndroom 
Conform de huidige consensus wordt de diagnose van PDS gesteld op basis van de 
aanwezigheid van typische klinische symptomen die zijn opgenomen in de Rome criteria, 
namelijk buikpijn en een afwijkend ontlastingspatroon zoals obstipatie, diarree of een 
combinatie van beide. De Rome criteria zijn over de jaren steeds enigszins gewijzigd op 
basis van wetenschappelijk onderzoek, waardoor afhankelijk van de gehanteerde versie 
van de Rome criteria de PDS-patiënten populaties van elkaar kunnen verschillen. De 
meest recente versie van de criteria is de Rome IV, gepubliceerd in 2016, die naar 
verwachting strenger zou zijn dan de voorgaande Rome III criteria, vanwege het 
criterium dat er ten minste sprake dient te zijn van één keer per week buikpijn in plaats 
van drie dagen per maand. Bovendien dient er sprake te zijn van pijn en is enkel de 
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aanwezigheid van ongemak onvoldoende. In hoofdstuk 2 vergeleken we de prevalentie 
van PDS afhankelijk van het gebruik van de Rome III of IV criteria in een goed 
gekarakteriseerd cohort van PDS-patiënten, het Maastricht IBS Cohort. Van de 404 
patiënten bij wie PDS werd gediagnosticeerd met behulp van de Rome III criteria, 
voldeed tussen 87% en 62% waarschijnlijk ook aan de strengere Rome IV criteria. Bij het 
vergelijken van klinische kenmerken tussen Rome III PDS-patiënten en patiënten die ook 
voldeden aan de Rome IV criteria, ontdekten we dat de Rome IV PDS-populatie een 
subgroep weerspiegelde die vaker vrouwelijk was, met ernstigere maag-darm klachten, 
meer psychologische co-morbiditeit en een lagere kwaliteit van het leven. Dit betekent 
dat de resultaten van wetenschappelijk onderzoek binnen de Rome III PDS-populatie 
mogelijk niet direct vergelijkbaar zijn met die van een Rome IV PDS-populatie. In de 
klinische praktijk is het echter belangrijk om beide groepen als PDS te beschouwen en 
zodanig te behandelen. 
 
Naast variaties in populatiekenmerken als gevolg van verschillen in de gebruikte 
diagnostische criteria over de tijd, is het ook bekend dat symptomen binnen patiënten 
kunnen variëren over de tijd. Aangezien kennis over het natuurlijke ziekteverloop kan 
helpen bij het zoeken naar nieuwe, op de patiënt toegesneden, gerichte 
behandelstrategieën, evalueerden we in hoofdstuk 3 de variatie van symptomen over 
een periode van vijf jaar en zochten we naar voorspellers van ziektebeloop. Na vijf jaar 
follow-up rapporteerde 30% van 161 Rome III PDS-patiënten van het Maastricht IBS 
cohort gemiddeld minder maag-darmklachten en hieraan gerelateerde angst en voldeed 
deze 30% niet langer aan de Rome III criteria. Psychologische klachten, zoals angst en 
depressie, en de kwaliteit van leven waren echter vergelijkbaar tussen patiënten die nog 
wel en zij die niet meer aan de diagnostische criteria voldeden op het moment van 
follow-up. Er konden geen duidelijke voorspellers voor het ziekteverloop worden 
gevonden. Deze resultaten suggereren dat het algemeen welbevinden en de kwaliteit 
van leven op de lange termijn mogelijk meer afhangen van psychologische symptomen 
op dat moment, dan van verbetering van maag-darm klachten in de loop van de tijd. 
Deze resultaten pleiten tevens voor therapeutische interventies voor PDS die gericht 
zijn of mede gericht zijn op mentale gezondheid.  
Deel II - Transient Receptor Potential kanalen als therapeutisch 
doelwit 
Hoewel het aantal behandelopties voor PDS de afgelopen decennia is toegenomen, blijft 
de behandeling van met name buikpijn een uitdaging en is deze vaak onbevredigend. In 
de zoektocht naar kosteneffectieve therapieën zijn Transient Receptor Potential (TRP) -
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receptoren veelbelovende aangrijpingspunten voor therapeutische interventies. Van 
TRP-receptoren is bekend dat ze temperatuurgevoelige eigenschappen hebben, naast 
vele andere functies. Zo is de TRPM8 receptor verantwoordelijk voor het gevoel van 
koude en wordt dit aangrijpingspunt ook geactiveerd door menthol, wat het frisse 
gevoel van menthol verklaart. De TRPV1 receptor is verantwoordelijk voor een gevoel 
van warmte en wordt ook geactiveerd door capsaïcine, een stofje in chilipepers. 
Activatie van de TRPV1 receptor door capsaïcine verklaart het hete pittige gevoel van 
rode peper. Toenemend bewijs toont dat TRP-receptoren die zich op cellen in het 
maagdarmkanaal bevinden (in het slijmvlies), betrokken zijn bij de signalering, 
verspreiding en verwerking van buikpijnsignalen. De verhoogde prikkelgevoeligheid en 
gevoelsgewaarwording vanuit de darm wordt viscerale hypersensitiviteit genoemd. 
 
Om een overzicht te krijgen van de huidige kennis over de rol van verschillende TRP-
receptoren in pijnverwerking en prikkelgevoeligheid bij PDS, hebben we eerst een 
literatuuronderzoek uitgevoerd en de bevindingen samengevat in hoofdstuk 4. Een 
uitgebreid overzicht van kennis over TRPV1, TRPV4, TRPA1, TRPM8 en hun mogelijke 
implicaties voor de behandeling van mensen met PDS werd gegeven. Van deze 
receptoren is TRPV1 het meest bestudeerd en wordt de stimulatie ervan geassocieerd 
met verhoogde prikkelgevoeligheid, viscerale hypersensitiviteit en ontstekingsreactie 
oftewel inflammatie. Hoewel bleek dat een directe blokkering oftewel antagonisme van 
TRPV1 tot uitstekende pijnstilling leidde, belemmerden veiligheidsproblemen het 
klinische gebruik ervan. Kennis over een andere belangrijke receptor, de TRPM8-
receptor, is grotendeels afkomstig uit dierstudies. Deze hebben ons laten zien dat 
TRPM8 een pijnstillende en mogelijk ontstekingsremmende werking lijkt te hebben. 
Interessant is dat pepermuntolie, dat al tientallen jaren wordt gebruikt om buikpijn bij 
PDS te behandelen, menthol als hoofdbestanddeel heeft en menthol de TRPM8 
receptor direct kan stimuleren. Dit suggereert mogelijk een gunstig effect van 
pepermuntolie via deze TRP-receptor. 
 
In hoofdstuk 5 hebben we vervolgens moleculaire mechanismen onderzocht die ten 
grondslag liggen aan het potentieel gunstige effect van TRPM8 stimulatie in PDS. 
Aangezien de wetenschappelijke kennis over TRPM8 bij mensen in de darm zich beperkt 
tot één enkele studie bij de ziekte van Crohn en een kleine studie naar polymorfismen 
oftewel genetische variaties bij PDS, was dit de eerste studie die TRPM8 expressie en 
activiteit in darmweefsel van PDS-patiënten onderzocht. In darm biopten van PDS-
patiënten uit Londen en Maastricht toonden we aan dat TRPM8 reactieve cellen zich 
vlakbij cellen van het immuunsysteem bevonden, en vlakbij zenuwuiteinden. Bovendien 
bleek dat TRPM8 activiteit en de genetische (mRNA) expressie verhoogd was bij PDS-
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patiënten in vergelijking met mensen zonder PDS. Behandeling van darmbiopten van 
PDS-patiënten met een middel dat de TRPM8 receptor kan stimuleren, iciline, 
verminderde de afgifte van stofjes die voor meer ontsteking kunnen zorgen oftewel pro-
inflammatoire cytokines. Deze resultaten tonen dat TRPM8 belangrijke 
ontstekingsremmende eigenschappen kan hebben en daardoor mogelijk de neuro-
immuun gerelateerde ziektemechanismen in PDS kan beïnvloeden. 
 
Een van de farmacotherapeutische middelen die momenteel voor PDS gebruikt wordt 
en die ook TRPM8 kan stimuleren, is pepermuntolie. Speciaal gecoate maagsap-
resistente capsules zorgen ervoor dat de pepermuntolie wordt afgegeven in de dunne 
darm en zijn verkrijgbaar in Europa zonder recept. Wetenschappelijke studies uit het 
verleden naar de klinische werkzaamheid van pepermuntolie bij PDS werden echter 
belemmerd door methodologische beperkingen die het moeilijk maken om eenduidige 
conclusies te trekken over de daadwerkelijke effectiviteit van pepermuntolie. Bovendien 
zijn de diagnostische Rome criteria herzien naar versie IV en hebben de European 
Medicines Agency (EMA) en de Food and Drug Administration (FDA) inmiddels nieuwe 
robuuste eindpunten gedefinieerd voor geneesmiddelenstudies binnen PDS. Derhalve 
was een methodologisch goed opgezette studie nodig om de werkzaamheid van 
pepermuntolie bij Rome IV PDS-patiënten te beoordelen. 
 
Hoewel het werkingsmechanisme van pepermuntolie multifactorieel is (bijv. relaxatie 
van de gladde spieren van de darmen, remming van serotoninereceptoren, 
antimicrobiële en antischimmel activiteit), wordt een deel van het effect waarschijnlijk 
bewerkstelligd door TRPM8-stimulatie via het hoofdbestanddeel, menthol. Onze 
hypothese was dat een toename van de lokale pepermuntolie concentratie in het colon 
oftewel de dikke darm wellicht de therapeutische werkzaamheid zou verhogen. Tevens 
zou een meer distale afgifte van de pepermuntolie kunnen leiden tot vermindering van 
bovenste gastro-intestinale bijwerkingen zoals zuurbranden en oprispingen. Daarom 
werd er een nieuwe pepermuntolie capsule ontwikkeld die de olie vanaf het ileocecale 
gedeelte van de darm in het colon afgeeft in plaats van in de dunne darm. De 
farmacokinetische eigenschappen van deze nieuwe capsule werden onderzocht en 
vergeleken met de reeds bestaande dunne darm pepermuntolie capsule in een cross-
over studie, beschreven in hoofdstuk 6. Bij acht gezonde vrijwilligers werd aangetoond 
dat de tijd om de maximale concentratie van de menthol metaboliet, 
mentholglucuronide, te bereiken significant langer was voor de capsule met dikke darm 
afgifte in vergelijking met capsules met dunne darm pepermuntolie afgifte, namelijk 360 
versus 180 minuten. De tijd waarin een systemische concentratie van menthol-
glucuronide bereikt werd was ook significant langer, namelijk 225 versus 37 min. Deze 
153719-Weerts_BNW.indd   262 08-09-2021   12:04153719- eerts_BN _compleet.indd   262 08-09-2021   12:07
 Dutch summary 
263 
A 
resultaten wijzen op de afgifte van pepermuntolie in het meer distale deel van de darm 
ofwel de dikke darm, het colon. 
 
Vervolgens zijn beide formuleringen van pepermuntolie onderzocht in de PERSUADE-
studie, beschreven in hoofdstuk 7. Het primaire doel van dit multicenter, 
gerandomiseerde, placebo-gecontroleerde onderzoek was het bepalen van de 
werkzaamheid van dunne darm afgifte pepermuntolie volgens de vernieuwde FDA- en 
EMA-richtlijnen. Bovendien wilden we de werkzaamheid van de nieuwe pepermuntolie 
met dikke darm afgifte onderzoeken. In 189 Rome IV PDS-patiënten, resulteerde 
pepermuntolie (beide formuleringen) echter niet in een statistisch significante 
vermindering in buikpijn of globale symptoomverlichting wanneer de strenge FDA en 
EMA aanbevolen eindpunten als primaire uitkomstmaat gebruikt werden. De dunne 
darm pepermuntolie gaf wel significante verbeteringen ten opzichte van placebo in 
secundaire uitkomstmaten, namelijk buikpijn, ernst van de PDS, en een algehele redelijke 
verlichting in symptomen. Bijwerkingen waren mild maar kwamen vaker voor in beide 
pepermuntoliegroepen ten opzichte van placebo. Onze resultaten toonden geen 
voordelen van pepermuntolie met dikke darm afgifte. Hoewel het voorkomen van 
enkele bovenste gastro-intestinale bijwerkingen inderdaad minder was, nam de 
gemiddelde mate van buikkrampen bij sommige patiënten toe. Onze bevindingen 
ondersteunen daarom de verdere ontwikkeling van pepermuntolie met dikke darm 
afgifte voor PDS niet. Op basis van de resultaten van de PERSUADE-studie, de grootste 
RCT met pepermuntolie tot nu toe, kan pepermuntolie met dunne darm afgifte echter 
worden beschouwd als een matig effectieve behandeling voor PDS. 
 
Idealiter is een behandeling niet alleen effectief, maar ook kosteneffectief. Het is namelijk 
bekend dat PDS niet alleen een grote negatieve invloed op de kwaliteit van leven heeft, 
maar ook geassocieerd is met verhoogde directe kosten van de gezondheidszorg 
(bijvoorbeeld kosten van een consult, spoedeisende hulp bezoeken) en indirecte kosten 
(bijvoorbeeld ziekteverzuim, verminderde productiviteit op het werk). In hoofdstuk 8 
hebben we de kosteneffectiviteit van dunne darm afgifte pepermuntolie vergeleken met 
placebo in een studie die werd uitgevoerd binnen het kader van het klinische 
gerandomiseerd onderzoek (PERSUADE-studie). De pepermuntolie groep toonde 
tijdens de behandeling een iets grotere stijging in kwaliteit van leven (uitgedrukt als 
‘quality adjusted life years’) dan de met placebo behandelde groep. Daarnaast bleek de 
pepermuntoliegroep tijdens de behandeling iets minder totale (gezondheid gerelateerde 
directe en indirecte) kosten te hebben. Resultaten van de kosteneffectiviteitsanalyse 
toonden dat pepermuntolie waarschijnlijk kosteneffectief is met een waarschijnlijkheid 
variërend tussen 56% en 89%, afhankelijk van de uitkomstmaat en de drempel van 
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betalingsbereidheid (willingness to pay) die gebruikt worden. Sensitiviteitsanalyses 
toonden enige onzekerheid rondom deze resultaten. 
 
Samenvattend vonden we dat pepermuntolie een overwegend positief effect heeft op 
PDS symptomen (hoofdstuk 7). Pepermuntolie is daarnaast goedkoop, overal 
verkrijgbaar en heeft weinig bijwerkingen. Samengenomen met de bescheiden winst in 
kwaliteit van leven en de resultaten van hoofdstuk 8, waar we tonen dat 
pepermuntolie capsules waarschijnlijk kosteneffectief zijn, kunnen we concluderen dat 
pepermuntolie een passende eerstelijnsbehandeling is voor patiënten met PDS. Meer 
onderzoek en data over effecten op langere termijn zijn nodig om de effectiviteit en 
kosteneffectiviteit van pepermuntolie verder te bevestigen. 
 
Aangezien er op dit moment nog geen betrouwbare biologische markers zijn voor PDS, 
worden dagelijkse symptoomdagboeken beschouwd als de gouden standaard om de 
respons op een behandeling te beoordelen. Voor de PERSUADE-studie gebruikten we 
een op maat gemaakt digitaal raamwerk voor het verzamelen van gegevens, bestaande 
uit een dagelijks digitaal symptoomdagboek (op basis van een smartphone-applicatie), 
elektronische vragenlijsten voor patiënten (met betrekking tot bijvoorbeeld demografie 
en leefstijl, ernst van PDS-symptomen en angst en depressie), en een elektronische case 
report file (eCRF) voor onderzoekers om verslag in te doen. Dit digitale raamwerk en 
de resultaten van ons onderzoek naar de haalbaarheid van deze methode van digitale 
gegevensverzameling worden beschreven in hoofdstuk 9. We toonden aan dat de 
gemiddelde compliance oftewel het nalevingspercentage van het symptoom dagboek 
88% was, wat inhoudt dat van alle dagen binnen het onderzoek het dagboek gemiddeld 
88% trouw werd ingevuld door de deelnemers. Compliance van patiënten betreffende 
de aanvullende elektronische vragenlijsten en compliance van onderzoekers betreffende 
het eCRF waren ook hoog, d.w.z. beide meer dan 99%. Dataverlies door technische 
problemen bleef beperkt tot één vraag. Kortom, het digitaal raamwerk resulteerde in 
een gestandaardiseerde dataverzameling van hoge kwaliteit met hoge mate van 
compleetheid en kan worden gebruikt voor toekomstige onderzoeken waarbij therapie-
effect gemeten dient te worden. Vanwege de lichte afname in patiënt compliance 
betreffende het digitale dagboek over de tijd, is deze methode mogelijk minder geschikt 
voor onderzoeken van langere duur. 
 
Ten slotte wordt in hoofdstuk 10 een overzicht gegeven van de belangrijkste 
bevindingen van dit proefschrift, integreerden we de onderwerpen die in de 
verschillende hoofdstukken werden besproken, plaatsten we de resultaten in breder 
perspectief en bespraken we nieuwe inzichten en toekomstmogelijkheden. 
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Hoewel dit proefschrift nieuwe inzichten biedt op verschillende vlakken binnen PDS-
onderzoek en behandeling, is verder wetenschappelijk onderzoek noodzakelijk vanwege 
de hoge prevalentie, de bijbehorende substantiële sociaaleconomische last en de impact 
op de kwaliteit van leven van patiënten met een aandoening van hersen-darm interactie 
waaronder PDS.  
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Irritable bowel syndrome is a highly prevalent disorder affecting 5-15% of the population 
and is associated with a substantial financial and societal burden. The studies described 
in this thesis contribute to the long-term goal to further optimize IBS treatment.  
Impact on healthcare providers 
The results from this thesis are relevant for people involved in the care of patients with 
IBS such as general practitioners, gastroenterologists, psychologists, and dieticians.  
 
Treatment of cardinal IBS symptoms such as abdominal pain is exceptionally challenging. 
The large randomized controlled trial on the efficacy of peppermint oil in IBS, the 
PERSUADE study, showed that peppermint oil is a moderately, though most-likely cost-
effective treatment. This allows for appropriate positioning of peppermint oil in the 
therapeutic arsenal and for more informed decision making. Upper GI symptoms may 
occur as side effects during treatment with peppermint oil. We demonstrated for the 
first time that belching severity decreases after three weeks of continues peppermint oil 
treatment. This particular finding can help healthcare providers who prescribed 
peppermint oil treatment to better inform patients when this highly burdensome but 
harmless side-effect occurs. 
 
Although part of this thesis focused on (GI-)targeted treatment with peppermint oil, we 
also showed that improvement in GI symptom severity does not necessarily result in an 
improvement in quality of life in patients with IBS. Furthermore, we showed that a large 
part of the total healthcare costs in patients with IBS was spent on mental healthcare. 
Findings like these can inform healthcare providers about the importance of a 
multidimensional and integrated treatment and will eventually help them in treating IBS 
patients successfully. 
 
Furthermore, results from the different studies described in this thesis are largely 
applicable to primary care where general practitioners diagnose and see the majority of 
patients with IBS. The Maastricht IBS Cohort studies included 28-33% of patients 
recruited from primary care. The PERSUADE study included 57.7% of patients recruited 
from primary care. This in itself represents the largest of such population examined with 
regards to peppermint oil efficacy and led to a high applicability of the results to every-
day clinical practice.  
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Impact on research 
This thesis is relevant for researchers in the field of functional gastrointestinal disorders. 
After redefinition of the diagnostic criteria our results were one of the first to show how 
this affected prevalence and characteristics of IBS patient populations.  
 
In addition, the studies included in this thesis provide a solid basis to optimize treatment 
response measurement in functional GI disorders by designing and describing a 
framework for digitalized data-collection in RCTs. This data-collection method showed 
excellent adherence from both patients and researchers in our PERSUADE study. In 
addition, future Dutch studies benefit from the national multicenter network established 
at the start of our peppermint oil RCT. Currently, the (slightly adapted) framework for 
data-collection is being used for symptom measurement in the multicenter RCT of our 
research group on the efficacy of face-to-face versus online hypnotherapy for patients 
with IBS.  
 
This thesis has contributed to science by giving an overview of current knowledge on 
transient receptor potential channels and by investigating the role of the TRPM8 
receptor in the human (IBS) colon. The results in this thesis showed for first time that 
colonic mRNA expression levels are significantly higher in patients with IBS compared to 
healthy volunteers and that intestinal TRPM8 activation results in a decrease of pro-
inflammatory cytokines. Shedding light onto this pathophysiological mechanism may lead 
to the proposal of new mechanistic studies of which the outcomes can eventually lead 
to the development of more targeted treatment for patients with IBS. 
Impact on patients with IBS and society 
Importantly, the research topics described in this thesis provide benefit to patients with 
IBS in a broad sense. By increasing knowledge on key factors involved in 
pathophysiology of IBS and in quality of life, more targeted treatment can be developed 
and investigated. This will then hopefully lead to improvements in healthcare with better 
health outcomes on the long-term for patients with IBS. 
 
Although there is long-standing appreciation for the magnitude of the societal and 
economic burden imposed by IBS, Dutch data are still sparse. Data included in this 
thesis indicated that a large part of the substantial healthcare costs incurred by Dutch 
patients with IBS was actually driven by mental and not GI-related healthcare. In 
addition, it was shown that patients who improve in GI symptom severity did not 
necessarily have a better quality of life. These findings point to a large impact of 
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psychological comorbidities on total associated costs and call for a change in quality of 
care models for IBS. Implementing the biopsychosocial model in healthcare systems 
could lead to an early recognition of psychological comorbidity in IBS patients, which 
may further lead to significant economic benefit for the healthcare system and society in 
general.  
 
In addition, this thesis provided the first trial-based data suggesting that treatment with 
small-intestinal release peppermint oil is cost-effective. This finding can impact clinical 
decision making, implementing the cost-effective peppermint oil in routine practice and 
hence lowering total IBS associated costs while high quality care is maintained. 
Knowledge translation 
A prerequisite for the implementation of novel scientific knowledge is the dissemination 
of research findings to the scientific community, healthcare providers, policy makers, 
and patients. Therefore, the chapters in this thesis were or will be published in 
international peer-reviewed journals. Moreover, results were presented at various 
national and international research meetings such as the Dutch Digestive Disease Days, 
the European NeuroGASTRO meeting, the United European Gastroenterology (UEG) 
congress, and the Federation of Neurogastroenterology and Motility Meeting.  
 
At this moment, the joint multidisciplinary clinical guideline of the Dutch College of 
General Practitioners (Nederlands Huisartsen Genootschap) and the Dutch society of 
gastroenterologists (Nederlandse Vereniging van Maag-Darm-Leverartsen) on IBS is 
under revision. As a result of the studies in this thesis, the novel guideline can 
incorporate data on prevalence after the change from Rome III to Rome IV diagnostic 
criteria. Furthermore, based on a meta-analysis that included data from our study1, it is 
expected that peppermint oil will be included as a moderately effective and low-cost 
first-line treatment option for IBS. Taken together with the publications on the 
PERSUADE study in Medisch Contact2, Nederlands Tijdschrift voor Geneeskunde3 and 
Huisarts en Wetenschap4, and the publication of trial results by the Maastricht University 
Medical Center and Zuyderland Medical Center websites and social media accounts, the 
national dissemination was successful and will likely lead to further implementation 
throughout the Netherlands. 
 
Results of this RCT have been picked up by the international gastroenterologist 
community as well. Features included an editorial about our study design and results in 
Gastroenterology5, a citation as one of the major highlights of the past decade by the 
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editors of The American Journal of Gastroenterology6, a laudatory summary in The New 
England Journal of Medicine (NEJM) Journal watch7, and a discussion and summary in the 
BMJ Evidence Based Medicine.8 Most recently, our study findings have been incorporated 
in the American College of Gastroenterology clinical guideline on the management of IBS.9  
 
With regards to knowledge distribution to patients with IBS, findings of the Maastricht 
IBS Cohort and PERSUADE study have been summarized and sent to patients who 
participated in the studies. Members of the Dutch IBS patient organization were 
informed about results in layman’s articles published in their members magazine Prikkels. 
In addition, Maastricht University Medical Center has organized various patient 
information evenings to keep patients up to date with current knowledge. 
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Het dankwoord, het meest gelezen hoofdstuk van ieder promotieboekje en laten we 
eerlijk zijn, onafhankelijkheid klinkt goed, maar effectieve afhankelijk is velen malen 
mooier. Zonder steun en hulp van velen zou dit proefschrift namelijk niet zijn wat het 
uiteindelijk geworden is, de kroon op jaren van hard werk. Graag bedank ik hier een 
aantal mensen persoonlijk.  
  
Mijn paranimfen. 
Lisa, lieve Lies, centraal in mijn promotietijd stond toch wel onze vriendschap. Vanaf 
dag één trokken we samen op en kon ik bij jou terecht voor goede raad en advies over 
onderzoek en het leven. Tweelingen werden we vaak genoemd. Eenieder die goed kijkt 
weet echter dat we bij verre na niet identiek zijn, maar wel in een opvallende symbiose 
kunnen functioneren. Perfect op elkaar ingespeeld waren we een heuse IBS-machine op 
de Uns50. Er hoefde maar iets voor te vallen en wij konden elkaars reactie al raden. Van 
werken tot lachen tot reizen en feesten, we deden het allemaal en allemaal samen. Ik 
ben trots op onze vriendschap en onze prestaties door de jaren heen. Een promotie en 
leven zonder jou aan mijn zijde kan ik me niet voorstellen. Je bent voor altijd welkom op 
onze slaapbank op de Minckelersstraat en toekomstige woningen. 
Mirjam, lieve Mir, Ik ontmoette je 13 jaar geleden op station Roermond en sindsdien 
waren we vriendinnen voor het leven. Van huisgenoot, reisgenoot, (werk-) 
kamergenoot, tot vriendinnen aan wederzijden van de maas, je bent altijd dichtbij 
geweest. Van lachen, gieren en brullen (letterlijk en met veel tranen) tot je nooit 
veroordelend luisterend oor, je vriendschap is door de jaren heen van groot belang 
voor mij geweest. Ook deze laatste maanden sta je altijd voor mij klaar. Het is bijzonder 
leuk dat we beide gekozen hebben voor een promotietraject, ware het binnen de maag-
, darm- en leverziekten versus de chirurgie. Dank voor je vriendschap en ik ben trots dat 
jij naast mijn zijde staat op deze belangrijke dag.  
 
Het promotieteam. 
Beste professor Masclee, beste Ad, toen ik in 2014 werd aangesteld als promovendus 
bij de maag-, darm-, en leverziekten werkte ik voor mijn gevoel voor het eerst voor een 
echte baas. Ik dank u voor uw vertrouwen tijdens het gehele traject. Soms was u streng, 
maar u was ook zeker niet te beroerd om complimenten te geven. Dit werkte enorm 
motiverend om de laatste loodjes te klaren. Ook u zult binnenkort een fase afsluiten: in 
november zullen we feestelijk terugkijken naar uw indrukwekkende carrière binnen de 
maag-, darm- en leverziekten. Ik wens u veel geluk en ben er zeker van ook na 
november nog over en van Prof. Masclee te horen. Veel dank! 
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Daniel, ik denk dat het met mijn Hongaarse naam in de sterren geschreven stond dat 
een Hongaar een dergelijke prominente rol in mijn loopbaan zou gaan spelen. Lisa en ik 
waren je eerste promovendi en wat hebben we samen veel meegemaakt. Ik heb je zien 
groeien in je rol als copromotor en ik kan alleen maar hopen dat ikzelf een klein 
percentage daarvan ben meegegroeid door de jaren. Je bent gepassioneerd in je vak en 
schiet nooit ideeën te kort. Naast copromotor ben je ook een mentor die zich 
bekommert over het welbevinden van je pupillen en die zich op feesten en partijen met 
zijn onderdanen mengt. Je publicatielijst in kwalitatief goede bladen is lang en je bent een 
internationale speler in de wereld van de neurogastroenterologie geworden. Hoe 
bewogen en druk je professionele leven ook is, je hebt altijd tijd gemaakt om snel en 
meestal binnen 48 uur naar stukken te kijken, iets wat enorm motiveert. Dr. Keszthelyi, 
jij gaat het nog ver schoppen en als je uiteindelijk de absolute top bereikt, dan roep ik 
trots dat Lisa en ik jouw eerste promovendi waren. Ik hoop dat je trots bent op dit 
boekje en je bijdrage hieraan. Dankjewel! 
 
Daisy, door de jaren heen heb ik ontzettend veel van je geleerd door je heldere blik en 
scherp commentaar. Je hebt altijd tijd gemaakt om samen naar presentaties te kijken, 
goede verbindingszinnen te creëren en het woordenaantal te verlagen. Dankzij jouw 
kwaliteit op inhoud zijn mijn stukken en dit boekje absoluut naar een hoger niveau getild. 
Terecht ben je door je inzet en kennis gepromoveerd tot hoogleraar en 
wetenschappelijk hoofd van Nutrim. Naast aandacht binnen het wetenschappelijk kader 
had je ook altijd oog voor mij als mens. Prof. Jonkers, dank voor je leiderschap tijdens 
mijn weg naar dit eindresultaat.  
 
Beoordelingscommissie. 
Prof. dr. Schoon, Prof. dr. Van Bredenoord, Prof. dr. Joore, dr. Vanmolkot, en 
dr. Van den Wijngaard, hartelijk dank voor jullie bereidheid om zitting te nemen in 
de beoordelingscommissie en dit proefschrift op haar wetenschappelijke waarde te 
beoordelen. 
 
Patiënten en proefpersonen. 
Zonder deelnemers geen wetenschappelijk onderzoek. Daarom wil ik patiënten en 
vrijwilligers die hebben deelgenomen aan de studies in dit proefschrift van harte 
bedanken. Tevens gaat er dank uit naar de PDS patiënt belangenvereniging en hun 
voorzitter, Theo Spaan, voor de hulp en steun bij wetenschappelijk onderzoek.  
 





Zlatan, dr. Mujagic, ik ken niemand zoals jij en heb veel bewondering voor het feit dat 
jij altijd vrolijk lijkt te zijn en overal het positieve van inziet. Je hebt je enthousiasme voor 
het vak overgedragen vanaf minuut één dat ik als WESP-student bij je kwam werken. 
Inmiddels hebben we veel werk verricht samen, maar ook veel genoten van congressen, 
reisjes en feestjes waarbij de nodige streken werden uitgehaald. Dankjewel voor je 
enthousiasme en vriendschap.  
Martine, dankjewel voor de bereidheid om door de jaren heen altijd te willen mee te 
denken, en de rust en geruststelling die je uitstraalt. 
Joanna, dr. Kruimel, dank voor het delen van uw klinische blik op aspecten betreffende 
IBS. Ik kijk uit naar onze verdere samenwerking tijdens de opleiding met u als opleider. 
Beste Carsten, dr. Leue, dank voor het delen van uw expertise vanuit de psychiatrie. 
 
PERSUADE onderzoek.  
Prof. dr. Koos Brouwers, Prof. dr. Erik Frijlink, jullie waren pioniers betreffende 
nieuw origineel onderzoek met pepermuntolie voor IBS, waarvoor veel dank. Prof. dr. 
Jean Muris en Prof. dr. De Wit, dank voor jullie invalshoek vanuit de 
huisartsengeneeskunde bij het opzetten en uitvoeren van de studie. 
Ron Pelsers, lab stein, dank voor de snelle sample analyse betreffende onze 
farmacokinetische studie. Prof. dr. Cees Neef, dank voor de inleiding binnen de 
analyse van farmacokinetische data. 
Leiden: dr. Cees Clemens, Mariëlle en Simone veel dank voor jullie hulp om de 
studie in de stad van ontdekkingen draaiende te houden. 
Ede: Prof. dr. Ben Witteman, Alina, Annieke, Audrey en Lieneke, dank voor al 
jullie inclusies en werk vanuit de Gelderse Vallei. 
Leeuwarden: Annieke en Audrey, dank voor jullie enthousiaste en harde werk vanuit 
het hoge Noorden. 
Maastricht: Andrea, dank voor je kracht en oneindige lading energie. Je bent top voor 
patiënten en collega’s en wist altijd wel weer deelnemers via je netwerk te werven. 
Dank ook aan de collega’s van ziekenhuisapotheek MUMC+ voor hun hulp met 
de opslag en distributie van de studiemedicatie. Veel dank gaat uit naar de huisartsen 
in regio Zuid Limburg voor hun waardevolle hulp bij de werving voor dit onderzoek. 
Memic. Paula, hartelijk dank voor je betrokkenheid en zorgvuldigheid betreffende oa. 
datamanagement van de PERSUADE studie. Als buurvrouw van mijn ouderlijk huis 
waren de overleggen altijd vol gezelligheid en ik ben blij dat we elkaar nog regelmatig 
tegenkomen. Koert, bedankt voor de oneindige inzet tijdens het bouwen van de app. 
Verder dank aan Dirk, Donavan, Jacqueline en Luc, samen zorgden jullie voor het 
reilen en zeilen van Ldot, Castor en de PERSUADE-app. 
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Absence of proof is not proof of absence, bedankt Bjorn, dr. Winkens voor je hulp bij 
analyses en statistische ondersteuning. 
Brigitte, dr. Essers, dank voor de samenwerking op het gebied van gezondheid 
gerelateerde economische evaluaties. Ons harde werk is gelukkig beloond met een 
gepubliceerd stuk nog vlak voor mijn promotie! 
Will Pharma. Veel dank gaat uit naar Maurienne Will en de werknemers van Will 
Pharma voor de financiële bijdrage en logistieke ondersteuning. 
Verder wil ik ZonMw bedanken voor de honorering van de aanvraag betreffende 
pepermuntolie bij IBS en het mogelijk maken van dit onderzoek middels hun sponsoring. 
 
Studenten. 
Tijdens mijn PhD hebben vele studenten bijgedragen aan de studies beschreven in dit 
proefschrift. Ik wil hen allen bedanken. In het bijzonder Amber, Deborah, Geertje, 
Jeresa en Nic voor jullie harde werk en inzet binnen het PERSUADE onderzoek. 
 
London Collaboration. 
A special thanks to Madusha Peiris, PhD, and Rubina Aktar, PhD, for the 
collaboration described in chapter 5. Montserrat, PhD and Pan, PhD, thank you for 
your help regarding the intestinal biopsies.  
 
Maastricht UMC Collega’s. 
Dank aan mijn lieve mede MDL-onderzoekers, zonder jullie was mijn tijd als 
promovendus nooit zo legendarisch geweest. Het wordt tijd dat covid uit ons leven 
verdwijnt en dat we tijdens een reünie alle herinneringen en anekdotes kunnen 
uitwisselen om opnieuw samen het glas te heffen en wellicht zelfs een dansje kunnen 
wagen. Van promotiefeesten, lab-uitjes tot de kerstborrels, congressen en symposia in 
binnen- en buitenland, wintersport- en fietsweekendjes, of gewoon get lekkers op de 
uns40/50, het was een waar genoegen. Bedankt Annick, Anke, Ankie, Bas, Bouke, 
Bram, Chantal, Corinne, Danyta, Dion, Elhaseen, Ellen, Evelien, Fabienne, 
Fedde, Gonny, Hao Ran, Heike, Kirsten, Laura, Lonne, Marin, Mark, 
Marlijne, Montserrat, Pan, Pauline, Quirine, Roel, Roy, Steven, Tim H., Tim 
K., Toon, Vince, Wenke, Wiesje en Yala. 
Jean, dr. Scheijen toen de resultaten van een studie leken tegen te vallen beschreef jij 
het werk van de wetenschapper als volgt: “je kunt met een schep zand scheppen en 
naar de overkant van de straat dragen, maar aan het eind van de dag is er geen garantie 
dat die zandberg ooit volledig aan de overkant raakt”. Met deze metafoor heb je zo de 
frustraties van de gemiddelde PhD student samengevat. Ook in de jaren nadien was je 




er als ik een peptalk nodig had. Dank dat je zo haarfijn aanvoelt wanneer anderen een 
steuntje in de rug kunnen gebruiken.  
Alle collega’s uit de kliniek, hartelijk dank voor de prettige samenwerking, alle MDL-
artsen van het MUMC+, bedankt. Chantal en Rogier in het bijzonder bedankt 
voor de mooie tijden onderweg naar en in het mooie Oostenrijk! Uiteraard ook dank 
aan de dames van de functiekamer Anja, Nicole, Rachelle, bedankt voor al jullie 
behulpzaam- en vrolijkheid. Elly, Mietsie en nadien ook Nienke, dank voor al jullie 
logistieke en organisatorische hulp vanuit het secretariaat. 
 
Zuyderland Medisch Centrum. 
Dank aan alle MDL-artsen en internisten van het Zuyderland voor hun 
enthousiasme en begeleiding. In het bijzonder dank aan dr. Jacqueline Buijs, dr. 
Frank Stifft en dr. Roderick Tummers als opleiders Interne Geneeskunde voor de 
fijne start in de kliniek en de begeleiding op weg naar MDL-arts. Dank aan dr. Yolande 
Keulemans en dr. Annick Van Nunen, opleiders MDL. De MDL voelt mede dankzij 
jullie als een warm bad.  
Lieve collega arts-assistenten, ik ga met plezier naar mijn werk en dat komt mede 
door jullie! De saamhorigheid, hulpvaardigheid en gezelligheid van jullie allen maakt dat ik 
me thuis voel in dit topteam. In het bijzonder dank aan de borrelbabes Edmee, Gitta, 
Inge, Loes en Raisa voor de gezellige tijden ook buiten de werkvloer. 
En natuurlijk alle lieve en bekwame verpleegkundigen en secretaresses van oa. 
O41, O43 en O51 met wie ik de afgelopen tijd fijn heb samengewerkt, dank! 
 
Promotieboekje. 
Tiny, veel dank voor het verzorgen van de lay-out van dit boekje.  
Advacom. Kirsten, bedankt voor je begeleiding in het verduidelijken van mijn 
aanvankelijk nog vage wensen voor de cover van dit boekje. Geweldig wat Patrick en jij 
ervan hebben gemaakt. Veel dank. 
 
Vriendinnen (en vrienden). 
I don’t know what I would have done so many times in my life, if I hadn’t had my 
girlfriends (Reese Witherspoon). 
Mijn thuishaven: lieve Anne, Annemieke, Kirsten en Marieke, wat ben ik blij met 
jullie! Jullie hebben mijn promotietijd van dichtbij meegemaakt, van de pieken tot de 
diepe dalen. Jullie kennen mij en mijn tekortkomingen als geen ander en zullen altijd voor 
mij waken. Geweldig om te zien wat voor een mooie succesvolle vrouwen jullie allemaal 
geworden zijn. Naast onze geweldige vakanties in o.a. New York, Thessaloniki en 
Mallorca, onze oneindige borrelavonden en legendarische jeugdherinneringen (we zijn 
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helaas inmiddels geen jeugd meer te noemen), hoop ik nog veel avonturen met jullie te 
mogen meemaken. Lafja Poeskes!!! 
 
Clubgenootjes, lieve Jacqueline, Janneke, Margot, Susan en Valerie. Wat zijn we 
ver gekomen sinds we elkaar voor het eerst ontmoetten. Van onze stinkende 
ontgroeningspakjes in de Capucijnenstraat, tot sophisticated champagne sippen in 
Noord-Frankrijk, we zien en steunen elkaar gelukkig nog steeds. Wat ben ik trots op de 
carrièrevrouwen die jullie allen geworden zijn en wat heb ik zin om deze mijlpaal met 
jullie te vieren! 
 
Lieve sterke Lieke, dank voor de fijne vriendschap door de jaren heen. Ik heb 
bewondering voor hoe je het allemaal combineert, en dat met oog voor je medemens. 
Het was een hele eer dat ik ceremoniemeester op je grootse bruiloft mocht zijn.  
Lieve Lizzy, partner in crime en rots in de branding. Als ik je nodig heb ben je er. Je 
blijft dicht bij jezelf, bent goudeerlijk en vooral reuze gezellig! Jammer dat je er niet bij 
kunt zijn op deze dag, maar dat halen we vast een keer in. 
 
Helaas kan ik onmogelijk iedereen uitgebreid bedanken, toch nog een shoutout naar 
andere lieve mensen zoals Karlijn, Liyanne, Lizanne en Thomas, Joep en 
Susanne, Ruud, Berrie en Wim – dank voor jullie vriendschap. 
 
Familie. 
Lieve Elsie, en Leonardo dankjewel dat jullie altijd voor ons klaarstaan. Ik verheug me 
op al onze toekomstige gezellige momenten y abrazos en had me geen betere 
schoonouders kunnen wensen. Ik weet dat jullie trots zijn op de prestaties van Eric en 
mij en dat doet goed. Carolina, je wordt gemist maar ik hoop dat je de beste tijd 
beleeft in Japan. 
 
Ronald, Esther en Frank, ik had me geen betere bonusbroers en -zus kunnen 
wensen en ik geniet telkens weer van de grote familiemomenten met ons allen samen. Ik 
ben blij dat jullie er op deze dag bij kunnen zijn en ik hoop dat we nog veel tijd samen 
zullen doormaken. Op naar dat familiehuis in Frankrijk! 
 
Lieve Marieke, dank voor je warmte en dat we altijd welkom zijn in Drenthe. Het doet 
mij deugd te zien hoe gelukkig jij pap maakt! 
 
Lieve Jos, wat bof ik met een bonusvader zoals jij! Jij staat altijd voor mij klaar, of het nu 
een noodgeval zoals een lege tank of een kapot kettingslot is, of dat ik een portie wijze 




raad kan gebruiken, jij bent er. Je kookt de heerlijkste gerechten vol passie waar we met 
z’n allen Bourgondisch van mogen genieten, vertelt de meest levendige verhalen en hebt 
daarnaast nog eens heel veel kennis over geschiedenis, planten en van alles en nog wat. 
Niet onbelangrijk: jij maakt mijn mamma gelukkig. Merci merci merci.  
 
Lieve oma, Ik zal nooit vergeten wat voor een fijne tijd we altijd samen hebben gehad, 
samen met opa, Marlon en Roman. Het is geweldig dat je mijn promotie kan meemaken 
en je zult altijd een speciaal plekje in mijn hart hebben.  
 
Pap, lieve pappa, als kind heb je me altijd laten weten trots op me te zijn, en dat is goud 
waard. In onze huidige communicatie zijn er geen taboes en ik kan jou altijd om goede 
eerlijke raad vragen en dat voelt goed. Terwijl ik dit dankwoord afschrijf dreigt de maas 
uit zijn voegen te barsten en begint de evacuatie van enkele wijken van Maastricht. Dit 
raakt je. Je weet wat ze zeggen toch, eens een Limburger, altijd een Limburger. Ook al 
ben je op afstand in Drenthe, je blijft gelukkig verbonden met ons en het Zuiden in je 
hart. Dank voor je steun en toeverlaat, dank voor wie je bent voor mij als vader. 
 
Mam, lieve mamma, jouw wijze lessen gingen natuurlijk veel verder dan niet instappen 
bij vreemden met snoepjes en niet zomaar drankjes aannemen van mannen die je niet 
goed kent. Je leerde me tevens wat wel te doen. Samen op de brommer naar balletles in 
Geleen, samen zonnebaden in de tuin. Je was nooit te beroerd om mijn huiswerk na te 
kijken, mijn kennis te overhoren of om mij grammatica bij te brengen. Er is niemand op 
wie ik meer lijk, niet alleen wat betreft uiterlijk maar ook wat betreft doen en laten. En 
dat is voor iedereen zichtbaar. Ook tegenwoordig sta je nog altijd voor me klaar en 
steun je mijn keuzes in het leven. Dank voor de opofferingen die je voor mij hebt 
gemaakt en dank voor wie je bent voor mij als moeder. 
 
Be with someone that inspires you and makes you the best version of yourself (Roy T. 
Bennett). Lieve Eric, dank voor wie je bent en dat je altijd in mij gelooft. Jij bent mijn 
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Voor het bijwonen van




From Diagnostic Criteria 
to Targeted Treatment
Door 
Zsa Zsa Regina Maria Weerts













In verband met covid-maatregelen zijn 
een beperkt aantal genodigden in de 
aula toegestaan, graag vernemen we uw 
voorkeur: fysiek of digitale aanwezigheid. 
U hoort van ons wat de mogelijkheden 
zijn. Aansluitend aan de promotie 
vindt een receptie plaats.
Irritable Bow
el Syndrom
e    From
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iagnostic C
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